{
    "1": {
        "question": "<div class=\"qtext\"><p>A 60-year-old woman presents to clinic for BP management. Her medical history includes hypertension and diabetes. Her medications are lisinopril 20 mg daily and amlodipine 10 mg daily, and she is adherent as indicated by prescription refill records. She considers her diet to be “heart healthy,” and restricts sodium reliably to less than 2 g/day. Over the past 6 months, her BP has fluctuated from visit to visit and between morning and evening. Home records indicate that her BP ranges from 118–162/63–94 mm Hg; her average of 20 readings over the past month is 133/80 mm Hg. She does not have headache, nausea, vomiting, or blurry vision, and her creatinine has been stable at 1.5 mg/dL (reference range, 0.5–1.1).</p>\n<p>Examination shows a BP of 145/92 mm Hg, similar to 152/88 mm Hg obtained at a visit 3 months ago but higher than 125/74 mm Hg obtained 6 weeks ago. BP is equal in both arms, and there are no postural changes. Her heart rate is 78/min. Lungs are clear, heart is regular without murmur or gallop, and there is no abdominal bruit or lower extremity edema. Laboratory evaluation shows a potassium of 4.8 mEq/L (reference range, 3.5–5.0) and creatinine 1.45 mg/dL. Her urine albumin-to-creatinine ratio (ACR) is 28 mg/g (reference range, &lt;30). Twenty-four hour urine collection reveals 2,200 mg/day sodium excretion.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 10px;\"><strong>Which of the following is the next BEST STEP to manage her BP?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase lisinopril to 40 mg daily"
            },
            {
                "label": "B.",
                "text": "Obtain ambulatory BP monitoring"
            },
            {
                "label": "C.",
                "text": "Add labetalol 100 mg twice daily"
            },
            {
                "label": "D.",
                "text": "Decrease sodium intake to <1000 mg daily"
            },
            {
                "label": "E.",
                "text": "Add chlorthalidone 12.5 mg daily"
            }
        ],
        "correct_answer": "Add chlorthalidone 12.5 mg daily",
        "abim_content_category": "Hypertension",
        "explanation": "Adding a thiazide diuretic to this patient’s regimen would best decrease BP variability, improve overall control, and reduce cardiovascular (CV) risk.Short-term BP variation (BPV) is defined as fluctuations over 24 hours as demonstrated with an ambulatory BP monitor, whereas long-term BPV is defined as changes over days to months, such as those identified at office visits. A “normal” degree of BPV has not been established, but higher levels of BPV compared with a population mean are associated with increased CV risk as well as an increased prevalence of CKD.In one study, 402 patients with CKD from nephrology clinics in Italy between 2001 and 2009 had their short-term (24-hour) BPV measured by ambulatory BP monitoring and long-term BPV measured by at least 4 outpatient office BP measurements. The mean long-term and short-term BPV were 12.7 mm Hg and 12.6 mm Hg, respectively. Over a median follow-up of 3.2 years, visit-to-visit BP variability was associated with higher risk for a composite outcome of death and CV events (hazard ratio 1.24). In this population, there was no significant association between short-term BPV and adverse outcomes, in contrast to studies in patients with hypertension and normal kidney function, which have identified higher risk.This patient demonstrates both short- and long-term BPV and has an average home BP above optimal values. Although an ambulatory BP monitor would be informative, there is already enough information to justify an increase in therapy.Calcium channel blockers and thiazide diuretics appear to be beneficial to reduce BPV. In a cohort of patients with CKD, those in the lowest quartile of visit-to-visit BPV were more likely to be taking a calcium channel blocker than those in the higher quartiles. Similarly, the participants in the ALLHAT trial randomized to receive chlorthalidone and amlodipine had lower visit-to-visit BPV 6–28 months after randomization, whereas those randomized to receive lisinopril had higher variability. Similar patterns were observed in the SPRINT trial, with lower BPV seen in participants receiving thiazide-type diuretics and calcium channel blockers.Thus, adding a thiazide diuretic to this patient’s antihypertensive regimen is likely to be most successful in stabilizing her BP. Lisinopril was associated with high BPV in ALLHAT. Because her ACR is reasonably controlled with her current dose, an increase in lisinopril would not be preferred. There is no evidence that α-blockers or β-blockers stabilize BP. Data concerning the impact of a 1,000-mg sodium diet on hypertension is lacking, both in terms of overall control and in terms of variability. Meta-analyses and observational studies have suggested a J-shaped relationship between dietary sodium and CV outcomes such that very low intake is correlated with higher CV morbidity and mortality. This patient’s sodium excretion (and intake, at steady state) is already close to the recommended goal of 2,000 mg daily. Therefore, more intensive sodium restriction would not be warranted.",
        "references": []
    },
    "2": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 59-year-old woman with a history of diabetes mellitus, hypertension, breast cancer, and CKD stage 4 is evaluated for anemia. Her breast cancer has been treated with surgery, and she is currently undergoing combination chemotherapy with curative intent. Symptoms include fatigue and dyspnea with exertion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Iron\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                90 µg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                50–150\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Total iron binding capacity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                270 µg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                250–310\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                305 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                11–307\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\"><strong>Which of the following is the next BEST step in anemia management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Erythropoietin"
            },
            {
                "label": "B.",
                "text": "Roxadustat"
            },
            {
                "label": "C.",
                "text": "Testosterone"
            },
            {
                "label": "D.",
                "text": "Periodic transfusion"
            },
            {
                "label": "E.",
                "text": "IV iron"
            }
        ],
        "correct_answer": "Periodic transfusion",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient with CKD, symptomatic anemia, and a history of cancer should be treated with periodic transfusion of red blood cells (RBCs).Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been the cornerstone of management of anemia in patients with CKD. However, randomized trials have identified an increased risk for progression or recurrence of neoplasm in patients treated with ESAs. KDIGO guidelines suggest that ESA be “used with great caution” in patients with active malignancy, particularly if there is potential for cure, and grade the evidence for this recommendation 1B. They make the same recommendation for patients with a history of malignancy but grade the evidence 2C. For this patient undergoing treatment for breast cancer, periodic transfusion of RBCs is the preferred option. IV iron is indicated to maintain adequate iron available for erythropoiesis. In this case, both the transferrin saturation (33%) and the ferritin levels are satisfactory. Androgens have been used to treat anemia in CKD, but evidence for safety and benefit is sparse and the potential for adverse effects significant. In some cases, the use of an ESA may be justified despite the potential impact on malignancy. In these cases, a risk evaluation and management strategy (REMS) is used. This situation might occur if there are barriers or increased risks to transfusion, such as the presence of anti-RBC antibodies or preexisting iron overload.A promising approach to the management of anemia in CKD involves the use of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHI) such as roxadustat. These agents work by stabilizing the HIF complex (by inhibiting prolyl hydroxylation of HIF) and stimulating endogenous erythropoietin production, even in patients with ESRD. HIF stimulates erythroferrone and increases erythropoietin production. HIF facilitates plasma transport of iron to tissues and improves intestinal absorption of iron by upregulating divalent metal transporter genes. Thus, HIF-PHIs do not increase iron requirement to the same extent as erythropoietin. HIF-PHIs are administered orally, which may be a more favorable route for patients not undergoing HD. One significant concern regarding the long-term use of these agents is their possible effect on tumor growth, so these agents would not be appropriate for the patient described in this vignette.",
        "references": []
    },
    "3": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 54-year-old man with ESRD of undetermined cause, HD dependence for 10 years, hypertension, and peripheral vascular disease presents with right-sided abdominal pain that worsens after meals. He has been anuric for several years but has a remote history of kidney stones. His medications include lisinopril, amlodipine, atorvastatin, sevelamer, erythropoietin, and a multivitamin.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">\n    Examination is notable for right upper quadrant tenderness. A CT scan of the abdomen and pelvis demonstrates acute cholecystitis. Incidentally, a complex, enhancing cyst measuring 4 cm is identified in the right kidney. Both kidneys are atrophic and display\n    multiple cysts. After antibiotic treatment and resolution of the cholecystitis, the patient undergoes cholecystectomy and right nephrectomy. Histopathology of the complex cyst demonstrates a renal neoplasm with cribriform architecture and numerous\n    deposits of calcium oxalate both within the tumor and in the surrounding renal parenchyma.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 10px;\"><strong>Which of the following conditions is MOST likely associated with renal cell carcinoma in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acquired cystic kidney disease"
            },
            {
                "label": "B.",
                "text": "Erythropoietin toxicity"
            },
            {
                "label": "C.",
                "text": "Hereditary leiomyomatosis"
            },
            {
                "label": "D.",
                "text": "Polycystic kidney disease"
            },
            {
                "label": "E.",
                "text": "Nephrocalcinosis"
            }
        ],
        "correct_answer": "Acquired cystic kidney disease",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "The most likely diagnosis in this patient who has been dialysis-dependent for 10 years and has atrophic kidneys with multiple cysts is acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC).The most common forms of renal cell carcinoma (RCC) in patients receiving dialysis are ACKD-RCC, clear cell carcinoma, and papillary carcinoma. ACKD-RCC was recognized as a distinct entity beginning in 2013 and is part of the 2016 World Health Organization classification of tumors of the urinary system. It is seen exclusively in patients with ESRD and acquired cystic kidney disease. Detection usually occurs incidentally because the tumors are often asymptomatic. Clinical risk factors include longer duration of dialysis (>10 years) and male sex. Histologically, the tumors can have a cribriform, microcystic, or sieve-like architecture, with eosinophilic or clear cytoplasm or both. Although calcium oxalate deposition is not required for diagnosis, it is often present, both in the tumor as well as the surrounding non-neoplastic kidney. Screening for acquired cystic disease and by extension RCC, in patients receiving dialysis is controversial. CT and ultrasound are the most common strategies. Based on expert opinion, screening transplant candidates with a dialysis vintage of 3 years or more is a reasonable approach. Investigation into the biologic behavior, prognosis, and treatment response is ongoing, as there is little definitive information to date.Neither nephrocalcinosis nor nephrolithiasis is known to predispose directly to RCC in the absence of ESRD and ACKD. Erythropoietin use has been associated with progression or recurrence of cancers in patients with ESRD but has not been linked specifically to RCC.The incidence of RCC may be higher in patients with ESRD related to ADPKD, although this finding is controversial. The appearance of this patient’s kidneys by CT scan is typical of ACKD rather than ADPKD. Nephromegaly persists in ADPKD patients and cyst growth may even continue after progression to ESRD, whereas transplantation has been associated with regression.Hereditary leiomyomatosis is one of several genetic conditions characterized by increased risk of RCC. In this syndrome, a mutant form of fumarate hydratase (one of the tricarboxylic acid cycle enzymes) predisposes to cutaneous leiomata, uterine fibroids, and papillary RCC, which tends to metastasize early. The histopathology of this patient’s tumor favors ACKD-RCC rather than papillary carcinoma.",
        "references": []
    },
    "4": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 65-year-old man with ESRD attributed to type 2 diabetes and hypertension is evaluated for BP variability. He has received 4 hours of HD thrice weekly for the last 3 years. Weight gain between treatments is consistently &lt;3 kg. His BP has been high pre-dialysis; post-dialysis BPs has been variable. Medications include carvedilol 37.5 mg twice daily, nifedipine 60 mg twice daily, and lisinopril 40 mg daily. He is adherent to his antihypertensive medicines. Attempts to reduce the target weight have led to intradialytic hypotension. </span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Vital signs are significant for pre-dialysis BP 180/100 mm Hg and post-dialysis BP 110/84 mm Hg with a heart rate of 88/min. Hypotension occurred at 2 hours, 45 minutes into dialysis but improved when the ultrafiltration rate was reduced. Physical exam reveals 1+ edema bilaterally.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST step to manage BP?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Reduce sodium intake to <1000 mg daily"
            },
            {
                "label": "B.",
                "text": "Add furosemide 120 mg daily"
            },
            {
                "label": "C.",
                "text": "Obtain 44-hour interdialytic ambulatory BP"
            },
            {
                "label": "D.",
                "text": "Add spironolactone 50 mg daily"
            },
            {
                "label": "E.",
                "text": "Add metoprolol succinate 50 mg daily"
            }
        ],
        "correct_answer": "Obtain 44-hour interdialytic ambulatory BP",
        "abim_content_category": "Hypertension",
        "explanation": "A 44-hour ambulatory BP is needed to determine whether additional antihypertensive therapy is indicated in this patient with pre-dialysis hypertension and intradialytic hypotension.In patients with ESRD treated with HD, hypertension is common and is often poorly controlled. Elevated BP detected by home or ambulatory BP monitoring (ABPM) is associated with shorter survival. Observational studies suggest that ABPM predicts all-cause and cardiovascular (CV) mortality better than BP measurements obtained at the dialysis session. The presence of a non-dipping nocturnal BP pattern is very common among patients with ESRD and has been associated with left ventricular hypertrophy and increased risk of all-cause and CV mortality. When neither ABPM nor home BP measurements are available, hypertension can be diagnosed by office BP measurements taken during the interdialytic interval. In contrast to pre-dialysis BP, which has a U-shaped relationship with mortality, the average of 3 office measurements (obtained using appropriate technique) is almost linearly related to risk.BP control in patients with ESRD can be frustrating because of its variability before, during, and immediately after HD and during the interdialytic period. In this patient, who despite taking several antihypertensive medications has persistent elevation of pre-dialysis BP, it is important to identify the pattern of hypertension. Thus, before changing therapy, interdialytic ABPM is helpful to assess CV risk and avoid overtreatment. Sodium restriction is a reasonable adjunct in hypertensive patients receiving dialysis, particularly those with edema, but limiting intake to <1 g daily imposes significant hardship without evidence of benefit.",
        "references": []
    },
    "5": {
        "question": "<div class=\"qtext\"><p>A 45-year-old woman with a history of ESRD secondary to ADPKD status post kidney transplantation presents with gross hematuria, low-grade fever, nasal congestion, and conjunctivitis. Two months prior to presentation, she underwent simultaneous deceased donor kidney transplantation and bilateral nephrectomy for large painful kidney cysts. The induction regimen included anti-thymocyte globulin. Antibodies to CMV were present prior to the transplant in both donor and recipient (CMV D+/R+). She had immediate allograft function and an uncomplicated postoperative course. Her baseline creatinine is 0.9 mg/dL. Medications include prednisone, tacrolimus, mycophenolate, trimethoprim-sulfamethoxazole, valganciclovir, amlodipine, vitamin D, and supplemental calcium. On day 3 of her hospitalization, she undergoes a kidney biopsy.</p>\n<p>Physical examination is notable for BP 108/65 mm Hg, heart rate 103/min, respiratory rate 15/min, and temperature 38.2°C. The allograft is tender to palpation.</p>\n<p>Laboratory data at the time of biopsy are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Blood</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2700/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11.4 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelets </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">264,000/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Tacrolimus, trough</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">13 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–15 (0–3 months post-transplant)</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">139 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">110 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">28 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">17 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.6 mg/dL (1.2 on admission)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Prothrombin time</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11 s</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11–13</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Activated partial thromboplastin time </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">30 s</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25–35</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BK virus polymerase chain reaction (PCR)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Undetected</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Undetected</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BK virus PCR</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Undetected</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Undetected</td>\n</tr>\n</tbody>\n</table>\n<div><br/></div>\n<p>Urinalysis: 3+ blood, trace albumin, &gt;150 RBC/hpf. Urine gram stain is negative, and a urine culture is pending.</p>\n<p>Ultrasound with Doppler of the kidney allograft and bladder is unremarkable, and cystoscopy shows mild inflammation of the bladder mucosa.</p>\n<p>The patient undergoes kidney biopsy, with histopathology remarkable for an infiltrate of neutrophils and histiocytes with marked tubulitis and smudgy nuclear inclusions, as shown below.</p>\n<figure><img alt=\"Picture 2\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/139_blobid0.jpg\" style=\"width: 5.5in;\"/>\n<figcaption><em>Image courtesy of Mazdak Khalighi, MD, Oregon Health &amp; Science University</em></figcaption>\n</figure>\n<p></p>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 20px;\"><span><strong>Which one of the following is the MOST likely cause of the observed findings?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "BK virus"
            },
            {
                "label": "B.",
                "text": "Cytomegalovirus"
            },
            {
                "label": "C.",
                "text": "Adenovirus"
            },
            {
                "label": "D.",
                "text": "Influenza A virus"
            },
            {
                "label": "E.",
                "text": "Lymphoproliferative disease"
            }
        ],
        "correct_answer": "Adenovirus",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "Infection with adenovirus is most likely in this kidney transplant recipient with fever, hematuria, bladder inflammation, and interstitial nephritis with viral inclusions.Among kidney transplant recipients, clinically significant adenovirus infection is infrequent, affecting 4% of patients. Adenovirus infection usually presents with fever and gross hematuria within the first 3 months following transplantation. Hemorrhagic cystitis is a well-described complication, although this finding tends to occur more frequently in recipients of stem cell transplants. Rarely, adenovirus can cause multi-organ disease, including pneumonitis, orchitis, gastroenteritis, and lymphopenia.Diagnosis of adenovirus infection can be made by serum or urine PCR, but kidney biopsy is often performed to evaluate for other causes of allograft dysfunction. Histologic features of adenovirus nephropathy are tubular cell necrosis, nuclear enlargement, basophilic nuclear inclusions, and granulomatous tubulointerstitial nephritis. Immunohistochemical stains confirm the presence of adenovirus antigens. EM shows adenovirus particles 70–80 nm in diameter within tubular epithelial cells. Features of tubular inflammation may be difficult to distinguish from those of cellular rejection.There is no standard of care for adenovirus disease in kidney transplant recipients. Treatment often includes IV immunoglobulin as well as reducing immunosuppression. Cidofovir has been used with inconsistent response. Treatment response can be monitored through serial PCR testing.Risk factors for CMV infection are serologic CMV mismatch between the donor (+) and recipient (-) and use of lymphocyte-depleting induction therapies, such as the anti-thymocyte globulin this patient received. This recipient and donor are both positive for CMV, and the recipient is currently receiving CMV prophylaxis with valganciclovir, both of which reduce the likelihood of CMV disease. The clinical symptoms of nasal congestion and conjunctivitis are more consistent with adenovirus infection than with CMV disease. Although immunohistochemical staining of viral antigens would help differentiate between CMV and adenovirus infection, the clinical scenario is much more consistent with the latter.BK nephropathy is unlikely given the negative blood and urine PCR results.EBV reactivation is associated with post-transplant lymphoproliferative disease (PTLD) and less commonly with AKI and gross hematuria. PTLD manifests as a lymphocytic infiltrate on biopsy.Influenza infection does not cause gross hematuria and the histologic findings in this biopsy.",
        "references": []
    },
    "6": {
        "question": "<div class=\"qtext\"><p>An 84-year-old woman is brought to the emergency department after being found at home unresponsive. She is unarousable, and she is immediately intubated and given an infusion of 0.9% saline. A subsequent review of her record demonstrates a history of partial thyroidectomy and resected malignant melanoma. She is not known to be taking any medications, although aspirin and acetaminophen were found in the medicine cabinet in her apartment.</p>\n<p>Examination reveals an atraumatic but cachectic patient with a Glasgow coma scale (GCS) score of 3 (eye 1, motor 1, verbal 1). Her systolic BP is 60 mm Hg, heart rate 40/min, and temperature 33°C. Her initial weight is 60 kg. No explanation for her depressed level of consciousness is apparent. Cultures are obtained and broad-spectrum antibiotics are infused. Mechanical ventilation is provided and 6 L of warmed 0.9% saline is infused. Eight hours later, her temperature and BP improve to 36°C and 110/50 mm Hg, respectively. Her GCS score improves to 9.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Result (Hour 0)</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Result (Hour 8)</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                144\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                121\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Arterial blood gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.17\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.26\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"bottom-margin: 10px;\"><span><strong>Which of the following is the MOST likely explanation for this patient’s acid-base disturbance at hour 8?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Saline infusion"
            },
            {
                "label": "B.",
                "text": "Aspirin overdose"
            },
            {
                "label": "C.",
                "text": "Lactic acidosis"
            },
            {
                "label": "D.",
                "text": "Acetaminophen toxicity"
            },
            {
                "label": "E.",
                "text": "Correction of hypercarbia"
            }
        ],
        "correct_answer": "Saline infusion",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "The most likely explanation for this patient’s hyperchloremic metabolic acidosis is saline infusion.In this case, the patient presents with a combined respiratory acidosis and metabolic acidosis with a modestly elevated anion gap. After 8 hours, the respiratory acidosis has resolved and the anion gap has normalized, but a non-anion gap metabolic acidosis (NAGMA) is now apparent. In this situation, the new NAGMA is most likely due to rapid infusion of isotonic saline. Although the mechanism of the NAGMA in this setting is incompletely understood, a common explanation is that the extracellular volume is expanded while the total bicarbonate remains fixed, resulting in a lower concentration of bicarbonate. This mechanism is referred to as dilutional acidosis.An alternative explanation invokes the Stewart model, which proposes that the cause of normal anion gap acidosis related to isotonic saline infusion is due to a large amount of chloride in the infused saline, which functions as a strong anion and leads to the development of NAGMA.Lactic acidosis and aspirin overdose are not likely because they would be expected to result in an elevated anion gap. Acetaminophen toxicity can cause the accumulation of 5-oxoproline, but this too results in an elevated anion gap. Acute correction of the hypercarbia results in metabolic alkalosis, rather than NAGMA.",
        "references": []
    },
    "7": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 27-year-old man who sustained a T2 spinal cord injury is evaluated for hypercalcemia. The patient was involved in a motor vehicle crash 10 weeks ago. He was transferred from the inpatient rehabilitation service after developing labile BP, nausea, flushing,\n    and fatigue. His current medications include pantoprazole, docusate, and baclofen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 191/105 mm Hg and heart rate 58/min. He has scattered rhonchi on lung examination. Cardiovascular exam demonstrates bradycardia. His abdomen is slightly distended with hypoactive bowel sounds. Abdominal x-ray shows large stool\n    burden. Laboratory studies yield the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                108 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Bone-specific alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Intact PTH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Parathyroid hormone–related protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 pmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25-Hydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1,25-Dihydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15–60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                N-telopeptide-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                160 nmol BCE (bone collagen equivalent) per mmol creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                21–83\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely cause of hypercalcemia in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Pheochromocytoma"
            },
            {
                "label": "B.",
                "text": "Sarcoidosis"
            },
            {
                "label": "C.",
                "text": "Immobilization"
            },
            {
                "label": "D.",
                "text": "Familial hypocalciuric hypercalcemia"
            },
            {
                "label": "E.",
                "text": "Pantoprazole"
            }
        ],
        "correct_answer": "Immobilization",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "Immobilization is the most likely cause of this patient’s hypercalcemia. The presence of an elevated serum calcium with suppressed PTH and elevated urine N-telopeptide-to-creatinine ratio is consistent with hypercalcemia due to bone resorption. The absence of mechanical stimulation for bone formation, which occurs during immobilization, reduces osteoblastic activity, leading to relatively unopposed osteoclast-mediated bone resorption. As serum calcium levels rise, PTH is appropriately suppressed, and urinary calcium excretion is increased.Measurements of bone turnover markers in the serum and the urine may be useful to diagnose bone-related disease and assess efficacy of therapy. Bone-specific alkaline phosphatase is found in osteoblasts and is a marker of bone formation. Conversely, bone resorption mediated by osteoclasts leads to liberation of the collagen peptides N-telopeptide crosslink (NTX) and C-telopeptide crosslink, whose levels reflect the rate of bone resorption. The presence of elevated NTX with a normal bone-specific alkaline phosphatase indicates active bone resorption with the absence of bone formation, which suggests hypercalcemia due to immobilization. Urinary N-telopeptide is a sensitive and specific marker of bone resorption and has been demonstrated to increase significantly in patients with immobilization. Bisphosphonates and denosumab, an inhibitor of receptor activator of nuclear factor-κB (RANK), have been used to treat immobilization hypercalcemia by inhibiting osteoclast activity.Lymphoma and chronic granulomatous disorders such as sarcoidosis are associated with enhanced 1α-hydroxylase activity, which increases nonrenal, endogenous production of 1,25-dihydroxyvitamin D with resulting hypercalcemia. With other causes of hypercalcemia, such as immobilization, 1,25-dihydroxyvitamin D should be suppressed, as in this case, making sarcoidosis an unlikely diagnosis.Although pheochromocytoma may be associated with hypercalcemia, it usually is secondary to concurrent hyperparathyroidism in the setting of multiple endocrine neoplasia type 2 or the result of tumoral production of PTH-related protein, neither of which would explain hypercalcemia in this case. The patient’s labile BP is likely due to autonomic dysreflexia, a complication associated with spinal cord injuries at or above the level of the sixth thoracic spinal cord segment. Autonomic dysreflexia is characterized by episodic hypertension with concomitant baroreflex-mediated bradycardia. Additional symptoms include headaches, flushing, anxiety, nausea, and diaphoresis. The injury to the spinal cord causes dissociation of spinal sympathetic neurons from supraspinal modulation, leading to uninhibited or exaggerated sympathetic reflexes. Autonomic dysreflexia is typically triggered by noxious stimuli below the lesion such as bladder distension or bowel impaction.Patients with familial hypocalciuric hypercalcemia (FHH) do not usually have symptoms of elevated serum calcium. This autosomal dominant disorder is associated with hypocalciuria, mild hypercalcemia with a normal or slightly elevated serum PTH, and normal or increased serum magnesium levels. FHH is caused by an inactivating mutation in the calcium-sensing receptor such that higher levels of serum calcium are required to suppress PTH.Long-term proton pump inhibitor therapy may result in hypomagnesemia. Low serum magnesium in turn results in resistance to or deficiency of PTH, which causes hypocalcemia rather than hypercalcemia.",
        "references": []
    },
    "8": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 59-year-old woman with ESRD due to HIV-associated nephropathy status post deceased donor kidney transplant 7 months ago is admitted for treatment of acute cellular rejection (Banff grade IIA, mild to moderate intimal arteritis, with interstitial inflammation and tubulitis). Both the donor and recipient were seropositive for CMV and EBV prior to transplantation. She received induction therapy with basiliximab 7 months ago and completed antiviral prophylaxis with valganciclovir 1 month ago. She feels well on the day of admission and does not report fever, chills, nausea, vomiting, or diarrhea.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>In addition to antiretroviral therapy, her current medications include tacrolimus 1 mg twice daily, mycophenolate mofetil 1 g twice daily, sulfamethoxazole/trimethoprim 400/80 mg daily, nifedipine 30 mg daily, and famotidine 20 mg daily.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Her BP is 145/90 mm Hg. She appears well and has no thrush, rash, or adenopathy on examination. Heart and lungs are normal. The allograft is nontender. HIV viral load is undetectable and CD4 cell count is 750/μL (reference range, 530–1570). Chest x-ray is normal.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Tacrolimus and mycophenolate mofetil doses are reduced by 50%, and she is treated with her usual medications. Methylprednisolone 500 mg IV is given, and anti-thymocyte globulin (ATG) 1.5 mg/kg IV is infused over 4 hours. Later that day, the patient develops fever, headache, and severe hypotension that persists despite IV fluid infusion. She is transferred to the intensive care unit for vasopressor therapy.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely cause of this patient’s refractory hypotension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CMV viremia"
            },
            {
                "label": "B.",
                "text": "Endotoxin"
            },
            {
                "label": "C.",
                "text": "Interleukin-6"
            },
            {
                "label": "D.",
                "text": "Anaphylaxis"
            },
            {
                "label": "E.",
                "text": "EBV viremia"
            }
        ],
        "correct_answer": "Interleukin-6",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "The refractory hypotension is most likely related to interleukin-6 (IL-6), and other pro-inflammatory cytokines, induced by ATG administration.Cytokine release syndrome (CRS) is a form of systemic inflammatory response that can occur after ATG infusion. Although the pathophysiology is incompletely understood, CRS is thought to be due to immune cell activation and release of inflammatory cytokines, including IL-6. The presentation of CRS can vary from a mild flu-like illness to distributive shock with vascular leakage, disseminated intravascular coagulation, and multiorgan failure. Other immunosuppressive antilymphocyte antibody therapies, such as alemtuzumab and rituximab, have also been observed to provoke CRS. This phenomenon appears to be more common with the first exposure or soon thereafter, but late presentations may also occur. The differential diagnosis includes sepsis and anaphylaxis. Specific risk factors have not been identified, and all patients receiving these therapies should be premedicated with acetaminophen, antihistamines, and corticosteroids. Noncardiogenic pulmonary edema is a frequent severe complication that may be exacerbated by preexisting volume overload. Treatment of CRS-related hypotension consists of volume expansion if tolerated, vasopressors, corticosteroids, and sometimes anti-cytokine therapy with tocilizumab, an IL-6 receptor targeted monoclonal antibody. A recent case report found that treatment with methylene blue improved hemodynamic status in a patient with vasopressin-refractory hypotension related to ATG.In this case, the timing of shock shortly after ATG infusion and the absence of evidence of current infection makes hypotension due to septic shock, mediated by endotoxin, less likely. Anaphylaxis may be difficult to distinguish from CRS because both can result in severe vasodilation and capillary leak. Anaphylaxis tends to occur during ATG infusion, often within minutes of exposure. In this case, the delay in hypotension until after the infusion is completed favors CRS. CMV viremia might be more likely with the increased intensity of immunosuppression, but rapid onset of shock without a prodrome or specific organ involvement would not be typical. EBV likewise would not be unexpected after intensive immunosuppression and would increase her future risk of post-transplant lymphoproliferative disorder. Acute EBV syndromes may occur as well with intense immunosuppression, but a severe mononucleosis-like illness or undifferentiated fever rather than refractory hypotension would be the usual manifestation.",
        "references": []
    },
    "9": {
        "question": "<div class=\"qtext\"><p>A 30-year-old woman with ESRD presents to the emergency department with left shoulder pain. She initiated CAPD 1 week ago and has been performing 4 cycles daily without problems. She instilled 2 L of dialysate before bedtime as usual but awoke in the early morning with sharp left shoulder pain. The pain is 7/10 in intensity and minimally related to respiration but is not positional or worsened by movement and does not radiate. She does not report fever, chest pain, abdominal pain, or dyspnea. Her peritoneal effluent has been normal in appearance.</p>\n<p>She appears uncomfortable. BP is 120/70 mm Hg, respiratory rate 18/min, heart rate 84/min, temperature 37°C, and oxygen saturation 99% while breathing room air. The lungs are clear, and there are no murmurs, rubs, or gallops. Abdominal exam reveals no guarding or rebound, and the PD catheter exit site and tunnel are unremarkable. Both shoulders are without tenderness to palpation, erythema, or warmth and exhibit full active and passive range of motion.</p>\n<p>Peritoneal dialysate white blood cell count is 90/µL, with 30% neutrophils on differential. Chest x-ray is below.</p>\n<figure><img alt=\"Chest x-ray\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/86_Q9.jpg\" style=\"width: 5.5in;\"/>\n<figcaption><em>Image courtesy of Cybelle Ghossein, MD, Northwestern University</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 10px;\"><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Air instilled during exchange"
            },
            {
                "label": "B.",
                "text": "Pneumothorax"
            },
            {
                "label": "C.",
                "text": "Perforated abdominal viscus"
            },
            {
                "label": "D.",
                "text": "Pulmonary embolism"
            },
            {
                "label": "E.",
                "text": "Shoulder bursitis"
            }
        ],
        "correct_answer": "Air instilled during exchange",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The most likely explanation of left shoulder pain in this patient is referred pain from subdiaphragmatic irritation by air instilled inadvertently into the peritoneal cavity during PD exchange.Air can enter the peritoneum if the dialysate bag and inflow tubing are not properly flushed prior to instillation of fluid. Intra-abdominal free air is demonstrated on the chest x-ray as a crescent-shaped air-density lucency seen just underneath the left hemidiaphragm. In contrast, a normal gastric air bubble would typically appear as a round or ovoid air density rather than crescent shaped. Air trapped in this position can cause referred pain to the shoulder via irritation of the phrenic nerve. During PD training, patients are instructed to flush the dialysate inflow line to clear residual air prior to connecting the line to the peritoneal dialysis catheter. If this step is not completed, air enters the peritoneal cavity and often tracks superiorly to interpose between the liver and diaphragm, although in this case, it accumulated under the left hemidiaphragm. The pain usually gradually resolves over a week’s time. The condition is benign, and no further evaluation or management is required, although it may be important to review instillation technique with the patient to prevent future episodes.The absence of fever and peritoneal fluid leukocytosis (WBC count >100/µL and neutrophil fraction >50%) decreases the likelihood of peritonitis, either due to skin flora contamination or a perforated viscus. Abdominal perforation may manifest with free air under the diaphragm on imaging but would also normally be accompanied by signs and symptoms of severe abdominal pathology and abnormal peritoneal fluid, both of which are absent in this case.Pulmonary embolism may be associated with shoulder discomfort, but other symptoms or signs, such as tachycardia, tachypnea, hypoxemia, or pleuritic chest pain, are expected. In addition, pulmonary embolism would not explain the radiographic finding. Likewise, although pneumothorax can produce shoulder pain, it would usually have additional pulmonary manifestations. Furthermore, the chest x-ray does not demonstrate a pneumothorax.Shoulder bursitis would be suspected on physical exam with pain elicited by movement and limited range of motion, both of which are absent in this patient.",
        "references": []
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man with ESRD due to type 2 diabetes is evaluated in the dialysis unit for poor catheter flow. He has received maintenance HD for 5 years. His medical history is significant for hypertension, peripheral vascular disease, and 3 failed arteriovenous fistulas. He currently receives dialysis via a right internal jugular tunneled, cuffed catheter (TCC) that was inserted 8 months ago. Over the past month, his treatments have frequently been interrupted by high negative arterial pressure alarms, which occur even when arterial and venous connections are reversed. Arterial pressure readings average -280 mm Hg, and the blood flow rate (Qb) has been reduced from 400 mL/min to 250 mL/min in order to reduce treatment interruptions. His Kt/V has declined.</p>\n<p>On the day of evaluation, dialysis is initiated uneventfully, but high negative arterial and venous pressures are encountered and persist despite further reduction in Qb, resulting in interruption of the treatment. A forceful saline flush through both ports of the TCC does not improve blood flow.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Exchange TCC using guidewire"
            },
            {
                "label": "B.",
                "text": "Instill heparin"
            },
            {
                "label": "C.",
                "text": "Instill alteplase"
            },
            {
                "label": "D.",
                "text": "Instill sodium citrate"
            },
            {
                "label": "E.",
                "text": "Reverse arterial and venous lines"
            }
        ],
        "correct_answer": "Instill alteplase",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The next best step in management for this patient with TCC dysfunction is instillation of alteplase, a recombinant version of the fibrinolytic agent tissue plasminogen activator, into both lumens.TCC dysfunction in this patient is manifested by arterial pressures more negative than -250 mm Hg, causing pressure alarms and limiting blood flow. Other signals may include decreased HD adequacy. Occasionally, dialysis staff may recognize catheter dysfunction as resistance during catheter flush or withdrawal by syringe.Causes of early dysfunction soon after catheter placement may be related to insertion technique, such as catheter malposition or kinking. Rarely, the catheter lumens may be compressed by a purse string suture placed at the catheter exit. Causes of late dysfunction, as in this patient, include intraluminal and catheter tip thrombus and fibrin sheath formation. A fibrin sheath can start forming within 24 hours of catheter placement and over time encases the intravascular part of the catheter like a sleeve. As the sheath enlarges, it can cover the inlet or the outlet holes at the tip of the catheter and decrease blood flow and catheter efficiency. It can also trap bacteria and platelets and increase the risk of catheter thrombosis and infection. On angiographic imaging with partial retraction of the catheter, the residual fibrin sheath has a “wind sock” appearance. Depending on the nature of the obstruction, impedance to flow may affect one limb of the catheter more dramatically, or withdrawal of blood may be impeded more than return. If this is the case, it may be possible to achieve improvement in Qb by reversing the direction of flow in the circuit. This is often referred to as “running reversed.” Although a reduction in dialysis efficiency might occur, this effect is modest, and some studies have even demonstrated no significant reduction in dialysis efficiency. If a substantially better Qb can be achieved, running reversed may delay the need for catheter replacement. In this case, there is evidence of catheter flow impediment in both arterial and venous ports, and line reversal has not previously been successful for this patient.The initial treatment of catheter dysfunction in the dialysis unit involves a forceful saline flush to dislodge a possible small thrombus. If this is ineffective, instillation of alteplase or a similar thrombolytic should be the next step. Dwell times of 30–60 minutes are often used with similar efficacy. Infusions over 3 hours have also been successful. If thrombolysis fails to restore Qb to target, or if the issue recurs quickly, diagnostic angiography and invasive treatments such as catheter exchange ormechanical disruption of the sheath (sheath stripping) would be the next step.Heparin at various concentrations and 4% trisodium citrate are primarily used to prevent thrombus formation and maintain TCC patency between dialysis treatments, but they are not effective in restoring patency or flow once thrombosis or sheath formation has occurred.",
        "references": []
    },
    "11": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 42-year-old woman with a history of chronic low back pain, fibromyalgia, and gastritis is referred to the outpatient clinic for evaluation of hypokalemia. Review of systems is positive for fatigue, occasional nausea, and low back pain. Her appetite has been poor. Medications include acetaminophen, pantoprazole, and a multivitamin.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Her BP is 118/60 mm Hg, heart rate 91/min, temperature 36.8°C</span><span>, and weight 60 kg. Although the patient appears thin, the examination is otherwise normal.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                140 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine, 24-hour</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                210 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                107 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;300\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–290\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15–25 mg/kg body weight\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST likely cause of this patient’s hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Pantoprazole"
            },
            {
                "label": "B.",
                "text": "Diuretic abuse"
            },
            {
                "label": "C.",
                "text": "Chronic laxative abuse"
            },
            {
                "label": "D.",
                "text": "Gitelman syndrome"
            },
            {
                "label": "E.",
                "text": "Surreptitious vomiting"
            }
        ],
        "correct_answer": "Pantoprazole",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "The most likely cause of this patient’s hypokalemia and hypomagnesemia is proton pump inhibitor (PPI) use.The expected renal response to hypokalemia is potassium conservation manifested by a daily urinary potassium excretion of <20 mEq. The high urinary potassium in this patient signals renal wasting. The expected renal response to hypomagnesemia is magnesium conservation, which is demonstrated in this case by the low magnesium excretion. The hypomagnesemia therefore must be of nonrenal origin, such as gastrointestinal (GI) losses or failure to absorb dietary magnesium. PPIs such as pantoprazole are well known to cause hypomagnesemia, possibly because PPI-mediated alkalinization of the intestine inhibits TRPM6/7-mediated magnesium absorption. The proposed mechanism of urinary potassium wasting in hypomagnesemia is insufficient intracellular magnesium causing persistently open potassium channels (renal outer medullary potassium channel, or ROMK) in the distal tubule and cortical collecting duct. Thus, this patient’s hypokalemia may be attributed to hypomagnesemia, which in turn has resulted from pantoprazole toxicity.The differential diagnosis of renal potassium wasting includes Gitelman syndrome, vomiting, and diuretic use, but none of these etiologies would account for the low urinary magnesium.Gitelman syndrome, caused by a genetic defect in the thiazide-sensitive sodium chloride channel in the distal tubule, results in renal losses of potassium and magnesium. Diuretic abuse would be expected to cause similar findings. Chronic laxative abuse would cause GI potassium losses with renal conservation, which is not supported by the high 24-hour urine potassium. Surreptitious vomiting could cause renal potassium wasting but would also be expected to cause metabolic alkalosis with normal serum magnesium.",
        "references": []
    },
    "12": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 67-year-old man with ESRD receives HD thrice weekly via a left brachiobasilic arteriovenous fistula. His dialysis prescription is as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Dialyzer surface area</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">1.8 m<sup>2</sup></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Blood flow rate</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">400 mL/min</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Dialysate flow rate</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">800 mL/min</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Treatment time</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">4 h</td>\n</tr>\n</tbody>\n</table>\n<p>Single-pool Kt/V (spKt/V), measured monthly, has ranged from 1.6–1.8.</p>\n<p>More recently, spKt/V was 1.1. Repeat measurement by an experienced nurse confirms a value of 1.0. The patient is adherent with the prescribed treatment time, and blood and dialysate flows are delivered as prescribed. Additional testing reveals the following data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Systemic BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">70 mg/dL<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Pre-dialyzer arterial BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">50 mg/dL<br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 53.5679%;\">Post-dialyzer venous BUN<br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 46.1388%;\">10 mg/dL<br/></td>\n</tr>\n</tbody>\n</table>\n<p>Systemic BUN is drawn from the arterial hemodialysis line 30 seconds after slowing blood flow to 50 mL/min.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase blood flow rate to 500 mL/min"
            },
            {
                "label": "B.",
                "text": "Measure equilibrated Kt/V (eKt/V)"
            },
            {
                "label": "C.",
                "text": "Refer for fistulagram"
            },
            {
                "label": "D.",
                "text": "Prescribe heparin 2000 unit bolus and 500 units/h"
            },
            {
                "label": "E.",
                "text": "Prescribe dialyzer with surface area 2.1 m2"
            }
        ],
        "correct_answer": "Refer for fistulagram",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The next best step in management for this patient with an acute decrease in dialysis clearance and likely access recirculation is to refer for fistulagram and possibly angioplasty.The decreased Kt/V indicates inadequate dialysis delivery, as measured by urea clearance. In about 25% of the cases, decreased HD adequacy is due to access recirculation, in which dialyzed (venous) blood re-enters the extracorporeal (arterial) circuit, decreasing dialysis efficiency. Recirculation is often attributable to a dysfunctional dialysis access, frequently due to venous stenosis or thrombosis. Access recirculation can be measured by urea-based or non-urea-based methods. The method described in this case is the urea-based, 2-needle, slow flow method, using the following formula:Recirculation % = ([P - A] ÷ [P - V]) × 100% =(70-50)÷(70 - 10)× 100% = 33%P is the systemic or peripheral BUN, A is the BUN in the pre-dialyzer arterial line, and V is the BUN in the post-dialyzer venous line. A and V are drawn after approximately 30 minutes of treatment and with ultrafiltration turned off. P is obtained from the arterial needle 30 seconds or less after blood flow is reduced to 50 mL/min. Recirculation of more than 10–15% indicates significant access recirculation. This patient has an access recirculation measurement of 33% indicating the need to obtain a fistulagram.Increasing blood flow rate and dialyzer surface area are appropriate ways to improve clearance in the absence of access dysfunction, but in this case, addressing the cause of acute access recirculation is likely to be more effective and should be done as the next step. Heparin is commonly given during HD treatments but is not necessary in all cases, especially in the absence of needle or circuit clotting. eKt/V values are routinely lower than spKt/V values but do not provide any additional information or suggest therapeutic options in patients with reduced dialysis adequacy.",
        "references": []
    },
    "13": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 77-year-old woman is evaluated for 2 weeks of generalized weakness. Earlier in the day, she tripped on her carpet and fell but was not injured. She has chronic obstructive pulmonary disease (COPD) related to past tobacco use.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Her home medications include diltiazem extended-release 120 mg daily and hydrochlorothiazide 25 mg daily.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>She is afebrile; her BP is 146/62 mm Hg without orthostatic changes, heart rate 88/min, and weight 55 kg. She is in good spirits but confused. Examination is remarkable for mildly increased work of breathing, scattered wheezes, and diminished breath sounds. Heart exam and jugular venous pressure are normal, and there is no peripheral edema.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>The following laboratory test results are obtained:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                108 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                226 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                82 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                368 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><strong>In addition to discontinuing hydrochlorothiazide and implementing a 1-L fluid restriction, which of the following would be the NEXT BEST STEP in management?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "3% saline at 50 mL/h for 6 hours"
            },
            {
                "label": "B.",
                "text": "0.9% saline at 200 mL/h for 6 hours"
            },
            {
                "label": "C.",
                "text": "3% saline at 100 mL/h for 6 hours"
            },
            {
                "label": "D.",
                "text": "0.9% saline 500 mL bolus"
            }
        ],
        "correct_answer": "3% saline at 50 mL/h for 6 hours",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation": "3% saline at a low infusion rate is the most appropriate initial fluid management for this woman with severe, symptomatic hyponatremia.IIn the absence of antidiuretic hormone (ADH), patients with hyponatremia should be able to produce dilute urine with urinary osmolality <100 mOsm/kg H2O. Thiazides can limit the ability to produce dilute urine because they act in the distal convoluted tubule on the Na-Cl cotransporter. This region is sometimes called the “diluting segment,” because this segment is impermeable to water and therefore absorbs sodium and chloride without water. In the presence of a thiazide, the kidney may not be able to dilute the urine properly. Additionally, thiazide diuretics may cause hypovolemia with consequent non-osmotic stimulation of ADH secretion and water retention. In this case, the relatively high urine osmolality implies ADH activity, while the relatively high urine sodium concentration implies activity of the thiazide diuretic.In this case, the excess ADH may be related to volume depletion from chronic thiazide use or to COPD, but physical exam and laboratory data (BUN/creatinine ratio, urine sodium) do not support hypovolemia. If hypovolemia is the cause of hyponatremia, the patient is at risk for rapid correction of hyponatremia with volume resuscitation. It is likely that she also has the syndrome of inappropriate ADH (SIADH), but until potential volume depletion is addressed and the thiazide effect has been removed, this diagnosis cannot be clearly established. In the meantime, because of the severity of her hyponatremia and her symptoms of confusion, weakness and a recent fall, acute treatment is indicated to increase her sodium level. Because an increase of 4–6 mEq/L in the serum sodium is both safe and sufficient to reverse serious manifestations of hyponatremia, current recommendations target a 6 mEq/L increase in the serum sodium over 24 hours. With severe symptoms, the therapy should be designed to increase the sodium over the first 6 hours and then limit further increase such that the net change over 24 hours does not exceed the target of 6 mEq/L.Although hyponatremia represents a state of relative water excess compared with sodium, acute therapy is based on the addition of solute, usually as an infusion of sodium-containing solutions, rather than the removal of water, which occurs subsequently as the solute load is excreted in the urine.One strategy to accomplish this correction safely uses the following formula:Vol-inf = Δ[Na] × TBW/(inf Na + K) – NafVol-inf represents the infusate volume necessary to correct plasma sodium by the incremental goal or desired change in the sodium concentration.Δ[Na] represents the desired change in sodium concentration.TBW represents total body water (0.5 × body weight in kg for an older woman).Inf Na + K represents the sum of the sodium and potassium concentrations in the infusate.Nafrepresents the final (targeted) serum sodium.In this case, the Δ[Na] is 6 mEq/L. Therefore, for 3% saline, Vol-inf = 6 × (0.5 × 55)/(513 – 114) = 0.41 L.Thus, an infusion of 3% saline at 50 mL/h for 6 hours would accomplish the goal to increase the sodium concentration by 6 mEq/L. Because 3% saline has a [Na + K] of 513 mEq/L, which exceeds the urine [Na + K] of 182 mEq/L, there is no risk of worsening the hyponatremia with this fluid.Using this formula for 0.9% saline, Vol-inf = 6 × (0.5 × 55)/(154 – 114) = 4.1 L; thus, an infusion of 0.9% saline at 200 mL/h for 6 hours would be insufficient. More importantly, however, because 0.9% saline has a [Na + K] of 154 mEq/L, which is similar to the urine [Na + K] of 142 mEq/L, hyponatremia is unlikely to improve significantly with infusion of this fluid.Another strategy that has gained popularity is to infuse 3% saline at a fixed bolus volume of 100–150 mL as a one-time dose, especially in settings in which accurate and timely measurement of urine and serum parameters in symptomatic patients is not feasible, such as during marathon running. This approach is gaining popularity in the hospital setting as well because of its demonstrated safety and efficacy.A smaller volume of 0.9% saline of just 500 mL provides only 77 mEq of sodium and similarly provides insufficient correction of hyponatremia. This approach would be appropriate if it was determined that hypovolemia was the driver of ADH release, but this is unlikely in this case in which the patient is hypertensive without signs of volume depletion.This calculation for sodium deficit does not account for ongoing gain or loss of sodium, potassium, and water that must be considered over longer time periods (>6 hours). In addition, these calculations are used for the initial prescription, but repeated testing of the serum sodium is essential so that the infusion rate can be altered or discontinued altogether if the rate of change is too slow or too fast. Patients with thiazide-induced hyponatremia are at particular risk for rapid correction, and frequent measurement of plasma sodium concentration is mandatory. If the rate or magnitude of correction exceeds the target, relowering of plasma sodium concentration with water and desmopressin may be necessary.",
        "references": []
    },
    "14": {
        "question": "<div class=\"qtext\"><p>A 45-year-old woman with CKD stage 5 (eGFR 11 mL/min/1.73 m<sup>2</sup>) attributed to lupus nephritis presents to the emergency department with nausea, pruritis, shortness of breath, weight gain, dyspnea on exertion, and orthopnea. She has not experienced fever, chest pain, night sweats, rash, or arthralgias. She has never smoked.</p>\n<p>Medications include furosemide, calcitriol, sevelamer, sodium bicarbonate, and hydroxychloroquine.</p>\n<p>Her BP is 180/60 mm Hg, heart rate 85/min, temperature 36.8°C, and weight 80 kg, increased from 72 kg 1 month ago. Exam is significant for crackles to the middle of both lung fields and 3+ pitting edema to the knees bilaterally. She has asterixis. She has no murmurs or rubs, no jaundice or rashes, and no swollen joints.</p>\n<p>Her laboratory tests yield the following results:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>1 Month </strong>A<strong>go</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5700/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6200\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                183,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                162,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                95\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Antinuclear antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:120\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1:40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                110 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C-reactive protein (CRP)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤0.8\n            </td>\n</tr>\n</tbody>\n</table><p>Chest x-ray shows an enlarged heart with prominent vascular markings and cephalization. EKG shows normal sinus rhythm, low voltage, and left axis deviation. Echocardiogram shows a moderate pericardial effusion without signs of tamponade.<br/><br/></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><strong>Which of the following is the MOST likely diagnosis?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Bacterial pericarditis"
            },
            {
                "label": "B.",
                "text": "Uremic pericarditis"
            },
            {
                "label": "C.",
                "text": "Malignant pericardial effusion"
            },
            {
                "label": "D.",
                "text": "Lupus-related pericarditis"
            },
            {
                "label": "E.",
                "text": "Hemopericardium"
            }
        ],
        "correct_answer": "Uremic pericarditis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient with advanced CKD, volume overload, and a moderate pericardial effusion most likely has uremic pericarditis.Uremic pericarditis manifesting as pericardial effusion appears to be common in patients initiating dialysis, with a reported incidence of 32–56%. It is often asymptomatic, with one study reporting 36% of patients had an asymptomatic pericardial effusion at dialysis initiation, compared with only 6% who had the classic signs and symptoms of a pericardial friction rub and chest pain. Asymptomatic effusions are typically associated with signs of volume overload, including edema and radiographic evidence of fluid overload. Classic EKG findings of diffuse ST-segment elevations are rare. The treatment is dialysis initiation, which often will improve symptoms.Malignancy can be associated with pericarditis and pericardial effusions, but this is a rare finding, and often there would be a history or additional evidence of malignancy.Hemopericardium is similarly unlikely in this patient without thrombocytopenia, coagulopathy, or a history of trauma.Bacterial pericarditis is typically purulent and associated with high fever, tachycardia, chest pain, cough, and leukocytosis. It is not asymptomatic and will often present with the classic features, including diffuse ST-segment elevations on EKG.Although this patient has a history of lupus nephritis, she has no active symptoms and her markers of disease activity (C3, C4, and CRP) are all normal or minimally elevated, suggesting her lupus is quiescent. Lupus-related pericarditis occurs in the setting of active disease and is often symptomatic.",
        "references": []
    },
    "15": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old man presents to the emergency department with 2 days of recurrent chest pain. His medical history is significant for diabetes, hypertension, and CKD stage 4, with an eGFR of 22 mL/min/1.73 m<sup>2</sup> Home medications include aspirin, insulin, and lisinopril. He describes his chest pain as left-sided, radiating to the left arm, with associated nausea and shortness of breath. He has had similar pain with exertion in the past, but now symptoms occur at rest. He currently works full-time at a desk job. He smokes 1 pack of cigarettes per day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 100/52 mm Hg and heart rate 110/min. He appears diaphoretic and uncomfortable. He has no edema, heart exam is normal, and lungs are clear.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Medications given by the emergency medicine physicians include atorvastatin, clopidogrel, and heparin. Serial EKGs show 0.6-mm ST-segment depressions in leads I and aVL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>His laboratory tests yield the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>1 Month </strong>A<strong>go</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                47\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Troponin I\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                N/A\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.04\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 15px; margin-bottom: 20px;\">The cardiology team plans urgent coronary angiography and revascularization.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>In addition to volume expansion with isotonic fluid, which of the following is the MOST appropriate recommendation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "N-acetylcysteine IV"
            },
            {
                "label": "B.",
                "text": "Postprocedural hemodialysis"
            },
            {
                "label": "C.",
                "text": "Avoid IV contrast during revascularization"
            },
            {
                "label": "D.",
                "text": "No additional management"
            },
            {
                "label": "E.",
                "text": "Fenoldopam IV"
            }
        ],
        "correct_answer": "No additional management",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "The most appropriate recommendation is to proceed with volume expansion and coronary revascularization with no additional medical management.This patient with a TIMI (thrombolysis in myocardial infarction) risk score of 6 has a 41% risk of all-cause mortality, new or recurrent MI, or severe recurrent ischemia at 14 days. He should undergo cardiac catheterization and revascularization, in accordance with American Heart Association guidelines for high-risk patients. Studies show that patients with CKD do not receive angiography at the same rate as those without CKD, and it is speculated that fear of contrast-associated AKI (CA-AKI) leads to therapeutic nihilism, such that patients with CKD are managed without coronary angiography despite a high risk of mortality. Recent analyses and the 2018 update to the European Society of Urogenital Radiology Contrast Medium Safety Committee guidelines suggest that the risk of CA-AKI has been overstated and that beneficial therapies and imaging are frequently, and inappropriately, withheld from patients deemed to be at high risk for CA-AKI.Several large trials, including the 5100-patient PRESERVE trial, failed to show any benefit of oral N-acetylcysteine (NAC) on renal or other long-term outcomes. KDOQI guidelines state, “We suggest using oral NAC, together with IV isotonic crystalloids, in patients at increased risk of contrast-induced AKI,” which is graded as 2D (a weak recommendation based on low quality evidence). However, no organization recommends IV NAC, which is expensive, confers a risk of anaphylaxis, and could delay life-saving angiography.Fenoldopam, a dopamine agonist, showed some benefit in CA-AKI in uncontrolled studies. However, 2 prospective, randomized controlled trials did not confirm this result.There is no established benefit of post-procedure HD or hemodiafiltration to remove contrast. This patient has no other indication for renal replacement therapy.To date, is impractical to avoid IV contrast during coronary revascularization, as the most commonly used alternative agent, carbon dioxide, may precipitate cardiac arrhythmia. Successful coronary intervention without radiocontrast, using ultrasound guidance, has been reported in small series, but these patients first had conventional coronary angiograms to define anatomy.",
        "references": []
    },
    "16": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 20px;\">A 65-year-old woman with ESRD is evaluated for poor sleep and chronic fatigue. She receives CAPD using four 2-L exchanges each day. Her most recent weekly Kt/V was 1.7. Her iron studies show a ferritin of 80 ng/mL (reference range, 11–307) and a transferrin saturation of 19% (reference range, 20–50). A sleep study reveals that she has obstructive sleep apnea (OSA). Nocturnal continuous positive airway pressure is prescribed and titrated, but poor sleep and associated fatigue persist.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is MOST likely to improve this patient’s obstructive sleep apnea?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change to nocturnal PD"
            },
            {
                "label": "B.",
                "text": "Prescribe cognitive behavioral therapy"
            },
            {
                "label": "C.",
                "text": "Change to HD"
            },
            {
                "label": "D.",
                "text": "Prescribe IV iron"
            },
            {
                "label": "E.",
                "text": "Increase exchange volume to 2.5 L"
            }
        ],
        "correct_answer": "Change to nocturnal PD",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "Changing this patient’s dialysis modality to nocturnal PD is the most appropriate next step in the management of OSA.Nocturnal dialysis has been shown to improve the apnea-hypopnea index (the number of apnea or hypopnea episodes per hour of sleep). Even a modest degree of fluid shift while recumbent can increase neck circumference and airway resistance. Nocturnal PD offers improvements in the apnea-hypopnea index compared with CAPD, possibly by mitigating any fluid shift. Nocturnal HD has also been shown to reduce the apnea-hypopnea index compared with conventional HD, but there are no data comparing PD with HD.Iron deficiency is associated with restless legs syndrome, and its correction may offer relief. There is no evidence that iron deficiency or its correction affect OSA.Cognitive behavioral therapy has been proposed as a treatment for insomnia in patients receiving dialysis but is not effective in managing OSA.",
        "references": []
    },
    "17": {
        "question": "<div class=\"qtext\"><p>A 42-year-old woman is referred for evaluation of CKD stage 3, hypocalcemia, and hyperphosphatemia after her primary care physician identified abnormal laboratory findings on routine testing. Prior to this evaluation, she had not seen a physician in several years. She has no significant medical history, although she recalls that in her 20s, she was prescribed calcium and vitamin D to correct “low calcium levels.” She took these for more than a decade but stopped several years ago. Her father and a male first cousin also had a “calcium problem.” She is currently asymptomatic. Her physical exam is unremarkable.  A recent ultrasound shows normal-sized kidneys with calcifications in the renal medulla.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory test results are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                48 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24-Hour calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                300 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;250\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 15px;\"><strong>Which of the following is the MOST likely pathophysiologic explanation for this patient’s findings?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fibroblast growth factor 23 (FGF-23) resistance"
            },
            {
                "label": "B.",
                "text": "Impairment of proximal tubular sodium phosphate transport"
            },
            {
                "label": "C.",
                "text": "Hypocitraturia"
            },
            {
                "label": "D.",
                "text": "Overactivation of the calcium sensor"
            },
            {
                "label": "E.",
                "text": "Underactivation of the calcium sensor"
            }
        ],
        "correct_answer": "Overactivation of the calcium sensor",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "The clinical presentation, along with the family history, suggests that this patient likely has autosomal dominant hypercalciuric hypocalcemia (ADHH), a condition of overactivity of the calcium-sensing receptor (CaSR).ADHH is a genetic disorder characterized by an activating mutation of theCASRgene. The result of this mutation is that the relationship between calcium and PTH is altered such that calcium concentrations that normally trigger PTH release no longer do so. PTH levels are often low or low-normal. Patients with ADHH have low calcium levels due to insufficient PTH release. In the kidney, insufficient PTH leads to a decrease in active calcium reabsorption and hypercalciuria. Activation of the CaSR in the kidneys also exerts a loop diuretic-like effect in the thick ascending loop of Henle (TAL), reducing sodium chloride reabsorption and decreasing lumen positivity, leading to a decrease in renal calcium reabsorption. Medullary nephrocalcinosis can be precipitated by attempts to normalize the serum calcium via administration of calcium and vitamin D.Magnesium handling is also altered with CaSR activation via the same mechanism. Decreased TAL lumen positivity decreases magnesium absorption, predisposing to renal magnesium wasting and hypomagnesemia. Thus, serum magnesium levels are often low in this disorder.Insufficient PTH increases the abundance of the renal sodium-phosphate cotransporters (Npt2a, Npt2c, and PiT-2) on the apical membrane of the proximal convoluted tubule, leading to increased phosphorus reabsorption and mild hyperphosphatemia. Urine phosphorus in this situation will be low, not high.An inactivating mutation of theCASRgene results in the syndrome of familial hypocalciuric hypercalcemia.Both inherited and acquired syndromes of FGF-23 resistance have been described. The inherited form is associated with ectopic calcifications and painful tumoral calcinosis. The serum calcium in these disorders is normal or high, rather than low.X-linked rickets is a hypophosphatemic disorder of impaired proximal tubular phosphate reabsorption leading to renal phosphate wasting. Although female carriers can display abnormalities, it most commonly presents in male children as bone and dental abnormalities and lower extremity bowing.Hypocitraturia is a nonspecific feature of a variety of renal disorders that can lead to nephrocalcinosis but would not account for hypocalcemia or hyperphosphatemia.",
        "references": []
    },
    "18": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 68-year-old woman with CKD stage 3 attributed to hypertension and previously treated lymphoma with suspected recurrence is evaluated for a change in kidney function. The patient feels well and has not experienced dysuria, urgency, or gross hematuria or noticed any change in urine output.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data reveal that the serum creatinine has increased from 1.5 mg/dL to 2 mg/dL over the past 2 weeks (reference range, 0.5–1.1). Kidney ultrasound shows right-sided hydronephrosis and new pelvic lymphadenopathy. Diuretic scintigraphy reveals split kidney function of 35% (right) and 65% (left) and delayed excretion from the right kidney after diuretic challenge.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A urinary catheter is placed. Three days later, the serum creatinine is unchanged. Urine output is 2.5 L/d.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Retrograde pyelography is performed, demonstrating extrinsic compression of the right ureter; right ureteral stent placement is attempted but unsuccessful.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Two hours later, the patient becomes anuric. Her BP is 124/86 mm Hg, heart rate 70/min, and oxygen saturation 98% on room air. Repeat kidney ultrasound shows persistent right hydronephrosis, normal arterial and venous flow, and no stones. Urinalysis shows 1+ protein and no RBCs or WBCs.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Anuria persists over the next 12 hours, and serum creatinine increases to 4 mg/dL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the MOST likely cause of this patient’s anuric AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute tubular necrosis"
            },
            {
                "label": "B.",
                "text": "Bilateral renal vein thrombosis"
            },
            {
                "label": "C.",
                "text": "Reflex anuria"
            },
            {
                "label": "D.",
                "text": "Progressive obstruction"
            },
            {
                "label": "E.",
                "text": "Contrast-associated AKI"
            }
        ],
        "correct_answer": "Reflex anuria",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "The most likely cause of this patient’s anuric AKI is reflex anuria (RA).RA is described as cessation of urine output frombothkidneys in response to irritation of or trauma to one kidney or its ureter or severely painful stimuli to other organs. The pathogenesis remains incompletely understood. Proposed mechanisms of RA involve reflex bilateral intrarenal arteriolar spasm or ureteral spasm. RA has been reported in cases of unilateral ureteral obstruction, in which the contralateral kidney appears nonfunctional despite an absence of anatomic obstruction or any direct manipulation of the unobstructed kidney or ureter.RA is a diagnosis of exclusion. Other causes of anuria, such as bilateral ureteral obstruction, renovascular occlusion, acute tubular necrosis (ATN), cortical necrosis, intrinsic kidney disease, severe infection, and hemodynamic instability, must all be excluded. Importantly, RA is a functional condition, not a parenchymal disease.This patient experienced acute anuria 2 hours after ureteral manipulation with attempted stent placement, consistent with the diagnosis of RA. She had preexisting AKI from unilateral obstruction, but this alone would not account for the sudden loss of urine output, particularly given the normal left kidney on prior functional imaging. Moreover, repeat kidney ultrasound did not show any evidence of progressive or new anatomic obstruction.ATN is a common cause of AKI, but more commonly presents with oliguria than anuria. In this case, there is no identifiable cause of ATN, such as hypotension, ischemia, or toxin exposure.Bilateral renal vein thrombosis can cause acute anuria but more commonly would present with hematuria, proteinuria, decreased kidney function, or some combination of these features. It can also be clinically silent. In this case, neither the clinical history nor the ultrasound findings suggest this diagnosis.Contrast-associated AKI (CA-AKI) is an established potential cause of post procedure AKI. Retrograde pyelography, however, does not involve IV contrast exposure and would not explain AKI in this patient. Anuria would not be expected to result from CA-AKI.",
        "references": []
    },
    "19": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">An 83-year-old man with ESRD receiving long-term HD expresses his wish to stop dialysis and transition to hospice care.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient has been hospitalized with multilobar pneumonia for the past 2 weeks. He is extremely fatigued, and his functional status has markedly declined. He spends most of the day in bed. Prior to this admission, he had also experienced back pain,\n    itching, leg swelling, and poor appetite.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, vital signs include temperature 37°<span>C, BP 100/50 mm Hg, heart rate 94/min, and oxygen saturation 98% while receiving 3 L/min supplemental oxygen. He has bilateral lung crackles and 1+ lower extremity pitting edema.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14,200/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                226,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                135 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                94 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 20px; margin-bottom: 20px;\">The patient asks how long he is expected to live after stopping dialysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the BEST APPROXIMATION for this patient’s life expectancy after withdrawal from dialysis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "2–3 weeks"
            },
            {
                "label": "B.",
                "text": "7–10 days"
            },
            {
                "label": "C.",
                "text": "3–4 weeks"
            },
            {
                "label": "D.",
                "text": ">4 weeks"
            },
            {
                "label": "E.",
                "text": "<3 days"
            }
        ],
        "correct_answer": "7–10 days",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient’s life expectancy after discontinuing dialysis is 7–10 days.Several early studies described typical survival times of 7–10 days after discontinuing long-term dialysis. A more recent study by O’Connor et al. also showed that in patients who discontinued HD, the mean survival after hospice enrollment was 7.4 days but ranged from 0–40 days. Predictors of rapid decline among patients who discontinued dialysis included male sex, supplemental oxygen requirement, presence of peripheral edema, poor functional status (Palliative Prognostic Score <20), and admission to hospice from an inpatient setting. Another single-center study performed in 2018 corroborated these findings, demonstrating a median time to death of 7 days (interquartile range 4–11), with the majority of deaths occurring <10 days after withdrawal from long-term dialysis.Of note, when counseling patients with advanced CKD regarding anticipated prognosis without dialysis, it is important to distinguish between expected survival of patients withdrawing from long-term dialysis versus those opting not to initiate dialysis at all. Long-term dialysis is associated with progressive loss of residual renal function such that the anticipated survival after dialysis discontinuation is usually in the range of days, as discussed above. In contrast, those patients with CKD stage 5 who have selected conservative management (also called medical management, maximal conservative management, or non-dialysis care), often experience some preservation of residual renal function. A systematic review of several studies suggests that median survival after electing to forgo dialysis is at least 6 months but may range widely between 6–23 months depending on factors such as age, functional status, and comorbid conditions.",
        "references": []
    },
    "20": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 75-year-old woman with a history of osteoarthritis and hypertension presents to the emergency department with lethargy and a 2 day history of diarrhea and vomiting. Her home medications include aspirin 81 mg daily and hydrochlorothiazide 25 mg daily.\n    On her arrival at the emergency department, blood is drawn for analysis, and she is infused with 1 L of 0.9% saline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 92/54 mm Hg and heart rate 110/min. Examination reveals an older woman in no distress with dry mucous membranes and reduced skin turgor. She is confused and slow to respond to directions but is without focal motor or sensory abnormalities\n    on neurologic examination.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                114 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                92 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                250 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolarity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                550 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–1400\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>In addition to discontinuing hydrochlorothiazide, which of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "3% saline at 30 mL/h"
            },
            {
                "label": "B.",
                "text": "3% saline at 30 mL/h with 2 µg desmopressin IV"
            },
            {
                "label": "C.",
                "text": "Water restriction to 1 L/d and 0.9% saline at 200 mL/h"
            },
            {
                "label": "D.",
                "text": "0.9% saline at 200 mL/h with 2 µg desmopressin IV"
            },
            {
                "label": "E.",
                "text": "Water restriction to 1 L/d and salt tablets 1 g three times daily"
            }
        ],
        "correct_answer": "3% saline at 30 mL/h with 2 µg desmopressin IV",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation": "Controlled correction of hyponatremia with a combination of 3% saline and IV desmopressin is indicated for this patient with severe hyponatremia of uncertain duration and a risk for over-rapid correction.This patient presents with hyponatremia of unknown duration, and as a result, she is at risk for osmotic demyelination should she correct too rapidly. Her history—vomiting and diarrhea, thiazide use, low BP, rapid heart rate, poor skin turgor, and low urine sodium—suggests that her hyponatremia is hypovolemic in origin. She is therefore at a high risk for over-rapid correction now that she has received a bolus of normal saline in the emergency department.In patients with severe hyponatremia, the administration of desmopressin along with 3% saline at the time of presentation has been shown in 2 studies to lead to a predictable rate of increase in serum sodium concentration without over-rapid correction. This proactive approach induces a state similar to the syndrome of inappropriate antidiuretic hormone (SIADH) and prevents the water diuresis seen in patients with hypovolemic hyponatremia after volume resuscitation. Desmopressin should be given every 8 hours until the serum sodium concentration is >125 mEq/L. The rate of administration of 3% saline can be adjusted to achieve the goal increase in sodium of 6–8 mEq/L every 24 hours until the sodium concentration approaches normal. Note that over-rapid correction can occur in the setting of thiazide-associated hyponatremia on withdrawal of the offending agent, even in the absence of IV volume expansion.Water restriction with normal saline could result in over-rapid correction, whereas desmopressin with normal saline could impair correction of hyponatremia by allowing “desalination” of the fluid administered. Similarly, 3% saline administered alone could cause over-rapid correction. Water restriction with salt tablets would likely be insufficient to correct this patient’s profound hypovolemia, and its effect on her sodium concentration would be less predictable.",
        "references": []
    },
    "21": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 79-year-old man with ESRD due to diabetic nephropathy was started on long-term HD 3 weeks ago via an AV fistula (AVF). He is tolerating dialysis treatments well but continues to have poor glycemic control and recently began taking insulin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His medical history includes congestive heart failure and chronic obstructive pulmonary disease. He receives 2 L/min supplemental home oxygen via nasal cannula. An echocardiogram has demonstrated pulmonary hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Social history reveals remote tobacco and marijuana use. The patient describes having little social support; he is widowed and lives alone, and his only daughter resides in another state.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data show the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient hopes to attend his daughter’s wedding in 3 months but worries that his time may be limited.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is MOST strongly associated with an increased risk of death in this patient in the next 3–6 months?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Reduced serum albumin level"
            },
            {
                "label": "B.",
                "text": "Limited social support"
            },
            {
                "label": "C.",
                "text": "Poor glycemic control"
            },
            {
                "label": "D.",
                "text": "Cause of ESRD"
            },
            {
                "label": "E.",
                "text": "Use of AVF"
            }
        ],
        "correct_answer": "Reduced serum albumin level",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient’s reduced serum albumin level predicts an increased risk of death in the next 3–6 months.Prognostic models have been developed to more accurately predict early mortality for patients with ESRD receiving HD. Investigators created a risk stratification algorithm assessing mortality in the first 3 months of dialysis for patients older than 75 years using a French national registry (Renal Epidemiology and Information Network, or REIN). Male sex, age >85 years, congestive heart failure, severe peripheral vascular disease (PVD), dysrhythmia, severe behavioral disorders, active malignancy, decreased serum albumin (significant if <3.5 g/dL; greatest effect if <2.5 g/dL), and impaired mobility were independently associated with 3-month mortality.Cohen et al. also developed a prognostic tool assessing 6-month mortality for patients receiving maintenance HD in the United States. Five variables were independently associated with earlier mortality: negative response to the Surprise Question (“Would I be surprised if this patient died within the next 6 months?”), older age, decreased albumin level, dementia, and PVD. Further evaluation of this model is warranted; nevertheless, it provides insight into risk factors for increased mortality for patients receiving dialysis.Based on these findings, various sources have proposed guidelines to help patients better anticipate survival on dialysis. The Renal Physicians Association recommends further conversation with patients at high risk of poor outcomes with dialysis, i.e., those with 2 or more of the following: age >75 years; high comorbidity index (e.g., Charlson Comorbidity Index); poor functional status or disability (e.g., Karnofsky Performance Status); and evidence of severe chronic malnutrition and/or inflammation as manifested by serum albumin <2.5 g/dL. Hyponatremia also appears to confer a worse prognosis but may be confounded by its association with other conditions. Despite concerns that AVFs with high flow rates may contribute to pulmonary hypertension, they remain the preferred vascular access and are associated with lower mortality rates than either AV grafts or tunneled catheters.The cause of ESRD, poor glycemic control, and limited social support have not been identified as predictors of increased early mortality for patients receiving HD.",
        "references": []
    },
    "22": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 70-year-old man with CKD stage 5 receiving maximal conservative management (non-dialysis care) is seen in follow-up.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His kidney function has remained stable, but he has experienced progressively severe itching of his back, chest, and arms. The itching causes him severe frustration and interferes with his quality of life.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient uses skin moisturizers daily and avoids scratching. His medications include phosphate binders, cholecalciferol, sodium bicarbonate, and IV iron. He declines initiation of dialysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Physical examination shows a thin, older man. Vital signs are BP 124/70 mm Hg, heart rate 68/min, and oxygen saturation 99% on room air. His skin is warm, dry, and intact; there are no localized lesions, excoriations, or ulcerations.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Laboratory studies include the following:</strong></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"width: 60%; border-collapse: collapse; border: 1px solid rgb(0, 0, 0);\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"50%\"><br/></td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25%\">\n<p dir=\"ltr\"><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"25%\">\n<p dir=\"ltr\"><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">WBC count</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">8800/μL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">10.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Platelets</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">438,000/μL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Sodium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">141 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Potassium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">5.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">BUN</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">38 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Creatinine</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">4.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Calcium</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">8.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Phosphorus</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">3.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">PTH, intact</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">235 pg/mL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">10–65</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">14 U/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">13 U/L</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">0.3 mg/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">0.3–1.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"224\">\n<p dir=\"ltr\">Albumin</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">3.0 g/dL</p>\n</td>\n<td style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"156\">\n<p dir=\"ltr\">3.5–5.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\">The patient asks if there are any other treatments that might ameliorate his itching.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is MOST likely to decrease this patient’s pruritus?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acupuncture"
            },
            {
                "label": "B.",
                "text": "Gabapentin"
            },
            {
                "label": "C.",
                "text": "Cholestyramine"
            },
            {
                "label": "D.",
                "text": "Tacrolimus ointment"
            },
            {
                "label": "E.",
                "text": "Ultraviolet A"
            }
        ],
        "correct_answer": "Gabapentin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "Gabapentin is most likely to decrease this patient’s pruritus.Uremic pruritus (UP) is a common symptom in patients with CKD and ESRD. Patients frequently describe generalized itching, but the clinical presentation is variable. Non-uremic causes of pruritus (e.g., dermatologic, hepatobiliary, neurologic) must be ruled out. Unfortunately, evidence for the treatment of UP is limited; many proposed therapies are not well studied.There are no formal guidelines for UP treatment, but a stepwise approach is recommended. After optimizing dialysis adequacy (if the patient receives dialysis) and calcium-phosphorus-PTH parameters, the progression of interventions includes a trial of (1) intensive skin moisturization using emollients and lotions, for which there are limited data but little downside; (2) gabapentin or pregabalin; and (3) opioid receptor modulators, ultraviolet (UV) B phototherapy, or acupuncture. Additionally, difelikefalin was approved for HD-related pruritis in 2021. This drug is injected thrice weekly post-HD. It is not approved for patients with CKD who are not receiving HD, nor is it approved for patients receiving PD.The strongest evidence exists for the use of gabapentin in UP treatment. The pathophysiology of UP is not fully understood but is believed to involve multiple mechanisms, including uremic neuropathy, nerve and skin inflammation, and μ-opioid receptor activity upregulation. In this context, gabapentin acts as a modulator of excitatory neurotransmitters.A recent systematic review evaluating more than 40 randomized controlled trials (RCTs) and 39 interventions for UP in patients receiving HD found the most robust support for gabapentin. Gunal et al. showed that administering gabapentin 300 mg three times weekly after dialysis for 4 weeks resulted in a statistically and clinically significant decrease in pruritus. Similarly, a qualitative systematic review of 7 studies demonstrated the effectiveness of gabapentin in refractory UP.Although most studies were conducted in patients receiving HD, gabapentin is thought to have similar efficacy in patients with CKD. Cheikh Hassan et al. demonstrated that in conservatively managed patients with CKD (non-dialysis), gabapentin decreased the severity of pruritus to a degree comparable with that of patients receiving HD. However, adverse effects were more common in those not receiving HD.UVA radiation has not been shown to improve UP. In contrast, UVB phototherapy has been associated with a significant reduction in UP, but is less readily available and less convenient than an oral medication.Cholestyramine and tacrolimus ointment are among several suggested therapies for UP, but their efficacy has not been established in RCTs. Data on naltrexone have been inconsistent. Acupuncture has been reported to improve UP, but because of the high risk of study bias, its use as first-line therapy is not widely supported. Antihistamines have not been reliably effective and are prone to sedative side effects. Thalidomide showed promise in a small study but published experience is limited.",
        "references": []
    },
    "23": {
        "question": "<div class=\"qtext\"><p>A 55-year-old woman is admitted to the ICU with pneumonia complicated by hypoxic respiratory failure and septic shock. On presentation, her BP is 80/46 mm Hg, heart rate 120/min, and temperature 38.4°C. Laboratory studies are notable for leukocytosis.</p>\n<p>The patient is intubated and treated with vancomycin 1 g every 12 hours and piperacillin/tazobactam 3.375 g every 8 hours. Because of persistent hypotension, she is also treated with norepinephrine and vasopressin to maintain her mean arterial BP &gt;60 mm Hg.</p>\n<p>Over the next 72 hours with this regimen, her BP improves to 100/62 mm Hg and heart rate to 96/min. She remains intubated and sedated. Physical exam demonstrates no edema. Laboratory data are notable for a gradual decrease in sodium concentration over 3 days from 141 to 130 mEq/L (reference range, 136–145). Urine osmolality is 410 mOsm/kg H<sub>2</sub>O (reference range, 38–1400). A chest x-ray demonstrates left lower lobe consolidation, but the other lung fields are clear.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>In addition to restricting free water, which of the following is the MOST appropriate next step to manage this patient’s hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer IV furosemide"
            },
            {
                "label": "B.",
                "text": "Replace vasopressin with epinephrine"
            },
            {
                "label": "C.",
                "text": "Infuse 3% saline"
            },
            {
                "label": "D.",
                "text": "Administer IV medications in saline"
            },
            {
                "label": "E.",
                "text": "Administer IV hydrocortisone"
            }
        ],
        "correct_answer": "Administer IV medications in saline",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation": "The most appropriate next step in management of this critically ill patient with hyponatremia is to restrict free water intake and administer medications in saline, rather than 5% dextrose, when possible.Hyponatremia is common in the ICU, occurring in up to 25% of patients. Even mild hyponatremia is an independent risk factor for mortality and increased length of ICU stay. The most likely etiology of hyponatremia in this case is baroreceptor-mediated release of antidiuretic hormone along with the administration of hypotonic fluids. Because the rate of decrease in the sodium level has not been dramatic and the sodium is >120 mEq/L, the administration of 3% saline would not be indicated. Minimization of hypotonic fluid load is a key component of the management of hypotonic hyponatremia. In this case, administration of medications in isotonic saline will reduce the hypotonic fluid load and ameliorate hyponatremia.Vasopressin acts on three G-protein-coupled receptor types. V1R receptors in vascular smooth muscle cause potent vasoconstriction. V2R receptor activation in the kidney results in free water reabsorption in the collecting duct. V3R receptors mediate the release of adrenocorticotropic hormone from the pituitary. In the initial phases of septic shock, there is rapid depletion of endogenous vasopressin and V1R expression decreases acutely, likely because of endotoxemia. However, prolonged vasodilatory shock leads to vasopressin hypersensitivity due to both an increase in receptor expression and a higher binding affinity of the V1R. In contrast, V2R expression decreases in vasodilatory shock. In addition, vasopressin stimulates the release of atrial natriuretic peptide, leading to higher urine sodium excretion and natriuresis. The functional effect of these physiologic changes is that vasopressin administration in patients with septic shock does not routinely lead to hyponatremia. In the Vasopressin and Septic Shock Trial (VASST), for example, in which norepinephrine was compared with vasopressin, only 1 of 396 patients treated with vasopressin developed severe hyponatremia (serum sodium <130 mEq/L). Thus, discontinuing vasopressin would not be indicated.Corticosteroids are sometimes administered to critically ill patients with septic shock and are also used to treat several other steroid-responsive disorders, such as obstructive lung disease exacerbations. However, hydrocortisone has not been shown to be effective in the treatment of hyponatremia in patients in the ICU in the absence of clear evidence of adrenal insufficiency. Furosemide might increase free water excretion once the medullary concentrating gradient is depleted but would not be indicated in this hypotensive, tachycardic patient without evidence of volume overload.",
        "references": []
    },
    "24": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with ESRD due to anti-GBM disease is admitted with shortness of breath. He has had subjective fever and a productive cough for 3 days prior to presentation. He last received HD yesterday and achieved his estimated dry weight (EDW). Two years ago, he was diagnosed with anti-GBM disease by kidney biopsy and serology. He underwent plasmapheresis and 6 months of immunosuppression with cyclophosphamide and corticosteroids. He did not recover kidney function, but pulmonary involvement abated and his anti-GBM antibody levels became undetectable. </p>\n<p>Other medical history includes prior tobacco use and hypertension. He quit smoking at the time of his diagnosis of anti-GBM disease. Current medications include lisinopril, carvedilol, phosphate binders, and vitamins. He is adherent to his dialysis regimen and typically undergoes ultrafiltration of 2 L over each 4-hour dialysis session.</p>\n<p>TThe patient appears breathless. His BP is 160/95 mm Hg, heart rate 80/min, temperature 37.9°C, and oxygen saturation 91% on ambient air. His weight is 0.5 kg above his EDW. Examination findings include bibasilar crackles, an S4 gallop, a well-functioning left radiocephalic arteriovenous fistula, and trace pretibial edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12,500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.3 g/dL (baseline 2 weeks ago, 11 g/dL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Troponin I\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.06 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.04\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                B-type natriuretic peptide (BNP)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                849 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;100\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                N-terminal pro-BNP\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1500 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤300 for age 0–75 years\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\">His chest x-ray shows bilateral interstitial and alveolar opacities with air bronchograms identified in the left lower lobe. EKG shows left ventricular hypertrophy but no evidence of ischemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Community-acquired pneumonia"
            },
            {
                "label": "B.",
                "text": "Chronic obstructive pulmonary disease (COPD) exacerbation"
            },
            {
                "label": "C.",
                "text": "Pneumocystis jirovecipneumonia"
            },
            {
                "label": "D.",
                "text": "Pulmonary hemorrhage"
            },
            {
                "label": "E.",
                "text": "Congestive heart failure"
            }
        ],
        "correct_answer": "Community-acquired pneumonia",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The most likely diagnosis in this patient with ESRD presenting with cough, dyspnea, and low-grade fever is community-acquired pneumonia (CAP). The terminology of pneumonia in non-hospitalized patients receiving HD is evolving and some authors prefer the terms “HD-associated pneumonia” or “healthcare-associated pneumonia” (HCAP) because respiratory infections in patients receiving HD may be similar to those acquired by hospitalized or healthcare-institutionalized patients. However, at least some studies have found that the bacteriology of pneumonia in patients receiving HD is more similar to CAP than HAP, and that prolonged IV antibiotic therapy may not be necessary.Dyspnea is a common presentation in patients with ESRD. Distinguishing among fluid overload, congestive heart failure, and infection is challenging and requires interpretation of clinical, laboratory, and radiographic data. Chest radiography alone has a sensitivity and specificity of only 50–60% for the diagnosis of pneumonia in patients with ESRD. Chest computed tomography and lung ultrasound are emerging as diagnostic tools that have improved accuracy but may not be immediately available in many emergency departments.B-type natriuretic peptide (BNP) is secreted from the left ventricle in response to volume overload and wall stress. BNP is secreted as pro-BNP, which is cleaved into active BNP and inactiveN-terminal pro-BNP (NT pro-BNP). Both BNP and NT pro-BNP levels are equally useful in establishing a diagnosis of acute decompensated heart failure in patients with normal kidney function, although NT pro-BNP levels show less variability than BNP. BNP is cleared by both receptor-mediated endocytosis andurinary excretion, whereas NT pro-BNP is mostly cleared by urinary excretion. Levels of both BNP and NT pro-BNP may be elevated in ESRD because of reduced clearance, volume overload, left ventricular hypertrophy, or left ventricular dysfunction. Thus, in patients with ESRD, BNP levels are not a reliable indicator of heart failure or volume status, and incorporation of BNP or NT pro-BNP levels have not been shown to improve management. However, several studies have shown that increased BNP levels are important predictors of mortality and adverse cardiovascular events in patients with ESRD.Pneumocystis jirovecipneumonia is an opportunistic infection that can occur in patients who have undergone intensive immunosuppression for autoimmune disease or transplantation. However, this patient has not received immunosuppression for 18 months and would no longer be at risk for this complication.Recurrent pulmonary hemorrhage can mimic either pulmonary edema or infection but would be unusual in patients with anti-GBM disease who have had successful normalization of anti-GBM antibody levels with immunosuppression.COPD exacerbation can present with features similar to those of CAP but requires a diagnosis of COPD, which is lacking in this patient. Furthermore, the history of fever and air bronchograms on chest x-ray favors a diagnosis of CAP.",
        "references": []
    },
    "25": {
        "question": "<div class=\"qtext\"><p>A 35-year-old man is referred to nephrology clinic for evaluation of hypokalemia and hypomagnesemia. He developed type 2 diabetes at age 11 years. His blood sugar is well controlled. He has no history of nephrolithiasis, gout, or liver disease. Family history is significant for ESRD in the patient’s father and paternal aunt. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His BP is 138/76 mm Hg, and the remainder of the physical examination is normal. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Laboratory studies are normal except for the following:</strong></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.3 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 20px;\">CT scan of the abdomen reveals numerous small cysts along the corticomedullary junction of both kidneys and an atrophic pancreas.</p>\n<p style=\"margin-bottom: 15px;\"><strong>A defect in which of the following is MOST likely cause of this patient’s clinical syndrome?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hepatocyte nuclear factor-1ß"
            },
            {
                "label": "B.",
                "text": "Claudin-16/paracellin-1"
            },
            {
                "label": "C.",
                "text": "H+-ATPase"
            },
            {
                "label": "D.",
                "text": "Fibrocystin/polyductin"
            },
            {
                "label": "E.",
                "text": "NaCl cotransporter"
            }
        ],
        "correct_answer": "Hepatocyte nuclear factor-1ß",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "A defect in hepatocyte nuclear factor-1β (HNF1β) is the most likely cause of this patient’s presentation characterized by hypomagnesemia, CKD, and early onset of type 2 diabetes mellitus. HNF1β is a transcription factor that is involved in the development of the kidney, urogenital tract, pancreas, parathyroid glands, brain, and liver; therefore, mutations in the gene for this transcription factor have a variable phenotype and may include multiple abnormalities. The most common presentation includes early-onset type 2 diabetes along with pancreatic atrophy, hypokalemia, and hypomagnesemia. This disorder was previously called maturity-onset diabetes of youth (MODY) type 5 or “renal cyst and diabetes syndrome.” This condition may mimic Gitelman syndrome because of hypomagnesemia and hypokalemia.Mutations in the gene encoding HNF1β is one of several disorders recognized recently that are characterized by autosomal dominant non-glomerular kidney disease, which results in progressive tubulointerstitial fibrosis and progression to ESRD. This family of disorders has been reclassified as autosomal dominant tubulointerstitial kidney disease (ADTKD). Typical features of these disorders include autosomal dominant inheritance, progressive CKD, bland urinary sediment, absent or mild proteinuria, and absence of hypertension in the early stages of disease. A renal concentrating defect is typically present. Histopathology usually features interstitial fibrosis, tubular atrophy, tubule microcysts, and basement membrane lamellation; immunofluorescence is negative for immunoglobulins and complement. ADTKD subtypes are further classified by the causative gene mutation.Mutations in the genes for uromodulin, renin, and mucin are some of the genetic defects described to date. Defects in theUMODgene for uromodulin are also associated with hyperuricemia and early-onset gout. Previous terminology for this disorder includes medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy (FJHN) type 1, and uromodulin-associated kidney disease. Mutations in theRENgene for renin, previously termed FJHN type 2, are associated with hyperuricemia, hyperkalemia, childhood anemia, and mild hypotension.Fibrocystin/polyductin is abnormal in autosomal recessive polycystic kidney disease, which is characterized by massive kidney enlargement and cystic dilation of the intrahepatic biliary system (Caroli disease). Claudin-16/paracellin-1 is dysfunctional in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. The NaCl cotransporter in the distal tubule is inactivated in Gitelman syndrome, the clinical presentation of which has been likened to the use of thiazide-type diuretics.Defective function of the cortical collecting duct H+-ATPase has been implicated in some cases of medullary sponge kidney.",
        "references": []
    },
    "26": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with a history of ANCA-associated vasculitis (AAV) is evaluated for recurrent infections. She initially presented 24 months ago with polyarthralgia, nasal crusting, recurrent sinusitis, and AKI. Microscopic analysis of the urine sediment was notable for glomerular hematuria. Kidney biopsy showed pauci-immune crescentic glomerulonephritis with tuft fibrinoid necrosis, cellular crescents, and minimal interstitial fibrosis and tubular atrophy (see photomicrograph). She underwent induction therapy with corticosteroids and 2 doses of rituximab 1 g IV administered 2 weeks apart. Her symptoms remitted and kidney function improved. She discontinued taking corticosteroids after tapering the dose over 6 months. Her maintenance immunosuppression regimen is rituximab 1 g IV every 6 months. She remains in clinical remission but has experienced multiple episodes of bronchitis, bacterial pneumonia, and urinary tract infections. Her medical history includes hypertension.</p>\n<p>Current medications include carvedilol 12.5 mg twice daily, calcium carbonate 1 g daily, vitamin D3 1000 IU daily, and trimethoprim-sulfamethoxazole daily. The most recent dose of rituximab was 4 weeks ago.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span> Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Result at Time of Diagnosis</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Result After 24 Months</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\"><strong>\n                Reference Range\n            </strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-myeloperoxidase antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                116 U/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.4 (negative)<br/>0.4–0.9 (equivocal)<br/> ≥1 (positive)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum immunoglobulin G (IgG)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                600–1700\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                CD19 B cells\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1% total lymphocytes\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.3–20\n            </td>\n</tr>\n</tbody>\n</table>\n<p>The image is a trichrome stain of a glomerulus from this patient at the time of diagnosis demonstrating tuft necrosis (thin arrow) and cellular crescent (thick arrow).</p>\n<p></p>\n<figure><img alt=\"Picture 1\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/140_blobid0.jpg\" style=\"width: 5.70241in; height: 4.77252in;\"/>\n<figcaption><em>Image courtesy of Harsharan Singh, MD, University of North Carolina</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><span><strong>Which of the following options is the NEXT best step in management?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Infuse IV immunoglobulin"
            },
            {
                "label": "B.",
                "text": "Discontinue rituximab"
            },
            {
                "label": "C.",
                "text": "Substitute cyclophosphamide for rituximab"
            },
            {
                "label": "D.",
                "text": "Substitute methotrexate for rituximab"
            },
            {
                "label": "E.",
                "text": "Continue current therapy"
            }
        ],
        "correct_answer": "Infuse IV immunoglobulin",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "This patient with AAV, recurrent infections, and hypogammaglobulinemia should be treated with IV immunoglobulin (IVIG).Hypogammaglobulinemia is frequently recognized in immunosuppressed patients and is particularly associated with B cell-depleting therapy such as rituximab. Some patients who develop hypogammaglobulinemia while receiving rituximab therapy may recover from their nadir immunoglobulin level despite ongoing treatment. Therefore, hypogammaglobulinemia is not necessarily an indication to discontinue rituximab. Patients receiving maintenance rituximab infusions should have serum immunoglobulin levels measured before and after treatment. Immunoglobulin replacement should be considered in patients with hypogammaglobulinemia who have recurrent infections despite prophylactic antibiotics. IVIG has anti-inflammatory properties, may be considered as an adjunct therapy for AAV, and usually doesn’t result in disease flare-up.The optimal duration of maintenance immunosuppression for patients with AAV has not been established, but many experts recommend ongoing maintenance for at least 2–3 years after successful induction of remission. Patients with high risk for relapse or little reserve may receive maintenance immunosuppression indefinitely. Discontinuation of rituximab could be considered in this patient who has maintained remission of AAV for 2 years, but this decision would not be relevant until the patient is due for her next dose. Even with discontinuation of rituximab, however, the patient may continue to experience recurrent infections, because the effect of rituximab on B cells may last for 6 months or longer.Although cyclophosphamide (CYC) has been historically used for maintenance therapy, prolonged exposure to CYC results in significant mortality and morbidity. Azathioprine could be substituted for CYC as maintenance therapy for patients who have achieved remission without increasing relapse rates. Use of CYC would not be indicated in a patient who has been in remission for almost 2 years and is now experiencing repeated infections.Methotrexate is used for induction in mild cases of AAV and for maintenance therapy in some cases of AAV with preserved kidney function. CKD can lead to retention of methotrexate, which increases the risk for adverse effects that include mucositis and cytopenia. It would not be preferred for this patient with CKD.",
        "references": []
    },
    "27": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 94-year-old man with a history of multiple strokes and vascular dementia is admitted to the hospital with a non-healing sacral decubitus ulcer and failure to thrive. He currently lives in a nursing home and is immobile. His daughter helps care for him. She acknowledges that over the past year, his nutritional intake has been limited due to poor appetite. His medications include simvastatin, levothyroxine, amlodipine, and aspirin.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>On examination, the patient is a </span>cachectic, noncommunicative elderly man. His BP is 102/45 mm Hg, heart rate 72/min and irregular, respiratory rate 24/min, and temperature 38.4°C. He weighs 30 kg, and urine output is 1.5 L daily. He is cachectic with contractures of his lower extremities. There is 1–2+ peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A chest x-ray reveals a 1.2-cm nodule in the right hilum.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13,500\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                178,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span><strong>Serum</strong></span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                27 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.1 mU/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Free thyroxine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8–1.8\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span><strong>Urine</strong></span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                36 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\"><span>Urine microscopy shows 1–2 granular casts/lpf, 20–30 WBC/hpf, 5–10 RBC/hpf, and many bacteria.</span></p>\n<p style=\"margin-top: 15px; margin-bottom: 15px;\"><strong>Which of the following is the MOST likely diagnosis for this patient’s proteinuria?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Membranous nephropathy"
            },
            {
                "label": "B.",
                "text": "Infection-associated glomerulonephritis"
            },
            {
                "label": "C.",
                "text": "Misleading urine protein-to-creatinine ratio"
            },
            {
                "label": "D.",
                "text": "Hyperthyroidism"
            },
            {
                "label": "E.",
                "text": "Acute tubular necrosis"
            }
        ],
        "correct_answer": "Misleading urine protein-to-creatinine ratio",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "The most likely diagnosis for the elevated urine protein-to-creatinine ratio (UPCR) in this malnourished, elderly man is misleading laboratory data.Because the collection of a 24-hour urine sample is burdensome and often incorrectly performed, the use of single morning urine samples to estimate proteinuria has replaced the 24-hour collection for the quantification of proteinuria in modern practice. The utility of the UPCR is based on a linear correlation between the UPCR and the 24-hour urine protein, which relies on the assumption that urine production and excretion rates are normal and relatively consistent throughout the day. The normal expected creatinine generation rate is 15–25 mg/kg per day, with rates in women and elderly people toward the lower end of this range. This patient’s urine creatinine is only 10 mg/dL, and because he makes 1.5 L/day, his creatinine generation rate is (10 mg/dL × 15 dL/day =) 150 mg/day, or (150 mg/day ÷ 30 kg =) 5 mg/kg per day, assuming steady state. This extremely low creatinine generation rate is consistent with his advanced age and severe malnutrition, as evidenced by the clinical history and low serum albumin. Consequently, the UPCR is exaggerated (high), erroneously suggesting nephrotic-range proteinuria. Note that the 24-hour urine protein in this case is only 540 mg/day (36 mg/dL × 15 dL/day), which is nonspecific and consistent with functional proteinuria (i.e., hemodynamic glomerular stress due to fever).Each of the other diagnoses may be associated with more severe proteinuria. Membranous nephropathy may be a paraneoplastic syndrome of lung cancer, suggested by the nodule on chest x-ray, but would be unlikely to present with only 0.54 g/day proteinuria. Infection-associated glomerulonephritis and acute tubular necrosis are causes of AKI and would be similarly unlikely in this case. Hyperthyroidism has also been associated with nephrotic syndrome, but the low-normal free thyroxine level suggests that the low thyroid-stimulating hormone concentration in this case is more likely attributable to sick euthyroid syndrome.",
        "references": []
    },
    "28": {
        "question": "<div class=\"qtext\"><p>A 50-year-old man is evaluated for worsening kidney function. He has a 10-year history of poorly controlled type 2 diabetes and hypertension. There is no history of NSAID or illicit drug use, kidney stones, or urinary symptoms. No family members have had kidney disease. Review of systems is positive for fatigue and myalgias, which the patient attributes to increased work hours. He does not have any rashes, swollen joints, or urinary or gastrointestinal symptoms.</p>\n<p>Six weeks ago, torsemide was increased from 40 mg to 60 mg daily and fenofibrate 48 mg daily was initiated. Two weeks ago, the dose of fenofibrate was increased to 145 mg daily. Other medications include extended-release metoprolol 50 mg daily, lisinopril 20 mg daily, and atorvastatin 40 mg daily.</p>\n<p>His BP is 128/76 mm Hg and heart rate 64/min, without orthostatic changes. Heart and lung examinations are normal, and there is no edema. There is no muscle tenderness or weakness. His skin is normal. A urinalysis is negative except for 1+ proteinuria, and the sediment is bland.</p>\n<p dir=\"ltr \" style=\"margin-bottom: 15px; \"><span><span>Laboratory data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\"><strong>6 Weeks Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\"><strong>2 Weeks Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\"><strong>2 Days Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">141 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">135</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">137</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.6 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.4</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.7</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">104 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">103</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">105</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">27 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">28</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">33 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">35</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">38</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.4 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.7</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Triglycerides</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">442 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">387</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">232 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;150</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Low-density lipoprotein cholesterol</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Not calculated</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">20</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;130</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">High-density lipoprotein cholesterol</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">32 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">35</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">41</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&gt;40</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total cholesterol</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">148 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">137</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">107</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;240</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine albumin-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">457 mg/g</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">350</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">300</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;30</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px; \"><strong>Which of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Discontinue torsemide"
            },
            {
                "label": "C.",
                "text": "Initiate coenzyme Q10"
            },
            {
                "label": "D.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "E.",
                "text": "Discontinue fenofibrate"
            }
        ],
        "correct_answer": "Discontinue fenofibrate",
        "abim_content_category": "Pharmacology",
        "explanation": "This patient has had an increase in creatinine associated with titration of fenofibrate, so discontinuation of fenofibrate would be the best initial management. Resolution of the acute rise in serum creatinine would confirm this as an adverse effect of fenofibrate.Fibric acid derivatives are used for patients with dyslipidemia, particularly when there is a need to control high triglyceride levels. A 20% increase in serum creatinine has been described in patients with CKD after initiation of fibrate therapy. The mean increase in serum creatinine is 0.37 mg/dL and is typically reversible with cessation of fibrates. The mechanism of this effect is uncertain. The benefit of fibrate therapy for management of hypertriglyceridemia is unclear in patients with CKD. KDIGO guidelines recommend statin therapy followed by lifestyle modification for management of hypertriglyceridemia in most cases, especially because statin and fibrate combination therapy has been associated with adverse outcomes, such as myopathy and rhabdomyolysis. There is even the possibility that these drugs may increase the risk for muscle injury when patients are exposed to other potentially myotoxic medications such as febuxostat, although a recent study found no definite association in this regard. This patient’s myalgias are a concerning symptom that suggest the possibility of muscle toxicity. Despite limited evidence, it is reasonable to prescribe fibrates for severe hypertriglyceridemia in patients at risk for pancreatitis, despitethe potential for muscle damage, provided that there is careful and ongoing observation for adverse events.Coenzyme Q10 has been advocated for the relief of muscle symptoms in patients being treated with statins but would not address the change in kidney function.Because the patient’s BP is controlled, and he is clinically euvolemic and without signs of volume depletion, discontinuation of torsemide or lisinopril would not be the best initial step. If the creatinine concentration failed to return to baseline after discontinuation of fenofibrate, it would be reasonable to explore renal hypoperfusion as a potential contributing factor.Kidney biopsy would be unlikely to change management in this patient with a bland urine sediment, whose proteinuria and underlying CKD are compatible with his history of diabetes and hypertension.",
        "references": []
    },
    "29": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 42-year-old man is seen in the hospital 3 days after undergoing living donor kidney transplantation. He has a history of ESRD attributed to hypertension and has received HD for the past 9 months. After transplantation, he had immediate graft function and adequate urine output, but kidney function and urine output subsequently worsened. Review of systems is positive for abdominal pain in the region of the surgical incision.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>His BP is 148/78 mm Hg and heart rate 88/min. Abdominal examination reveals tenderness to palpation over the allograft site in the right lower quadrant and copious fluid collected from local drains. An HD catheter in the right internal jugular vein and a urinary catheter are present, and there is 1+ edema in the right leg.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory and urine output data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n<strong>Preoperative</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n<strong>Day 1</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n<strong>Day 2</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n<strong>Day 3</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;20%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine output\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 L/d\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Variable\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><span>Urinalysis is positive for 2+ blood and 1+ albumin. Kidney ultrasound shows a 10.5-cm anechoic fluid collection adjacent to the allograft.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Percutaneous sampling and analysis of the fluid collection reveals potassium 14 mEq/L and creatinine 21 mg/dL.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Urinoma"
            },
            {
                "label": "B.",
                "text": "Hematoma"
            },
            {
                "label": "C.",
                "text": "Lymphocele"
            },
            {
                "label": "D.",
                "text": "Seroma"
            },
            {
                "label": "E.",
                "text": "Peritoneal fluid collection"
            }
        ],
        "correct_answer": "Urinoma",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "This patient has a postoperative urinoma, or urine leak.Urinomas tend to form within the first 2 weeks after kidney transplantation. These urine-containing fluid collections usually arise from extravasation of urine due to necrosis of the ureter or failure of the surgical ureteroneocystostomy. Urinoma manifests as increased wound drainage, abdominal pain, ipsilateral leg edema, and delayed or worsening allograft function, sometimes with fever. Ultrasound reveals an anechoic fluid collection with sharp borders and no septations. Chemical analysis of the fluid reveals high creatinine and potassium compared with serum levels. Urinomas may become infected, and management requires drainage and correction of the leak. Surgical exploration and intervention may be necessary, but a percutaneous nephrostomy tube or ureteral stent is often the initial approach.Many transplant surgeons place a ureteral stent at the time of transplantation. This strategy is associated with fewer major early urologic complications, including urine leak, but increases the risk for urinary tract infection and possibly other complications.Hematoma, lymphocele, and seroma can all present in similar fashion, manifesting as a fluid collection adjacent to the allograft by ultrasound imaging, but none would demonstrate increased concentration of creatinine or potassium in the collection fluid. Seromas are ultrafiltrates of blood, and lymphoceles are collections of lymphatic fluid. Lymphoceles generally present 4–8 weeks post-transplant. Hematomas often appear complex and echogenic on ultrasound because of clot debris and may develop cystic changes and septations over time; these features are not present in this case.Because the transplanted kidney is placed intraperitoneally, in the iliac fossa, a discrete peritoneal fluid collection would be unlikely.",
        "references": []
    },
    "30": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 68-year-old woman with ESRD attributed to hypertension is evaluated for pre-dialysis hyperkalemia. She has received HD for the past 10 years; her current schedule is thrice weekly for 4 hours via a left-arm AV fistula (AVF). Her dialysate contains 2\n    mEq/L of potassium. Single-pool Kt/V last month was 1.4. For the past 2 weeks, she has noted prolonged bleeding (25 minutes) from the AVF after needle removal. She feels well and does not have chest pain, palpitations, or other symptoms. Medications\n    include lisinopril, hydralazine, gabapentin, insulin glargine, and a multivitamin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Pre-dialysis laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Last Month</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6500/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6700\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                210,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "B.",
                "text": "Check whole blood potassium"
            },
            {
                "label": "C.",
                "text": "Obtain fistulagram"
            },
            {
                "label": "D.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            },
            {
                "label": "E.",
                "text": "Use 1 mEq/L potassium dialysate"
            }
        ],
        "correct_answer": "Obtain fistulagram",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "This patient’s hyperkalemia is likely attributable to a reduction in dialysis efficiency due to access recirculation, so the next step in management should be a fistulagram.One clue to the diagnosis is prolonged bleeding from the AVF, which suggests an outflow stenosis, thrombosis, or both. This lesion could be located anywhere from the venous outflow of the fistula to the superior vena cava. Central venous stenosis is common in patients who have received HD for many years and who may have previously received dialysis using a tunneled, cuffed catheter. Stenosis in the venous outflow increases BP within the access and can result in prolonged bleeding (as in this patient), edema, and pain, as well as access recirculation, which decreases the efficiency of dialysis. In this patient, decreased efficiency of HD manifests as increased potassium, BUN, and creatinine and decreased bicarbonate. A fistulagram with angioplasty would be diagnostic and therapeutic, respectively, in managing access recirculation associated with outflow stenosis.Checking whole blood or plasma potassium would be helpful in suspected cases of pseudohyperkalemia, including severe leukocytosis or thrombocytosis, or simply mechanical disruption of RBCs during phlebotomy. This patient does not have an elevated WBC or platelet count, and phlebotomy-induced pseudohyperkalemia (“hemolyzed sample”) is less likely in pre-dialysis blood draws, where blood is obtained at the initiation of dialysis without the use of a small needle or tourniquet.Although the use of dialysate with a lower potassium concentration of 1 mEq/L would marginally increase potassium removal, this approach is not recommended because of the potential for induction of transient hypokalemia and an increased risk forarrhythmia. Increasing treatment time would be a safer way to increase clearance and possibly reduce serum potassium but would not substitute for identification and correction of access malfunction.Blockers of the renin-angiotensin-aldosterone system, including lisinopril, may contribute to hyperkalemia in patients with residual kidney function, who depend on urinary excretion for potassium homeostasis. However, these agents are unlikely to contribute to hyperkalemia in ESRD, especially in the case of this patient, who has received HD for the past 10 years. Although mineralocorticoid-mediated colonic potassium secretion is upregulated in ESRD, concerns that spironolactone may cause hyperkalemia in this population seem unfounded. Discontinuing lisinopril would not address the decline in dialysis clearance manifested by high BUN and creatinine and low serum bicarbonate in addition to hyperkalemia. If hyperkalemia persisted despite optimization of access function, substituting an alternative antihypertensive agent for lisinopril could be considered.Sodium zirconium cyclosilicate requires several hours to lower the serum potassium, but more importantly, would not address inadequate clearance due to venous outflow stenosis. New potassium binders, sodium zirconium cyclosilicate and patiromer, may have a role in controlling hyperkalemia in patients with ESRD if the problem persists after reversible causes, such as access dysfunction, have been addressed.",
        "references": []
    },
    "31": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old woman with a history of hypertension, diabetes, and chronic lymphocytic leukemia is referred for evaluation of hyperkalemia. She denies chest pain, palpitations, and muscle weakness but does have chronic low back pain. Medications include lisinopril 40 mg daily, metformin 1 g twice daily, and ibuprofen 800 mg twice weekly.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Her BP is 130/80 mm Hg and heart rate is 90/min. Physical exam reveals normal heart and lungs and no edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                160,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Direct bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.1–0.3\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>In addition to obtaining an EKG, which of the following is the NEXT best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Check whole blood potassium"
            },
            {
                "label": "B.",
                "text": "Discontinue ibuprofen"
            },
            {
                "label": "C.",
                "text": "Prescribe patiromer"
            },
            {
                "label": "D.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "E.",
                "text": "Repeat potassium; transport blood with pneumatic tube system"
            }
        ],
        "correct_answer": "Check whole blood potassium",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "The most likely cause of asymptomatic hyperkalemia in this patient with normal kidney function is pseudohyperkalemia caused by in vitro lysis of fragile, leukemic WBCs.Although an EKG should be obtained urgently in any suspected case of severe hyperkalemia, high serum potassium levels are rare in patients with normal kidney function. Hyperkalemia and normal kidney function can occur in conditions that cause sudden shift or release of intracellular potassium, such as hemolysis. In this case, hemolysis is unlikely given the normal bilirubin. In the absence of an identifiable cause of hyperkalemia, pseudohyperkalemia should be considered.In patients with severe leukocytosis or thrombocytosis, cellular elements may degrade after phlebotomy but before laboratory analysis, causing a spurious elevation in potassium determination. In such cases, measuring whole blood or plasma potassium in a heparinized tube will yield a normal value.Fist clenching and tourniquet use during phlebotomy, vigorous aspiration of blood via a small-gauge needle, and pneumatic tube transport of blood samples can all result in mechanical disruption of blood cells in vitro and lead to pseudohyperkalemia (“hemolyzed sample”). Phlebotomy without using these techniques and transporting samples by hand, with rapid laboratory analysis, may be helpful in determining the true potassium concentration.Lisinopril or ibuprofen are unlikely to cause hyperkalemia in this patient with normal kidney function, but in any case, true hyperkalemia has yet to be confirmed. For this reason, prescribing a potassium-binding agent such as patiromer would not be the next best step in management.",
        "references": []
    },
    "32": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 48-year-old man with a kidney transplant is evaluated for a decline in kidney function. He is a native of Central America with ESRD of unknown cause. He received a kidney transplant 6 years ago, and his immunosuppressive regimen includes tacrolimus, mycophenolate, and prednisone. Allograft function has been stable since his transplant, with a baseline creatinine of 0.9–1.2 mg/dL. He recently returned from a prolonged family trip to Central America. While there, a relative was diagnosed and treated for pulmonary tuberculosis (TB).</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>One month after returning home, the patient presented to his local health department and relayed the information that he had potentially been exposed to TB. Skin testing with purified protein derivative and an interferon-γ release assay were both positive. His chest x-ray was unremarkable, and he displayed no signs or symptoms of TB. At that visit, his serum creatinine was 0.9 mg/dL without proteinuria. Treatment for latent TB with rifampin was initiated. He was instructed to continue his current maintenance immunosuppression and return in 6 weeks.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>He returns 6 weeks later for routine laboratory follow-up testing. He reports no new symptoms. </span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>The following laboratory tests are obtained:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                104 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                81 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\"><span>Urinalysis shows pH 6.5, trace blood, 1+ protein, negative leukocyte esterase, negative nitrite, negative glucose. Urine microscopy shows 5–10 WBC/hpf and 3–5 RBC/hpf.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely cause of this patient’s acute allograft dysfunction?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute rejection"
            },
            {
                "label": "B.",
                "text": "BK virus nephropathy"
            },
            {
                "label": "C.",
                "text": "Granulomatous interstitial nephritis"
            },
            {
                "label": "D.",
                "text": "Acute calcineurin inhibitor nephrotoxicity"
            },
            {
                "label": "E.",
                "text": "Mesoamerican nephropathy"
            }
        ],
        "correct_answer": "Acute rejection",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "This patient with acute allograft dysfunction has most likely has developed acute rejection.Many patients who have had functioning kidney transplants for years may be seen by their nephrologist or transplant center only rarely and obtain the bulk of their medical care from providers and clinics who may not be familiar with transplantation medications. In this case, the patient was treated appropriately for latent TB (LTB) with rifampin, which is one of several regimens considered acceptable by Center for Disease Control guidelines. Rifampin is a potent inducer of the enzyme cytochrome P450 (CYP) 3A4, which is responsible for tacrolimus metabolism. Induction of this enzyme results in more rapid metabolism of tacrolimus. Consequently, tacrolimus levels can become subtherapeutic or even undetectable if the tacrolimus dose is not increased in anticipation of this drug interaction. In this case, failure to increase the tacrolimus dose when rifampin was prescribed predisposed the patient to rejection. Use of an alternative agent, such as isoniazid, would also have been reasonable. Regardless of the known propensity of an agent to interact with immunosuppressant medications, it is good practice to monitor drug levels and assess the patient within a week or two whenever medications are added or withdrawn.Acute calcineurin inhibitor (CNI) toxicity can develop in response to drug interactions from CYP3A4 inhibitors, including antifungal azoles, non-dihydropyridine calcium channel blockers, and macrolide antibiotics, which result increased CNI concentrations. In this case, the drug interaction was with an inducer of CYP3A4, which would not precipitate CNI toxicity.Genitourinary TB is a common site of extrapulmonary TB. TB-related granulomatous interstitial nephritis is an uncommon manifestation that may develop if the kidney is infected by hematogenous spread during primary infection or reactivation. The course can be insidious and progressive. This diagnosis should be considered in patients with a history of TB exposure and otherwise unexplained CKD. The patient presented here does not have evidence of active pulmonary or miliary TB, which are identified in some cases of granulomatous interstitial nephritis. The diagnosis can’t be excluded without biopsy, but it is not the most likely.BK nephropathy typically presents in the first 1–2 years after transplantation and is more common with more intense immunosuppression. This patient has no known history of BK viremia or viruria. Furthermore, as discussed above, immunosuppression exposure has likely decreased since rifampin was initiated, which makes BK virus nephropathy less likely.Mesoamerican nephropathy is a form of non-proteinuric CKD of unknown cause. It is seen predominantly in young agricultural workers in or from the Pacific coast lowland regions of Central America, although similar syndromes are increasingly recognized in other parts of the world. The etiology of this condition has not been elucidated, but it is speculated to be due to recurrent episodes of volume depletion, dehydration, and AKI, possibly in conjunction with sucrose exposure. Excessive exposure to NSAIDs and agricultural chemicals are also possible contributing factors. This condition typically develops chronically over time. In this case, the patient was in Central America recently for only a short period of time without known risk factor exposures.",
        "references": []
    },
    "33": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 76-year-old man with CKD (baseline creatinine 2.4 mg/dL) is admitted to the ICU with altered mental status. His medical history includes hypertension and metastatic prostate cancer, with fourth-line chemotherapy paclitaxel recently discontinued because of cardiomyopathy. He is diagnosed with septic shock and intubated for respiratory failure. He subsequently becomes anuric.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On exam, BP is 98/46 mm Hg while receiving norepinephrine, heart rate 108/min and regular, temperature 38.8°C, and oxygen saturation 96% while receiving 40% inspired oxygen through the ventilator. Examination of the heart and lungs reveals regular tachycardia, an S3 gallop, and diffuse crackles. Moderate peripheral edema is present. Neurologic exam shows no purposeful movements after sedation withdrawal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                Admission\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                After 48 Hours</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">Reference Range\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                104 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactic acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–2.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">\n    CT shows new pulmonary metastases and small kidneys without hydronephrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The patient has a notarized advanced directive stating that he would never want dialysis under any circumstances. He did not share this information with his son but did express it to both his primary nephrologist and his primary care physician on multiple occasions. Now that the patient is incapacitated, his son, who is his healthcare surrogate, is requesting that dialysis be provided with a goal of improving his father’s mental status.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST APPROPRIATE course of action for the consulting nephrologist?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Recommend a time-limited trial of conventional HD"
            },
            {
                "label": "B.",
                "text": "Inform the son that his father is not a candidate for renal replacement therapy"
            },
            {
                "label": "C.",
                "text": "Recommend a time-limited trial of CRRT"
            },
            {
                "label": "D.",
                "text": "Consult the hospice service"
            }
        ],
        "correct_answer": "Inform the son that his father is not a candidate for renal replacement therapy",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "The most appropriate course of action for the consulting nephrologist is to inform the patient’s son that his father is not a candidate for dialysis based on the patient’s advanced directive.This case illustrates a common ethical dilemma regarding the management of severe kidney disease in the setting of an advanced incurable condition, such as metastatic cancer. In this situation, renal replacement therapy might result in a short-term benefit such as relief of uremic symptoms or fluid overload but would not alter the underlying trajectory. Furthermore, delivery of renal replacement therapy comes with significant procedure-related burdens, such as placement of vascular access, and sometimes prolongs life without meaningfully relieving symptoms. Whenever possible, patients with CKD and other chronic progressive illnesses should be counseled on this potential scenario so that they can make the best-informed decision to guide their care. Ideally, their wishes are documented both in a legal advanced directive and through discussion with their family. Physicians are ethically and legally required to honor a patient’s autonomy by adhering to a properly executed advanced directive. In the case of an incapacitated patient and in absence of an advance directive, substituted judgment may be used by the patient’s surrogate based on the surrogate’s understanding of the patient’s wishes. If the patient’s wishes are unknown, the surrogate must make decisions based on the best interests of the patient’s welfare.Patients may legally designate their surrogate as a healthcare proxy or power of attorney. If a designation has not been made prior to incapacitation, the role of surrogate may be assigned by the state based on a hierarchy determined by state law. These rules vary by state, and it is incumbent on the practitioner to be familiar with the rules in their location. A surrogate’s preference for or against an intervention may be different from that of the patient but cannot legally or ethically override the patient’s advanced directive.Even if a patient or their proper surrogate expresses a desire for certain therapeutic interventions, the principle of nonmaleficence must also be considered. As discussed in the 2010 consensus guidelines from the American Society of Nephrology and the Renal Physicians Association, there should be consideration to forgo dialysis in patients who are unstable, those who have a nonrenal terminal illness, and those with profound, irreversible neurological impairment, all of which are present in this case. In the situation of conflict between ethical principles, such as autonomy and nonmaleficence, consultation with a panel of experts is a reasonable approach.A time-limited trial of renal replacement therapy of either HD or CRRT would be inappropriate in this case, given the clearly expressed written and verbal advanced directives available. Conversely, it would be inappropriate to consult the hospice service without further guidance from the advanced directive and conferring with the patient’s son and referring physician.",
        "references": []
    },
    "34": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 45-year-old woman with hypertension is seen in the office for the evaluation of hyponatremia. Her medical history includes chronic obstructive pulmonary disease and bipolar disorder. She takes stable doses of hydrochlorothiazide, amitriptyline, lithium, and respiratory inhalers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, she is alert with a BP of 118/72 mm Hg and heart rate 67/min. She appears well, and there is no peripheral edema. The remainder of the examination, including the neurologic examination, is unremarkable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory values show the following:\n    </span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                121 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                89 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                262 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–1400\n            </td>\n</tr>\n</tbody>\n</table><p style=\"margin-top: 30px; margin-bottom: 20px;\">Urinalysis shows specific gravity 1.003, pH 6, and no protein. Microscopy shows no cells or casts. Urine volume is 8 L/24 h.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>\n        Which of the following is the MOST likely cause of hyponatremia?\n    </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Low solute diet"
            },
            {
                "label": "B.",
                "text": "Primary polydipsia"
            },
            {
                "label": "C.",
                "text": "Nephrogenic diabetes insipidus"
            },
            {
                "label": "D.",
                "text": "Thiazide-induced hyponatremia"
            },
            {
                "label": "E.",
                "text": "Syndrome of inappropriate antidiuretic hormone (SIADH)"
            }
        ],
        "correct_answer": "Primary polydipsia",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation": "Primary polydipsia is the most likely explanation for hypotonic hyponatremia in this patient.A urine osmolality of ≤100 mOsm/kg H2O generally indicates complete suppression of antidiuretic hormone (ADH), resulting in a maximally dilute urine and water diuresis. Hyponatremia with water diuresis is observed in the context of primary polydipsia when water intake exceeds excretory capacity, which can be estimated as approximately 10% of GFR. Patients with normal kidney function and solute intake are therefore typically able to excrete a daily water load of 15 L or more without developing hyponatremia. Patients with decreased GFR may develop hyponatremia at lower water intake levels. Water excretion can also be limited by a low solute intake or by diuretic therapy. This patient has a reduced GFR and is taking a diuretic, but excessive water intake is the dominant feature. Polydipsia sometimes relates to symptoms of dry mouth caused by anticholinergic side effects of medications but can occur without an identifiable explanation. Primary polydipsia is relatively common among patients with psychiatric diagnoses.Urine volume may be limited by daily solute excretion. A low solute diet (≤300 mOsm/day) can result in diminished water excretion and subsequent hyponatremia. In the case described, urine excretion of 720 mOsm/day (90 mOsm/kg H2O × 8 L/day) is consistent with the consumption of a typical Western diet (750–900 mOsm/day).Nephrogenic diabetes insipidus (DI) can present with polyuria and is associated with long-term lithium use. However, the serum sodium concentration in untreated patients with DI is often in the high normal range. Patients are usually able to compensate for urinary water losses by drinking copious amounts of water in response to thirst. In the event of an impaired thirst mechanism, overt hypernatremia ensues. In either scenario of nephrogenic DI, hyponatremia is not expected.Thiazide diuretics inhibit sodium and chloride reabsorption in the cortical distal tubule. Thus, thiazide diuretics impair diluting ability and preclude the maximal dilution of urine. Typically, a urine osmolality of >100 mOsm/kg H2O is seen. The mechanism of hyponatremia due to thiazide diuretics is likely multifactorial. Impairment of urinary dilution, stimulation of ADH due to volume contraction, and increased fluid intake due to an exuberant thirst response have all been proposed as contributing factors.The patient’s ability to maximally dilute the urine in the setting of hyponatremia indicates complete and appropriate suppression of ADH. There is no evidence for the inappropriate (non-physiologic) release of ADH.",
        "references": []
    },
    "35": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 45-year-old woman with resistant hypertension is seen in the emergency department for dyspnea on exertion that has worsened over the past month. Medical history includes CKD stage 3 with eGFR 45 mL/min/1.73 m<sup>2</sup> and heart failure with preserved ejection fraction. Her medications are lisinopril, metoprolol, extended-release nifedipine, torsemide, spironolactone, and minoxidil. The dose of spironolactone was increased 3 months ago during her last office visit.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">On examination, she is in mild respiratory distress with a respiratory rate of 24/min, BP 80/65 mm Hg, pulse 115/min, and oxygen saturation 94% on room air. Jugular venous distention is present to 8 cm of water above the sternal angle. The lungs are clear to auscultation. Heart sounds are regular, distant, and without murmur, rub, or gallop. Peripheral edema is 1+ and distal pulses are palpable. There is no asterixis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cardiac tamponade"
            },
            {
                "label": "B.",
                "text": "Right heart failure"
            },
            {
                "label": "C.",
                "text": "Type A aortic dissection"
            },
            {
                "label": "D.",
                "text": "Acute pulmonary embolism"
            },
            {
                "label": "E.",
                "text": "Flash pulmonary edema"
            }
        ],
        "correct_answer": "Cardiac tamponade",
        "abim_content_category": "Hypertension",
        "explanation": "This patient with underlying resistant hypertension receiving minoxidil is most likely presenting with cardiac tamponade.The combination of hypotension, dilated neck veins (elevated jugular venous pressure [JVP]), and muffled heart sounds (Beck triad) can be seen in the setting of cardiac tamponade. Other potential physical findings include a paradoxical increase in JVP during inspiration, known as Kussmaul sign, and dullness to percussion and egophony at the left lung base, known as Ewart or Pins sign. A pulsus paradoxus may be present but can be challenging to demonstrate in patients with tachypnea and tachycardia. Low cardiac voltage and electrical alternans may be present on EKG. Chest x-ray often demonstrates enlargement of the cardiac silhouette with a flask shape. Definitive diagnosis is by echocardiography or right heart catheterization.Pericardial effusion attributable to minoxidil is observed in about 3% of patients receiving this drug and is occasionally complicated by tamponade. Patients with CKD appear to be more likely to experience this complication. Minoxidil causes arteriolar dilation without venous dilation, resulting in reflex tachycardia and volume retention with edema. Therefore, the drug is sometimes prescribed in conjunction with a loop diuretic and a β-blocker. In some cases, pericardial and pleural fluid may accumulate. The precise etiology is unknown. Fluid analysis and pericardial biopsy may be unrevealing, without evidence of inflammation. Pericardial effusion may remain asymptomatic and discovered only incidentally when an imaging study is performed for another reason. However, if the intrapericardial pressure increases rapidly or reaches a critical point, dyspnea, chest discomfort, and other symptoms ensue because of impaired cardiac filling and diminished cardiac output. Hypotension with a narrow pulse pressure, as in this case, suggests the compromised stroke volume seen in cardiac tamponade. Management includes discontinuation of minoxidil and pericardial drainage when the effusion is large and symptomatic.Elevated JVP, hypotension, tachycardia, and dyspnea can be present in acute pulmonary embolism with right ventricular strain. However, the gradual progression of symptoms over weeks and the absence of risk factors for pulmonary embolism make this diagnosis less likely.Type A aortic dissection involves the ascending aorta. Severe chest pain occurs in 80–90% of patients with acute aortic dissection. Propagation of the dissection can cause loss of peripheral pulses (pulse deficit), a new-onset diastolic murmur from the rupture of the aortic valve, and cardiac tamponade, leading to sudden death. Again, the subacute onset of symptoms and absence of typical pain make aortic dissection less likely.Flash pulmonary edema is the rapid development of pulmonary edema, typically precipitated by hypertensive emergency, valvular abnormalities, or bilateral renal artery stenosis. This patient’s symptoms are subacute, and there is no evidence for pulmonary edema on examination of the lungs.Right heart failure, or cor pulmonale, involves right ventricular enlargement and dysfunction related to pulmonary hypertension secondary to lung disease (group 3 pulmonary hypertension). The clinical features include exertional dyspnea, loud S2, elevated JVP, and peripheral edema. In the absence of an underlying lung disorder, cor pulmonale is unlikely.",
        "references": []
    },
    "36": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 34-year-old woman presents with a complaint of fatigue, weakness, and cramping. She reports no significant medical history. She does not take prescription or over-the-counter medications or herbal supplements except for an oral contraceptive pill. She denies vomiting, diarrhea, and alcohol abuse. </span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 105/75 mm Hg, heart rate 73/min, temperature 36.7°C, and oxygen saturation 97% while breathing room air. Physical examination is remarkable for mild muscular weakness in the hips and shoulders. Rare fasciculations are observed.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory investigations include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                140 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.62 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                83 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin A<sub>1c</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0–5.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine (Random)</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                61 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                56 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;2.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                96 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\"><span>Hypomagnesemia persists despite ongoing replacement with oral magnesium oxide 800 mg three times daily. Further increases in magnesium dose have been limited by diarrhea.</span></p>\n<p style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hydrochlorothiazide"
            },
            {
                "label": "B.",
                "text": "Cetuximab"
            },
            {
                "label": "C.",
                "text": "Amiloride"
            },
            {
                "label": "D.",
                "text": "Indomethacin"
            },
            {
                "label": "E.",
                "text": "Furosemide"
            }
        ],
        "correct_answer": "Amiloride",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "This patient with hypomagnesemia associated with Gitelman syndrome should be treated with amiloride.The first step in the evaluation of a dysmagnesemia is to calculate the fractional excretion of magnesium (FEMg) to determine renal magnesium (Mg) handling:FEMg = (urine Mg÷urine creatinine)/([serum Mg × 0.7]÷serum creatinine) × 100%The serum Mg is multiplied by 0.7 to discount Mg bound to albumin. In the presence of hypomagnesemia, FEMg >2% indicates renal Mg wasting. In this case:FEMg = (3.5 mEq/L÷96 mg/dL)/([1.1 mEq/L × 0.7]÷0.62 mg/dL) × 100% = 2.9%Inappropriate renal magnesium excretion in the setting of hypomagnesemia, in addition to hypokalemia, metabolic alkalosis, and undetectably low urine calcium, are consistent with a diagnosis of Gitelman syndrome. Clinical manifestations commonly include fatigue, weakness, and cramping.Amiloride is a selective blocker of the epithelial sodium channel (ENaC). ENaC blockers are thought to increase magnesium absorption based on their alteration of transepithelial voltage. When ENaC is blocked, cells in the distal nephron are unable to absorb sodium, creating a positive luminal and negative intracellular charge. This electrical gradient favors magnesium absorption through transient receptor potential melastatin-6 and -7 (TRPM-6 and TRPM-7) channels. Aldosterone antagonists are felt to work in a similar manner. Thus, in patients with persistent hypomagnesemia, a potassium-sparing diuretic may help increase serum magnesium levels.Hydrochlorothiazide inhibits the sodium chloride cotransporter in the distal convoluted tubule and replicates the genetic defect already present in Gitelman syndrome, so it would not be helpful in this case and could worsen hypomagnesemia. Similarly, furosemide would block sodium, potassium, calcium, and magnesium paracellular uptake in the thick ascending limb of the loop of Henle and would increase magnesium excretion.Prostaglandin production is mildly increased in Gitelman syndrome and leads to renin-angiotensin-aldosterone system activation and worsened electrolyte abnormalities. Indomethacin has been used with some success in Gitelman syndrome, but because of its gastrointestinal and renal toxicity, it would be a second-line choice after a potassium-sparing diuretic.Cetuximab is an inhibitor of epidermal growth factor receptors (EGFRs) that is used to treat metastatic colorectal cancer. EGFRs are present on distal tubule cells and stimulate magnesium reabsorption. Cetuximab thus causes hypomagnesemia and would not be an appropriate treatment.",
        "references": []
    },
    "37": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 40-year-old woman with no significant medical history is evaluated for recent-onset hypertension. She has experienced headaches, pulsatile tinnitus, and occasional dizziness for the past 6 months. She does not use illicit drugs, over-the-counter medications, or herbal supplements. Antihypertensive therapy has been initiated and titrated, but the BP remains elevated. Current medications include amlodipine 10 mg daily, chlorthalidone 25 mg daily, and losartan 100 mg daily.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 145/90 mm Hg, pulse 88/min, and body mass index 28 kg/m<sup>2</sup>. Arteriovenous crossing changes are observed in the optic fundi. A carotid bruit is auscultated on the right side. Cardiac, pulmonary, and abdominal examinations are otherwise normal. There is no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                103 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aldosterone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.2 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤10 (supine or seated)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Renin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7 ng/mL/h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2–3.6 (normal diet, upright)\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\">CT angiography of the renal arteries demonstrates focal concentric stenosis in the midportion of the right superior segmental artery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Spironolactone"
            },
            {
                "label": "B.",
                "text": "Anticoagulation"
            },
            {
                "label": "C.",
                "text": "Surgical revascularization"
            },
            {
                "label": "D.",
                "text": "Percutaneous angioplasty"
            },
            {
                "label": "E.",
                "text": "Hydralazine"
            }
        ],
        "correct_answer": "Percutaneous angioplasty",
        "abim_content_category": "Hypertension",
        "explanation": "This relatively young patient with uncontrolled hypertension due to fibromuscular dysplasia (FMD) should undergo percutaneous transluminal angioplasty (PTA).This patient’s BP remains high despite three antihypertensive medications, including a diuretic. She has clinical features of FMD, and imaging studies confirm the diagnosis of focal variant FMD. FMD is a rare systemic vascular disorder that results in the non-atherosclerotic narrowing of the affected vessel. FMD is classified according to the nature of the stenotic lesions. Any of the arterial layers can be affected. FMD-related stenoses may be discrete and unifocal, multifocal, or web-like. The renal and carotid arteries are the most commonly recognized sites of involvement. Renal artery stenoses related to FMD usually occur in the mid- to distal artery, as opposed to atherosclerotic lesions that tend to occur in the proximal segment, at or near the origin. The condition affects women preferentially and likely has a genetic component. This patient has a carotid bruit, and all patients in whom FMD is identified should be screened for carotid artery disease, with subsequent management dictated by imaging findings. Hypertension may emerge spontaneously or be provoked by pregnancy or oral contraceptive use. Occasional patients may be identified later in life after a presentation masquerading as essential hypertension.Revascularization is recommended for patients who are relatively young, those with recent onset of hypertension, those who have uncontrolled or drug-resistant hypertension, and those with CKD. PTA, stent insertion, and surgery are the three options available for revascularization. Most patients do well with PTA; it provides a durable result without the need for stent insertion, which can be complicated by thrombosis, kink, fracture, or interference with subsequent surgery. Surgery is reserved for complex lesions not amenable to angioplasty. Aspirin 75–100 mg daily is recommended post-procedure.Although some subtypes of FMD are associated with a higher risk of thrombosis, there is no indication for primary anticoagulation. Patients with carotid lesions, particularly if multifocal, are often treated with antiplatelet therapy such as aspirin. Those who have experienced a dissection or thrombotic event should be considered for secondary anticoagulation. Neither antiplatelet therapy nor anticoagulation would directly address the hypertension in this patient.Most patients who undergo PTA will require fewer BP medications, and some may be cured. Studies have shown that younger patients tend to have better outcomes than older patients with PTA.Although BP control may be improved with spironolactone, which would inhibit the renin-angiotensin-aldosterone axis at a different step than losartan, medical therapy alone (with either spironolactone or hydralazine) would not be preferred for this young patient with a potentially curable cause of hypertension.",
        "references": []
    },
    "38": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 22-year-old woman with a history of lupus nephritis presents to clinic for routine follow-up. She initially presented 2 years ago with fatigue, joint aches, proteinuria, and hematuria. Kidney biopsy revealed class IV diffuse proliferative glomerulonephritis with moderate activity and minimal chronicity. Treatment with corticosteroids and mycophenolate mofetil led to complete remission by month 5. She feels well and has no complaints other than occasional fatigue. Current medications include mycophenolate mofetil 1000 mg twice daily and hydroxychloroquine 200 mg daily.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>On physical examination, BP is 110/60 mm Hg and heart rate 75/min. She appears well. There is no oral thrush. Heart and lungs and abdomen are normal. There are no skin rashes or edema.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data include the following:</span></span></p>\n<table>\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Today</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>3 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Blood</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5800\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                152,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                175,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                85 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Antibodies to double-stranded DNA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 IU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–7\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Specific gravity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.004\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.015\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.002–1.030\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Blood\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Microscopy\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Random protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Random creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ˂0.2 \n                 \n            </td>\n</tr>\n</tbody>\n</table><p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which ONE of the following is the next MOST appropriate step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Order 24-hour urine collection for protein"
            },
            {
                "label": "B.",
                "text": "Repeat urine protein-to-creatinine ratio in 2 weeks"
            },
            {
                "label": "C.",
                "text": "Restart prednisone 1 mg/kg daily"
            },
            {
                "label": "D.",
                "text": "Increase mycophenolate mofetil dose to 1500 mg twice daily"
            },
            {
                "label": "E.",
                "text": "Schedule kidney biopsy"
            }
        ],
        "correct_answer": "Order 24-hour urine collection for protein",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "A 24-hour urine collection to measure total protein excretion is the most appropriate way to ascertain if there has been a significant change in proteinuria that might warrant a change in therapy or repeat kidney biopsy.This patient has an increase in proteinuria on urinalysis and on urine protein-to-creatinine ratio (UPCR), which may suggest a lupus nephritis flare. However, in the absence of other definitive evidence for a flare, the increase in proteinuria should be verified with a 24-hour urine collection for protein before making management decisions.Spot UPCRs have been shown to have moderate to high correlation with timed urine collections for protein excretion under many circumstances and are widely used in clinical practice because of their convenience. The accuracy of the UPCR depends on a steady excretion rate of both urinary protein and creatinine. UPCR has been found to be reasonably accurate for classifying CKD, but the correlation is weaker for glomerular diseases and particularly for lupus nephritis. Urinary protein excretion follows an hour-to-hour circadian rhythm, which can be influenced by diet, posture, and exercise, making a single mid-day UPCR vulnerable to error. The first morning void UPCR is thought to be the most reliable predictor of 24-hour excretion and is preferred over other, random collection times.In addition, dilute urine samples (specific gravity <1.005) tend to overestimate urinary protein excretion, particularly when urine creatinine levels are <39 mg/dL. For these reasons, it would be prudent to confirm by 24-hour urine collection that the elevated UPCR in this patient actually represents worsening proteinuria. Repeating UPCR in 2 weeks would still be subject to the interpretation challenges outlined and would delay the evaluation.Resuming prednisone or adjusting the mycophenolate mofetil dose may be necessary if a lupus nephritis flare is confirmed, but such a step should wait until an increase in proteinuria is confirmed by a 24-hour collection.Because this patient was in complete remission, as defined by having proteinuria <500 mg/d, an increase in urine protein value would reasonably prompt another biopsy if the increased proteinuria were confirmed by 24-hour collection.",
        "references": []
    },
    "39": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 69-year-old woman with ESRD is evaluated for hyperphosphatemia. She has received HD through a right radiocephalic fistula for the last 3 years. She recently moved in with her daughter and no longer prepares her own meals. She is adherent to her thrice weekly, 4-hour dialysis sessions as well as her medications, which include erythropoietin, lisinopril, levothyroxine, ropinirole, and sevelamer carbonate 2400 mg with each meal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data reveal the following:</span></p>\n130–585 (dialysis patients only)<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;1.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Intact PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                346 pg/mL\n            </td><td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">130–585 (dialysis patients only)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                87 IU/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\">One month ago, her phosphorus level was 5.0 mg/dL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase sevelamer to 3200 mg with meals"
            },
            {
                "label": "B.",
                "text": "Prescribe cinacalcet"
            },
            {
                "label": "C.",
                "text": "Change sevelamer to calcium acetate"
            },
            {
                "label": "D.",
                "text": "Review dietary intakeof phosphorus"
            },
            {
                "label": "E.",
                "text": "Increase dialysis time to 4.5 hours"
            }
        ],
        "correct_answer": "Review dietary intakeof phosphorus",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "The most appropriate next step in management in this patient with variable phosphorus levels is to review dietary intake for high–phosphorus foods.An important determinant of serum phosphorus control is dietary intake. Most patients with ERSD will require restriction of phosphorus-containing foods to control hyperphosphatemia. The target phosphorus goal for patients with ESRD is 3.5–5.5 mg/dL per KDOQI guidelines. More recent KDIGO guidelines suggest maintaining phosphorus within the normal range.The average daily dietary intake of phosphorus is about 1550 mg for men and 1000 mg for women. These estimates are changing as phosphates are being added to processed foods, including meats, cheeses, dressings, beverages, and bakery products. Dark cola also contains phosphoric acid, which is rapidly absorbed and less amenable to pharmacologic binding. Phosphorus in the form of food additives may increase phosphorus intake by as much as 1 g/d, essentially doubling the daily intake. Nutrient composition tables usually do not include the phosphorus in the form of additives, resulting in an underestimate of projected dietary intake. Phosphate additives usually can be identified by reading the ingredients list on the food label. A typical goal for phosphate restriction for patients with ESRD is 900 mg/d.In this patient, despite adherence to her binders, the phosphorus level has fluctuated, suggesting variable intake. Patients receiving dialysis who do not prepare their own meals may be vulnerable to a diet rich in processed foods that contain copious phosphorus. Review of dietary intake coupled with counseling of the patient and her meal preparers may be effective in improving control.Patients with ESRD are subject to an enormous pill burden that is associated with adverse effects and a negative impact on quality of life. One survey found a median assignment of 19 pills per day, 49% of which were phosphate binders. In this study, there was no evidence that increasing the number of binders per meal led to better control of phosphorus. Increasing the sevelamer dose may not be effective, would increase her pill burden, and would risk hypophosphatemia during periods of relatively low phosphorus intake.Switching to calcium acetate does not address the underlying problem of variable dietary intake and could also result in hypercalcemia and enhance the risk for ectopic calcium deposition, including coronary calcification. There is emerging evidence that use of an iron-based phosphate binder, sucroferric oxyhydroxide, may be effective in controlling phosphorus with a lower daily pill burden.The patient’s current treatment time of 4 hours provides adequate clearance and good control of other electrolytes. Extending her time to 4.5 hours would be unlikely to affect the phosphorus level significantly.Both high PTH and the activated vitamin D treatment of hyperparathyroidism may contribute to high phosphorus levels. Cinacalcet would be expected to lower phosphorus levels but is not indicated in this scenario since the PTH is at target for patients with ESRD. In addition, the normal alkaline phosphatase level argues against the presence of excessive bone turnover.",
        "references": []
    },
    "40": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 33-year-old man is evaluated for CKD. He has been treated for hypertension for the past 3 years. Family history is significant for several relatives with ESRD, including his father at age 28 years, two sisters at ages 18 and 35 years, and two paternal aunts at ages 27 and 29 years. His only prescribed medication is lisinopril 5 mg daily, and he does not use NSAIDs or other nonprescription medications or herbal products.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.6 mg/dL (3 years ago, 1.7)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Specific gravity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.006\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.002–1.030\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Blood\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><span>The urine sediment is notable for a rare acanthocyte (0–2/HPF).</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>An MRI of the abdomen is shown below. The left kidney is 9.6 cm, and the right kidney is 10.5 cm, with no hydronephrosis. Multiple small, bilateral, medullary cysts are present (arrow), numbering at least 15 on the left and 5 on the right. Rare cortical cysts are also present. All cysts measure ≤1 cm in diameter.</span></p>\n<div align=\"left\">\n<figure style=\"margin-bottom: 20px;\"><img alt=\"Picture2\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/90_image_Arrow.jpg\" style=\"width: 600px;\"/>\n<figcaption><em>Image courtesy of Neera Dahl, MD, Yale School of Medicine</em></figcaption>\n</figure>\n</div>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following additional findings would be MOST CONSISTENT with this patient’s diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Nephrocalcinosis"
            },
            {
                "label": "B.",
                "text": "Interstitial fibrosis and tubular atrophy"
            },
            {
                "label": "C.",
                "text": "Hepatic fibrosis"
            },
            {
                "label": "D.",
                "text": "Hearing loss"
            },
            {
                "label": "E.",
                "text": "Hepatic and pancreatic cysts"
            }
        ],
        "correct_answer": "Interstitial fibrosis and tubular atrophy",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "The most likely additional finding would be interstitial fibrosis and tubular atrophy on kidney biopsy in this patient with features of autosomal dominant tubulointerstitial kidney disease (ADTKD).Defects in several genes have been linked to ADTKD, most commonlyUMOD,REN, andMUC-1, less oftenHNF1BandSEC61A1. All types of ADTKD are associated with small corticomedullary kidney cysts, mild hypertension, and progressive CKD with a bland urine sediment and minimal proteinuria. ESRD occurs in an autosomal dominant, early-onset pattern. Associated characteristics are shown in the table below. ADTKD is usually diagnosed clinically, although genetic testing may be done in certain circumstances. Biopsy may be performed if family history is unavailable or inconclusive for ADTKD.GeneProteinOther NamesAssociated FindingsUMODUromodulinMedullary cystic kidney disease (MCKD) type 2, familial juvenile hyperuricemic nephropathy (FJHN) type 1, uromodulin-associated kidney diseaseHyperuricemiaEarly-onset goutRENReninFJHN type 2HyperuricemiaEarly-onset gout Hyperkalemia HypotensionAnemiaMUC-1Mucin 1MCKD type 1NoneHNF1BHepatocyte nuclear factor 1βMaturity-onset diabetes of youth (MODY) type 5, renal cyst and diabetes syndrome (RCAD)HypokalemiaHypomagnesemiaPancreatic hypoplasiaKidney dysplasia or hypoplasiaEarly-onset type 2 diabetesGenital tract malformationsSEC61A1SEC61 translocon complexN/AIntrauterine growth retardationNeutropeniaADPKD is caused by mutations ofPKD1orPKD2.ADPKD is associated with nephromegaly and large cortical cysts, rather than the small, corticomedullary cysts seen in this patient.Liver fibrosis may be observed in juvenile nephronophthisis or autosomal recessive polycystic kidney disease but would not be expected in ADTKD. The inheritance of kidney disease in this family is autosomal dominant.Hearing loss is a common comorbid feature of hereditary nephritis, which most often demonstrates an X-linked transmission pattern. More prominent hematuria and proteinuria would be expected. Kidney imaging is normal early in the course, whereas atrophy is observed later. Although acquired cystic disease could be present in association with advanced CKD, medullary cysts would not be expected.Nephrocalcinosis and calcium-containing nephrolithiasis can be features of medullary sponge kidney (MSK). MSK is a congenital kidney malformation characterized by splaying of the renal calyces and a papillary “blush” or “paintbrush” appearance on contrast imaging. Although MSK is usually sporadic, clusters with an autosomal dominant inheritance pattern have been reported. Neither the severity of CKD with progression to ESRD nor the MRI findings in this case would be consistent with this diagnosis.",
        "references": []
    },
    "41": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old man with ESRD due to diabetes maintained with in-center HD is seen in follow-up. He was recently deemed to be an unsuitable candidate for kidney transplant because of severe atherosclerotic calcification of the aorta and bilateral iliac arteries. He feels well and has no complaints regarding dialysis. He is adherent with prescribed medications and diet. His current medications include lisinopril, aspirin, insulin glargine, sevelamer 3200 mg with each meal, and cinacalcet 180 mg nightly. He also receives doxercalciferol 2 µg with each dialysis treatment. His current dialysis prescription is 4 hours, blood flow rate 500 mL/min, and dialysate flow rate 800 mL/min.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, his BP is 153/82 mm Hg and heart rate 64/min. His lungs are clear to auscultation, and he has a regular heart rate and rhythm. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory studies are listed below.</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                79 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                168 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Intact PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1649 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585 (dialysis patients)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25-Hydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                52 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V, single-pool\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.23\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥1.2\n            </td>\n</tr>\n</tbody>\n</table><p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST appropriate treatment for this patient’s hyperphosphatemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase dialysis time to 4.5 hours"
            },
            {
                "label": "B.",
                "text": "Increase doxercalciferol to 4 µg with dialysis"
            },
            {
                "label": "C.",
                "text": "Surgical parathyroidectomy"
            },
            {
                "label": "D.",
                "text": "Change sevelamer to ferric citrate"
            },
            {
                "label": "E.",
                "text": "Change cinacalcet to etelcalcetide"
            }
        ],
        "correct_answer": "Surgical parathyroidectomy",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "This patient with hyperphosphatemia associated with refractory secondary hyperparathyroidism (SHPT) should undergo parathyroidectomy (PTX) in accordance with KDIGO 2017 guidelines.Initially, SHPT results from polyclonal proliferation of parathyroid tissue, which is responsive to medical treatment with vitamin D analogs and calcimimetics. However, with ongoing stimulation, progressive monoclonal expansion of adenomatous tissue may occur, at which point the patient progresses from SHPT to tertiary hyperparathyroidism. In either persistent SHPT or tertiary hyperparathyroidism, parathyroid cells may fail to respond to suppressive therapy because of reduced expression of vitamin D and calcium-sensing receptors. PTX should be considered for patients with persistent hypercalcemia or hyperphosphatemia despite optimized medical therapy, as well as those with symptomatic complications such as renal osteodystrophy, calciphylaxis, erythropoiesis-stimulating agent resistance, or severe vascular calcification (as in this patient).Although active vitamin D therapy has been shown to be effective in reducing PTH levels, this therapy has a narrow therapeutic window. Active vitamin D increases gut absorption of calcium and phosphorus, which promotes hypercalcemia and hyperphosphatemia and possibly vascular calcification. In addition, calcitriol and its analogs appear to promote higher levels of fibroblast growth factor-23 (FGF-23), which may also be undesirable. FGF-23 is strongly associated with adverse outcomes, including vascular calcification. This patient’s high phosphorus levels would prohibit further escalation of vitamin D therapy.Increasing dialysis time may lead to a small increase in phosphorus clearance, but 18–30 hours per week of HD is usually required for sufficient clearance to obviate the need for phosphorus binders. An increase in 30 minutes per treatment would not be expected to significantly lower serum phosphorus levels.Calcimimetics modulate the calcium-sensing receptor and increase sensitivity of parathyroid glands to calcium. These agents have proven to be a highly effective therapy for SHPT because of their ability not only to decrease PTH levels, but also to reduce serum calcium and phosphorus levels. Etelcalcetide is an IV calcimimetic that has been demonstrated to be as effective as cinacalcet in lowering PTH. In this patient who demonstrates severe, refractory SHPT despite adherence to maximum cinacalcet therapy, it is unlikely that changing the route of administration would result in significant improvement.Although a low-phosphorus diet and phosphate binders are essential to manage SHPT, they are insufficient if hyperphosphatemia is the result of endogenous release due to high bone turnover, often suggested by elevation of alkaline phosphatase, as in this patient. Bone biopsy studies have demonstrated that PTH levels are poor predictors of renal osteodystrophy; alkaline phosphatase has reemerged as the better predictor of high bone turnover. Thus, in a patient who is already adherent to diet and binders, switching from sevelamer to ferric citrate would be unlikely to significantly improve serum phosphorus levels.",
        "references": []
    },
    "42": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 50-year-old woman with ESRD due to immunoglobulin A (IgA) nephropathy who received a deceased donor kidney transplant 3 months ago is evaluated for decreased kidney function. Anti-thymocyte globulin (ATG) induction therapy was used, and graft function was immediate. The lowest creatinine was 1.2 mg/dL (reference range, 0.5–1.1) and remained stable at that level until increasing to 2.3 mg/dL over the past 3 weeks.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There were no donor-specific antibodies (DSA) detected prior to transplant. The patient had preexisting antibodies to CMV and EBV before transplantation. Current medications include tacrolimus, mycophenolate mofetil, prednisone, trimethoprim-sulfamethoxazole, and nifedipine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, her BP is 175/100 mm Hg. There is no tenderness over the allograft and no audible allograft, iliac, or femoral bruits. Cardiovascular and pulmonary examination findings are within normal limits. There is a left-sided brachiocephalic arteriovenous fistula with a normal bruit and thrill.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                162,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                335 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                123 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                DSA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                CMV DNA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Tacrolimus, trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5–10 (&gt;3 months post-transplantation)\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 30px;\">A kidney allograft biopsy is performed. Light microscopy reveals acute tubular necrosis, mesangiolysis, duplication of the GBM, and thrombi within glomerular arterioles and capillaries. Both simian virus-40 (SV-40) and C4d immunohistochemistry stains are negative. Immunofluorescence staining is negative for IgG, IgM, and IgA but 3+ for fibrin. Silver stain of the biopsy demonstrates an arteriolar thrombus (arrow), basement membrane thickening and wrinkling, podocyte swelling, and endothelial cell swelling.</p>\n<div style=\"align: left; margin-bottom: 20px;\">\n<figure><img alt=\"Picture 3\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/161_42ksapv6m1.jpg\" style=\"width: 511px; height: 334px;\"/>\n<figcaption><em>Image courtesy of Leonardo Riella, MD, Harvard Medical School</em></figcaption>\n</figure>\n</div>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue tacrolimus"
            },
            {
                "label": "B.",
                "text": "IV methylprednisolone"
            },
            {
                "label": "C.",
                "text": "IV immunoglobulin and plasmapheresis"
            },
            {
                "label": "D.",
                "text": "Anticoagulation"
            },
            {
                "label": "E.",
                "text": "IV immunoglobulin and rituximab"
            }
        ],
        "correct_answer": "Discontinue tacrolimus",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "Withdrawal of the calcineurin inhibitor (CNI) is the first step in management of this kidney transplant patient presenting with de novo thrombotic microangiopathy (TMA).De novo TMA after kidney transplant occurs in approximately 1%  of transplants and has multiple potential etiologies, including CNIs, antibody-mediated rejection (AMR), other immunosuppressants (such as mammalian target of rapamycin [mTOR] inhibitors), viral infections (e.g., CMV), and complement pathway mutations.  The mechanism by which these entities cause TMA has not been well established. Importantly, some of the classic features of TMA, such as hemolytic anemia, schistocytosis, thrombocytopenia, and AKI, may be lacking or subtle in patients with de novo TMA after transplant. Although not always successful, discontinuation of CNI is the mandatory first treatment strategy for patients with de novo TMA post-transplant. If TMA resolves, it is sometimes possible to reintroduce a CNI at a lower dose or alternative form without recurrent TMA. If TMA persists, complement inhibition with eculizumab may be helpful, as demonstrated in a small study in which 29% of patients with de novo TMA post-transplant were found to have complement mutations. Note that many patients will have normal C3 levels despite abnormalities in the alternative pathway.Given the absence of de novo DSA, and the absence of microvascular inflammation and C4d deposition on biopsy, acute AMR is unlikely, so therapies geared toward treatment of AMR, including IV immunoglobulin, plasmapheresis, and rituximab, would not be the next step.Anticoagulation has not been demonstrated to be safe or effective for patients with TMA. Antiplatelet therapy and deep venous thrombosis prophylaxis are sometimes added if there is no significant thrombocytopenia or active bleeding risk.A higher dose of prednisone or IV methylprednisolone might be indicated for management of acute rejection or to supplement maintenance immunosuppression if tacrolimus is withdrawn but would not address the TMA. Alternatively, a CNI may be replaced with belatacept in appropriate patients.",
        "references": []
    },
    "43": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old woman with relapsed diffuse large B-cell lymphoma is referred for evaluation of AKI. She has not yet initiated chemotherapy. She reports normal oral intake and has not experienced vomiting, diarrhea, or changes in urinary frequency or volume. She takes no prescription medications and does not use NSAIDs or herbal supplements.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, BP is 116/71 mm Hg and heart rate 75/min. Heart and lung examinations are normal, but there is bilateral ankle edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data are significant for creatinine 2.5 mg/dL, increased from 0.8 mg/dL 3 weeks ago (reference range, 0.5–1.1), and albumin 3.8 g/dL (reference range, 3.5–5.5). Urinalysis shows specific gravity 1.025, 2+ albumin, and no RBCs or WBCs on microscopy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A positron emission tomography (PET)-CT scan from 2 days ago shows numerous, enlarged abdominal, pelvic, and retroperitoneal. <sup>18</sup>fluorodeoxyglucose (FDG)-avid lymph nodes. The left kidney is 9.8 cm, and the right kidney is 8 cm. No other anatomic abnormalities are present.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>A renal diuretic scintigraphy scan reveals the following:</strong></p>\n<figure style=\"margin-bottom: 30px;\"><img alt=\"Picture 9\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/137_blobid0.png\" style=\"width: 75%; height: auto;\"/>\n<figcaption><em>Image courtesy of Victoria Gutgarts, MD, Memorial Sloan Kettering Cancer Center</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Based on the nuclear medicine scan, which of the following would be the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Refer for left ureteral stent"
            },
            {
                "label": "B.",
                "text": "Collect 24-hour urine for creatinine clearance and protein excretion"
            },
            {
                "label": "C.",
                "text": "Refer for right ureteral stent"
            },
            {
                "label": "D.",
                "text": "Initiate furosemide IV"
            },
            {
                "label": "E.",
                "text": "Obtain kidney ultrasound"
            }
        ],
        "correct_answer": "Refer for left ureteral stent",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "This patient with relapsed lymphoma, AKI, and evidence of left-sided obstruction on renal diuretic scintigraphy should be referred for insertion of a left ureteral stent.Renal scintigraphy is a nuclear medicine technique that uses radioactive isotopes, commonly technetium 99m (Tc-99m), to evaluate kidney function. Tc-99m is conjugated to ligands eliminated by glomerular filtration or tubular secretion to assess GFR\n        or renal plasma flow. It is an effective tool to identify obstruction in situations in which hydronephrosis is absent.Three components comprise a normal renogram, as shown in the figure below. The first phase reflects the bolus of the radioactivity that arrives via the renal artery to the kidney. The second phase indicates the accumulation of the tracer in the kidney\n        up to the peak. The third and final phase reflects the excretion of the radiotracer from the kidney.In obstructive AKI, phase 3 is absent, and the curve generated from the affected kidney shows a slow continuous accumulation of tracer with no downslope. Phase 3 may also be absent or blunted in the presence of significant CKD or AKI. A dose of a\n        loop diuretic can be administered to induce tracer elimination to distinguish between intrinsic AKI or CKD (elimination occurs and phase 3 is observed) and obstruction (no elimination). This patient’s left kidney renogram shows uptake of the tracer with\n        an absent phase 3, even after diuretic administration, consistent with obstruction. In comparison, there is rapid elimination of tracer from the right kidney after the administration of diuretic. Thus, a referral to urology for insertion of a\n        left ureteral stent is warranted. When obstruction is due to malignant or fibrotic encasement of the ureter and kidney, as can occur in lymphoma, hydronephrosis may be absent.Obtaining a kidney ultrasound is unnecessary because the renogram is diagnostic of left kidney obstruction. Of note, unilateral obstruction does not typically result in AKI unless the non-obstructed kidney is abnormal. In this case, the right kidney\n        is atrophic (8 cm) relative to the left kidney (9.8 cm) and probably functionally impaired at baseline. Therefore, unilateral obstruction of the left kidney can explain the AKI.Because the post-diuretic phase 3 (downward slope) of the right kidney renogram is normal, there is no evidence for right ureteral obstruction, and right ureteral stenting would be inappropriate.Twenty-four-hour urine collection for creatinine clearance and protein excretion would not address the obstruction identified on renal scintigraphy.Although a single dose of diuretic may be administered during the nuclear medicine study to increase specificity for obstruction, therapeutic administration of furosemide would not address this patient’s obstructive uropathy.",
        "references": []
    },
    "44": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 65-year-old woman </span><span>with a history of alcohol use disorder presents with a 2-day history of abdominal discomfort and a 1-day history of nausea, vomiting, and dyspnea. She does not have a headache, changes in vision or hearing, chest pain, diarrhea, or urinary symptoms. She acknowledges that she often drinks alcohol to the point of intoxication, but she abstained from alcohol the previous day because of abdominal pain. She does not take any prescription or over-the-counter medications. </span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Her BP is 112/68 mm Hg and heart rate 92/min. Heart and lungs are normal. She has mild, diffuse abdominal tenderness to palpation but no rebound. There is no edema.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>The following laboratory results are obtained:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                95 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.84 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                195 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactic acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–2.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                315 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ethanol\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Acetone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;49\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                β-Hydroxybutyrate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.37 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.4\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Methanol\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Pending (mg/dL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;49\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ethylene glycol\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Pending (mg/dL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;49\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Isopropanol\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Pending (mg/dL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;49\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Arterial blood gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.19\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                93 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                75–100\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Bicarbonate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–26\n            </td>\n</tr>\n</tbody>\n</table><p style=\"margin-top: 30px; margin-bottom: 15px;\">Urinalysis demonstrates specific gravity of 1.004, pH of 5.0, and no blood or protein. Ketones are strongly positive. There are no crystals identified in the sediment.</p>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hemodialysis"
            },
            {
                "label": "B.",
                "text": "Fomepizole"
            },
            {
                "label": "C.",
                "text": "Insulin and 0.9% saline"
            },
            {
                "label": "D.",
                "text": "Thiamine and dextrose"
            },
            {
                "label": "E.",
                "text": "0.9% saline"
            }
        ],
        "correct_answer": "Thiamine and dextrose",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "The most appropriate initial treatment for this patient presenting with features of alcoholic ketoacidosis (AKA) is the administration of thiamine and dextrose.This patient has an elevated anion gap metabolic acidosis (AGMA) in combination with an osmolal gap (OG) in the setting of recent abstinence from chronic alcohol consumption.The OG may be calculated as follows:Measured osmolality – calculated osmolality = OG315 mOsm/kg H2O – (Na×2 + BUN/2.8 + glucose/18)315 mOsm/kg H2O – (137 × 2 + 15/2.8 + 195/18)315 – 290 mOsm/kg H2O= 25 mOsm/kgIn this case, the OG is 25 mOsm/kg H2O.By dividing by its molecular weight (58 mg/mOsm) and converting dL to kg, the contribution of acetone to the OG can be estimated:(150 mg/dL×10 dL/kg)÷58 mg/mOsm = 25.9 mOsm/kg H2OThe index of suspicion must remain high for toxic alcohol poisoning in a patient presenting with AGMA and an elevated OG, but this patient does not demonstrate the visual disturbances that occur with methanol poisoning or the AKI and calcium oxalate crystalluria seen with ethylene glycol toxicity. In this case, acetone accounts for the OG, and it is not necessary to invoke the presence of a toxic alcohol that would indicate the need for fomepizole or HD.Profound ketoacidosis can develop in patients with chronic alcohol use. Contributing factors include poor nutritional status, which results in a reduction in the insulin-to-glucagon ratio, leading to accelerated fatty acid utilization as a source of energy. Lower insulin levels decrease carnitine acyltransferase activity, impairing the entry of fatty acids into mitochondria, where they would normally enter the citric acid cycle, and instead shunting them to ketone production. Chronic metabolism of ethanol in the liver leads to an increased NADH/NAD+ratio, causing a mass balance shift of acetoacetate to β-hydroxybutyrate to a greater extent than typically seen in diabetic ketoacidosis (DKA). Patients most often present after a period of abstinence when the ethanol level is low, because withdrawal increases circulating catecholamines, provoking more peripheral mobilization of fatty acids.Treatment of AKA includes infusion of dextrose, which stimulates insulin release, which in turn lowers peripheral fatty acid mobilization and hepatic output of ketoacids. When giving dextrose to patients who have alcohol use disorder, or any condition prone to malnutrition, it is important to also ensure that thiamine is given beforehand. Thiamine is an essential cofactor in the citric acid cycle and therefore necessary for energy production. In the absence of adequate thiamine, pyruvate accumulates and is reduced to lactic acid. Furthermore, the administration of dextrose can provoke consumption of depleted thiamine stores, potentially resulting in Wernicke encephalopathy. Note that patients with AKA may present with a normal, low, or, as in this case, modestly elevated blood glucose.DKA is treated with insulin and volume expansion. DKA results from the inability to use glucose as a source of energy and resultant fatty acid utilization. In general, patients with DKA have blood glucose levels >275 mg/dL. Euglycemic DKA has been described in patients with type 1 and type 2 diabetes treated with sodium glucose transporter-2 inhibitors. These patients require exogenous glucose and insulin because they have urinary glucose losses and an elevated glucagon/insulin ratio.Isopropyl alcohol poisoning presents with acetone accumulation but not with metabolic acidosis or ketoacidosis. Massive ingestions are associated with hemodynamic collapse and can be treated with volume expansion, vasopressors, and dialysis, but these features are exceedingly rare.Lactic acidosis can have multiple different etiologies and is most commonly seen in septic shock, where poor tissue perfusion results in decreased aerobic cellular respiration and thus increased lactic acid accumulation. Treatment in this setting is aimed at improving perfusion with volume expansion, vasoconstrictors, and treatment of the underlying cause, such as with antibiotics. This patient’s lactic acid level is at the upper limit of normal, and she does not appear to be in shock, with normal BP and pulse.",
        "references": []
    },
    "45": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 72-year-old man with history of seizure disorder, gastroesophageal reflux disease (GERD), and hypertension presents after a witnessed generalized seizure. He is postictal, and history is obtained from his wife. She reports that he has been more fatigued recently, but she did not observe any specific illness. His current medications include amlodipine, phenytoin, sucralfate, and simvastatin.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>His vital signs are remarkable for BP of 100/72 mm Hg, heart rate 90/min, respiratory rate 20/min, and oxygen saturation of 95% breathing room air. He is lethargic but arousable to stimuli. He moves all extremities spontaneously. His lungs are clear, and cardiovascular examination is normal.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span><span>His laboratory results are as follows:</span></span></span>\n</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9100/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                74 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatine kinase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1250 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55–170\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Free κ-to-free λ light chain ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.26–1.65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which the following is the MOST likely etiology for this patient’s hyperphosphatemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "AKI"
            },
            {
                "label": "B.",
                "text": "Phenytoin"
            },
            {
                "label": "C.",
                "text": "Rhabdomyolysis"
            },
            {
                "label": "D.",
                "text": "Sucralfate"
            },
            {
                "label": "E.",
                "text": "Multiple myeloma"
            }
        ],
        "correct_answer": "Multiple myeloma",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "This patient has pseudohyperphosphatemia associated with anemia, hypergammaglobulinemia, elevated free light chain ratio, hypercalcemia, and decreased kidney function, which together suggest a diagnosis of multiple myeloma.Immunoglobulin excess due to multiple myeloma, monoclonal gammopathy, or Waldenström macroglobulinemia may cause interference with colorimetric assays for phosphorus, causing pseudohyperphosphatemia. Alternatively, increased phosphate binding capacity of the paraproteins may result in an increase in total serum phosphate without an increase in biologically active phosphate. Re-analysis after removal of the paraprotein results in normalization of the spurious hyperphosphatemia.Although oral phenytoin is not associated with hyperphosphatemia, IV therapy with high dose fosphenytoin may be associated with acute serum phosphate elevation. Fosphenytoin is a prodrug that is metabolized to phenytoin, phosphate, and formaldehyde and is used for treatment of status epilepticus and prophylaxis of seizures associated with neurosurgery. As opposed to IV phenytoin, fosphenytoin is not associated with significant hemodynamic adverse effects and may be a preferred therapy in the acute setting. Although hyperphosphatemia is a rare complication of therapy, caution should be used when administering high dose IV fosphenytoin in patients with CKD and decreased renal phosphate clearance. Phenytoin is among the drugs that enhance degradation of 25-hydroxyvitamin D and can occasionally cause hypophosphatemia by this mechanism.This patient has a mild elevation of serum creatine kinase, likely due to subclinical rhabdomyolysis related to his recent seizure. Although phosphorus release from damaged cells may occur in the setting of rhabdomyolysis, the degree of hyperphosphatemia is much higher than one would expect for this modest degree of creatine kinase elevation. In addition, associated hypocalcemia typically occurs because of calcium sequestration by necrotic muscle cells and deposition of calcium salts, as opposed to the hypercalcemia present in this patient.AKI or CKD will reduce phosphate filtration and excretion. However, normal serum phosphate levels are typically maintained until GFR decreases below 20–25 mL/min/1.73 m2because of a reduction in proximal renal tubular phosphorus reabsorption mediated by increased secretion of PTH and fibroblast growth factor-23. These effects result in enhanced phosphaturia. When urinary excretion is maximally stimulated by these mechanisms but no longer sufficient to maintain balance between dietary intake and excretion, hyperphosphatemia ensues. The degree of decreased kidney function in this patient is unlikely to cause such a profound increase in serum phosphorus.Sucralfate is not associated with hyperphosphatemia. It contains aluminum, which binds phosphate and can lead to hypophosphatemia.",
        "references": []
    },
    "46": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 24-year-old woman presents to the emergency department after 3 days of fatigue, malaise, tingling in her legs, and restlessness. She also endorses nausea but denies emesis. Her medical history is notable for hospitalization at age 18 years for management of disordered eating, but she reports that this condition resolved before she entered college. She also has a history of persistent hypokalemia that was first identified when she was a teenager. She states she was informed that the hypokalemia relates to a genetic condition that results in excessive renal potassium excretion. Her medications include a potassium supplement of uncertain dose and calcium carbonate, which she takes occasionally for upset stomach. She is a graduate student and is due to present an update on her dissertation soon. She describes herself as highly energetic and often sleeps only 2–3 hours each night. She typically spends several hours each day dancing for exercise and stress reduction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Her BP while seated is 119/75 mm Hg, heart rate 89/min, respiratory rate 17/min, and body mass index 22 kg/m</span><span><sup>2</sup></span><span>. After she stands for 2 minutes, BP is 82/62 mm Hg and heart rate 121/min. She is alert and oriented. She appears anxious. Porcelain crowns are present on her anterior teeth. The heart and lungs are normal. Her abdomen is diffusely tender, but there is no guarding or rebound. Mild pretibial edema is present.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                135 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                82 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                52 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ionized calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.12–1.23\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25-Hydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                52 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                43 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY explanation for her condition?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Milk-alkali syndrome"
            },
            {
                "label": "B.",
                "text": "Gitelman syndrome"
            },
            {
                "label": "C.",
                "text": "Bartter syndrome"
            },
            {
                "label": "D.",
                "text": "Disordered eating"
            },
            {
                "label": "E.",
                "text": "Diuretic abuse"
            }
        ],
        "correct_answer": "Disordered eating",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "The most likely diagnosis for this patient with metabolic alkalosis, hypokalemia, and low urine chloride is vomiting related to disordered eating of the subtype bulimia with binging-purging behavior.Eating disorders are often concealed by patients who are not forthcoming about their behavior or may not recognize their behavior as pathologic. The diagnosis is particularly challenging in patients such as this one, in whom alternative diagnoses may have been erroneously postulated and then propagated.The differential diagnosis of metabolic alkalosis includes gastrointestinal hydrogen ion loss, renal hydrogen ion loss, and the addition of exogenous alkali. In this case, the divergence of urine chloride (very low) and urine sodium (not low) suggests vomiting as the primary driver of the derangements. Vomiting results in loss of hydrochloric acid in the emesis, which is accompanied by the addition of bicarbonate ion to blood. The resulting high level of filtered bicarbonate then exceeds the resorptive threshold in the proximal tubule and functions as a non-reabsorbable anion, carrying sodium and potassium into the urine. Urine chloride is low because of concomitant volume contraction and increased reclamation of chloride along the nephron, as well as a reduced filtered load due to the loss of chloride in the emesis. If a steady state is reached and emesis ceases, urine sodium decreases under the influence of aldosterone, but the alkalosis persists until chloride is replete. Of note, hypomagnesemia is commonly identified in patients with disordered eating. Inadequate intake and urinary losses may contribute. Refeeding can exacerbate this problem.Diuretic abuse, unless remote, is characterized by an inappropriately high urine chloride. Likewise, Bartter and Gitelman syndromes, inherited disorders of sodium reabsorption in the loop of Henle or distal tubule, respectively, mimic chronic exposure to loop or thiazide diuretics and manifest with metabolic alkalosis and hypokalemia and often hypomagnesemia as well. The urine chloride is inappropriately high in these disorders.Calcium carbonate is now the most common cause of milk-alkali syndrome and can result in severe metabolic alkalosis and decreased kidney function. However, it also results in hypercalcemia, which is not present in this case. It would be reasonable to discontinue calcium carbonate, but milk-alkali syndrome is not the most likely diagnosis.Eating disorders, including severe restriction of intake, self-induced vomiting, diuretic abuse, and laxative abuse, lead to a perpetual state of volume contraction, potently stimulating the renin-angiotensin-aldosterone system. Excessive renal excretion of potassium in this situation is multifactorial, with aldosterone action at the principal cell, increased distal sodium delivery, and bicarbonaturia all contributing. Chronic volume contraction may cause adrenal hypertrophy and persistently elevated aldosterone secretion, even during abatement of the disordered eating and after intravascular volume has been restored. This situation has been termed the “pseudo-Bartter” syndrome.Aggressive volume expansion is commonly used for such patients but may not be necessary in all cases. In the absence of signs of severe volume depletion, such as hypotension, a more circumspect approach is warranted. Large-volume saline infusion will increase sodium delivery to the distal tubule, which could further provoke urinary potassium wasting. Additionally, patients with pseudo-Bartter syndrome may develop acute edema in response to saline infusion due to aldosterone-induced sodium retention. Chloride repletion with potassium is preferred; sodium chloride can also be given at a modest rate. Spironolactone can may be useful, for a period of 3–4 weeks, to block aldosterone-mediated potassium and hydrogen wasting. Note that magnesium repletion is also necessary.HD has a limited role in the management of metabolic alkalosis but could be used in the setting of severe AKI or ESRD using a reduced bicarbonate bath. Acid infusion in the form of ammonium chloride or hydrochloric acid is no longer in common use because of the caustic properties of these agents. Acidic amino acid or ammonium chloride infusion may be used to treat severe metabolic alkalosis (bicarbonate >50 mEq/L) in patients who are unable to receive HD, but this therapy can result in azotemia or hyperammonemia.",
        "references": []
    },
    "47": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 36-year-old woman with Crohn disease is admitted to the hospital for a flare and undergoes small bowel resection with ostomy placement. During the first 24 hours after surgery, ostomy output is excessive. Subcutaneous octreotide is initiated with moderate reduction in stool volume by the third day. She reports incisional pain.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Medications include morphine as needed, methylprednisolone, lisinopril, and heparin subcutaneously.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"></p>\n<p>Her BP is 168/92 mm Hg and heart rate 104/min. She has normal heart and lung examinations. Her abdomen is tender consistent with her recent surgery. The surgical wound and ostomy appear healthy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>The following laboratory data are obtained:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Day 3</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                140\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                96 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                101\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                99 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                122\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                56 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                44 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\"><span>The patient is treated with 10 units of regular insulin and glucose, and repeat serum potassium is 4.9 mEq/L.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY cause of the hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Metoprolol"
            },
            {
                "label": "B.",
                "text": "Lisinopril"
            },
            {
                "label": "C.",
                "text": "Heparin"
            },
            {
                "label": "D.",
                "text": "Octreotide"
            },
            {
                "label": "E.",
                "text": "Methylprednisolone"
            }
        ],
        "correct_answer": "Octreotide",
        "abim_content_category": "Pharmacology",
        "explanation": "This patient is hyperkalemic because of relative insulin deficiency induced by octreotide. Insulin deficiency results in hyperkalemia by reducing the activity of Na-K-ATPase, resulting in reduced cellular uptake. Octreotide is a potent inhibitor of\n        insulin secretion, and patients can experience up to a 1 mEq/L increase in serum potassium after its administration. This effect can be more pronounced in patients with ESRD. Patients with relative insulin deficiency, as can occur in inflammatory\n        bowel disease and undernourishment, are also at greater risk. If discontinuation of octreotide is not feasible, patients may require exogenous insulin. Hyperkalemia in this case responded readily to exogenous insulin challenge.Lisinopril and heparin both cause hyperkalemia by decreasing the production of aldosterone. Heparin inhibits aldosterone synthase in the zona glomerulosa. Lisinopril inhibits ACE, decreasing the angiotensin II-mediated stimulus for aldosterone production. Hypoaldosteronism results in a reduction in renal potassium excretion. The urinary potassium concentration is of limited utility in the evaluation of hyperkalemia, but low concentration (urinary potassium concentration of <40 mEq/L or a urine potassium-to-creatinine ratio of <20 mEq/g) is consistent with impaired renal potassium excretion. In this case, the urine potassium concentration of 100 mEq/L suggests that renal potassium excretion is intact, which indicates that neither the lisinopril nor the heparin is the primary cause of hyperkalemia.Nonselective ß-blockers such as propranolol or labetalol can cause transcellular shift of potassium by reducing the activity of cellular Na-K-ATPase, mainly through antagonism of ß-2 adrenergic receptors. Metoprolol is a selective antagonist of ß-1\n        receptors, so it is less likely to cause hyperkalemia.Methylprednisolone and other corticosteroids may cause hypokalemia, not hyperkalemia, by stimulating the mineralocorticoid receptor in cells of the collecting tubule, causing potassium excretion.",
        "references": []
    },
    "48": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A 47-year-old man with long-standing bipolar disorder is evaluated for frequent urination. He has CKD stage G3a/A1 attributed to chronic lithium toxicity; lithium was discontinued 10 years ago. Current medications include valproic acid, fluoxetine, and olanzapine. The patient reports the need to urinate every hour during the day and several times every night. He complains of constant thirst and dry mouth.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Physical examination including postural vital signs is normal. Laboratory data are obtained at the time of the examination. He then refrains from food or liquid intake overnight and returns to the lab the following morning.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>The following results are obtained:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Day 1</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Day 2, 8:00 a.m.</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                144\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                105\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.37 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.34\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                408\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–1400\n            </td>\n</tr>\n</tbody>\n</table>  <br/><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Desmopressin"
            },
            {
                "label": "B.",
                "text": "Cinacalcet"
            },
            {
                "label": "C.",
                "text": "Hydrochlorothiazide"
            },
            {
                "label": "D.",
                "text": "Amiloride"
            },
            {
                "label": "E.",
                "text": "Drink to thirst"
            }
        ],
        "correct_answer": "Drink to thirst",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation": "This patient should be advised to let thirst guide his fluid intake. He likely has increased thirst secondary to his underlying psychiatric disorder, his atypical antipsychotic medications, or both.Patients with a history of long-term lithium use and urinary frequency may be erroneously diagnosed with nephrogenic diabetes insipidus (DI). The patient has a dilute urine on spot check, consistent with either primary polydipsia or DI. In this case, the appropriate increase in urine osmolality after water deprivation during sleep indicates intact urinary concentrating mechanisms, thereby ruling out DI. Primary polydipsia is strongly associated with psychiatric conditions and is frequently attributed to mood-stabilizing medications, whose anticholinergic properties cause dry mouth and stimulate drinking. Thus, the patient may be advised to drink to thirst. Rarely, primary polydipsia results in water intake that significantly exceeds water excretory capacity, causing hyponatremia. Such patients require fluid restriction. If dry mouth is the primary driver of intake, salivation stimulators such as sugar-free lemon drops or the use of artificial saliva may be helpful.Desmopressin is used to treat central DI and would not have a role in this case in which the presence and action of antidiuretic hormone can be inferred by the osmolality of the morning urine specimen.Hypercalcemia is another common cause of nephrogenic DI. Long-term lithium use can result in hyperparathyroidism, possibly by antagonizing the calcium-sensing receptor, and therefore result in mild hypercalcemia. The mechanism by which hypercalcemia causes nephrogenic DI is not completely understood but appears to involve inhibition of aquaporin-2 translocation to the apical membrane of cortical collecting duct principal cells. Treatment for this condition may include parathyroidectomy or cinacalcet. This patient’s calcium is at the upper limit of normal, so it would be unlikely to cause nephrogenic DI. The response to overnight water deprivation argues against hypercalcemia and DI as a cause of polyuria.Long-term lithium use is a classic cause of nephrogenic DI. Lithium entering the tubular lumen via glomerular filtration can re-enter principal cells in the cortical collecting duct via the epithelial sodium channel (ENaC). After gaining entry to the principal cells, lithium inhibits translocation of aquaporin-2 and impairs free water reabsorption. Patients with lithium-mediated nephrogenic DI who are still receiving lithium may benefit from amiloride, which blocks lithium reuptake into principal cells. Thiazide diuretics, by causing mild volume contraction and stimulating sodium and water reuptake in the proximal nephron, or via proximal tubule carbonic anhydrase inhibition, may also be of benefit in this condition by reducing polyuria. In this case, in the absence of evidence for nephrogenic DI, there is no indication for either amiloride or hydrochlorothiazide.",
        "references": []
    },
    "49": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">\nA 64-year-old woman with coronary artery disease, diabetes mellitus type 2, and hypertension presents with chest pain. She undergoes cardiac catheterization, which reveals multivessel disease. She subsequently undergoes coronary artery bypass graft surgery, which is complicated by AKI due to acute tubular necrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                54 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 mg/dL (baseline, 1.1)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Transferrin saturation\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                146 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11–307\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following treatment is the NEXT BEST STEP in anemia management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Packed RBCs"
            },
            {
                "label": "B.",
                "text": "Erythropoietin"
            },
            {
                "label": "C.",
                "text": "No additional management"
            },
            {
                "label": "D.",
                "text": "Desmopressin"
            },
            {
                "label": "E.",
                "text": "IV iron sucrose"
            }
        ],
        "correct_answer": "No additional management",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "Treatment of anemia in AKI is controversial. For this patient, conservative management would be appropriate given her hemoglobin of 9.2 g/dL.Outcomes, including progression of AKI or mortality, among patients with anemia and AKI are not clearly improved with treatments such as transfusion of packed RBCs or erythropoiesis-stimulating agent (ESA) administration. Therefore, neither of these treatments is indicated. Furthermore, a more restrictive packed RBC transfusion threshold (<7.5 g/dL), compared with a more liberal strategy, is associated with equivalent risk of AKI among those undergoing cardiac surgery.The patient’s iron saturation and ferritin levels are above the threshold usually associated with absolute iron deficiency but lower than targets established for management of anemia in patients with CKD or ESRD. Targets have not been established for patients with AKI. The safety of IV iron in this setting has not been extensively tested, although a small case-control study found no increase in adverse outcomes. At present, in the absence of an absolute iron deficiency or an inadequate response to an ESA, IV iron is not recommended in the setting of AKI.Desmopressin can be used to treat uremia-related platelet dysfunction resulting in bleeding but is not known to affect anemia in the absence of active bleeding.",
        "references": []
    },
    "50": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 40-year-old man with CKD stage G5/A3 due to type 2 diabetes mellitus and hypertension is initiated on HD. He has no history of jaundice, IV drug use, or blood transfusion. He has fatigue and anorexia that have improved since beginning HD. He does not have abdominal pain or nausea.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Physical exam reveals a BP of 148/68 mm Hg and heart rate 82/min. Examination reveals a normal heart, lung, and abdomen. There is no scleral icterus, jaundice, or stigmata of chronic liver disease.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span><span>Laboratory data include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antigen (HBsAg)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antibody (HBsAb)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B core antibody (HBcAb) IgG\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                HBcAb IgM\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 IU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16 IU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Prothrombin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11–13\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Immunity after hepatitis B infection"
            },
            {
                "label": "B.",
                "text": "Acute hepatitis B infection"
            },
            {
                "label": "C.",
                "text": "Recovery from hepatitis B infection"
            },
            {
                "label": "D.",
                "text": "Chronic hepatitis B infection"
            },
            {
                "label": "E.",
                "text": "Recent hepatitis B vaccination"
            }
        ],
        "correct_answer": "Recent hepatitis B vaccination",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient with a positive test for HBsAg but negative results for core antibody, and no other signs, symptoms, or laboratory evidence of hepatitis, was most likely recently vaccinated with recombinant HBsAg.There are several hepatitis B vaccines approved for use, including a recent 2-dose formulation. All use recombinant HBsAg to provoke protective immunity, manifested in the recipient by the brief appearance of HBsAg followed by the longer persistence of HBsAb in the serum.The hepatitis B vaccine is typically administered as 2–3 doses over 1–6 months, depending on the generation of vaccine administered. Measurement of HBsAg within 2 weeks of administration can potentially result in a positive test, erroneously suggesting acute or chronic infection. The HBsAg typically becomes undetectable (negative) by 14–20 days after vaccination. Because HBsAg-positive patients are typically isolated in an HD unit, with dedicated machines, checking a hepatitis B viral DNA can distinguish true acute infection from vaccination effects.In addition to positive HBsAg, chronic hepatitis B infection would be accompanied by positive HBcAb IgG; acute infection would be accompanied by positive HBcAb IgM and possibly positive serum e-antigen and hepatitis B DNA. In both cases, HBsAb would be negative.Vaccine-mediated immunity to hepatitis B would result in a positive HBsAb and negative HBsAg, whereas natural immunity after infection would also be accompanied by positive HBcAb.These expected findings are summarized in the following table:StatusHBsAgHBsAbHBcAb IgGHBcAb IgMAcute infection+-+/-+Chronic infection+-+-Recent (<14 days) vaccination+---Immunity following infection-++-Immunity following vaccination-+--",
        "references": []
    },
    "51": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>A 72-year-old man with type 2 diabetes mellitus, coronary artery disease, and ischemic stroke is admitted to the ICU because of emphysematous pyelonephritis, severe sepsis, and hemodynamic instability. His BP is 89/55 mm Hg while receiving a norepinephrine infusion. He develops oliguric AKI despite aggressive administration of IV fluids for the past 48 hours. CVVH with a predilution replacement fluid rate of 50 mL/min, blood flow rate of 150 mL/min, and a net ultrafiltration rate of 0 mL/min is initiated. Regional anticoagulation is also initiated with a prefilter infusion of 0.5% trisodium citrate at 20 mL/hour, along with IV calcium chloride at 20 mL/min via the return line to reverse anticoagulation. Laboratory studies show a hematocrit of 24% and a postfilter ionized calcium concentration of 0.25 mmol/L (reference range, 1.12–1.23; target level for extracorporeal anticoagulation, 0.3–0.4). CVVH therapy has been interrupted 3 times since it was initiated 18 hours ago because of repeated clotting of the extracorporeal circuit.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the most appropriate intervention to improve CVVH delivery?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase blood flow rate"
            },
            {
                "label": "B.",
                "text": "Increase ultrafiltration rate"
            },
            {
                "label": "C.",
                "text": "Increase citrate infusion rate"
            },
            {
                "label": "D.",
                "text": "Decrease calcium chloride infusion rate"
            },
            {
                "label": "E.",
                "text": "Increase replacement fluid rate"
            }
        ],
        "correct_answer": "Increase blood flow rate",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "The most appropriate intervention to reduce extracorporeal system thrombosis in this patient receiving CVVH is to increase the blood flow rate (Qb).The repeated clotting of the circuit in this patient is most likely the consequence of an excessively high filtration fraction (FF). Excessive FF results in marked hemoconcentration of the blood leaving the hemofilter, which promotes clotting. A FF of 20–25% is associated with a lower tendency for extracorporeal system thrombosis and is therefore desirable.FF is calculated as the ratio of the total rate of effluent flow (Qeff, which equals the replacement fluid rate [Qr] plus any other prefilter infusions [in this case Qcit], plus the ultrafiltration goal [Quf]) to the total rate of inflow (Qinf, which is equal to the replacement fluid rate [Qr] plus the citrate infusion rates [Qcit] plus the plasma flow rate [Qp]). The plasma flow rate is equal to Qb multiplied by (1 – hematocrit). In this case, the ultrafiltration goal is 0 mL/h, and the citrate infusion rate is 20 mL/min. The calcium infusion rate does not influence the filtration fraction because the infusion occurs post-filter. Note that many practitioners would adjust the Quf to account for the calcium infusion to avoid net positive fluid balance. In this case, for simplicity, we have set Quf to zero and the contribution of the calcium infusion to fluid balance is trivial at 20 mL/h.The FF is therefore calculated as follows:FF= Qeff/Qinf = (Qr + Qcit + Quf) / (Qr + Qcit + Qp)= (50 + 20 + 0) / [50 + 20 + 150(1 – 0.24)]= 0.38= 38%Increasing Qb to 300 mL/min would achieve a FF of 23%, within the target range.Increasing the replacement fluid rate would not result in a significant change in the FF because both the numerator and denominator would increase proportionally. Increasing the ultrafiltration target without increasing Qb would increase FF and worsen the tendency to extracorporeal thrombosis.Although it may be necessary to titrate the citrate solution infusion rate when Qb is increased to maintain a postfilter ionized calcium concentration in the target range, this patient has a postfilter ionized calcium concentration of 0.25 mmol/L, already below target, indicating adequate citrate effect. Increasing citrate infusion rate without an increase in Qb will not augment regional anticoagulation or reduce extracorporeal thrombosis. After the Qb is adjusted to achieve FF in the 20–25% range, the citrate infusion rate should be adjusted to provide a postfilter ionized calcium concentration of less than 0.35 mmol/L to provide adequate extracorporeal anticoagulation. The infusion of calcium post-circuit is necessary to prevent symptomatic hypocalcemia but does not affect anticoagulation within the CVVH circuit.",
        "references": []
    },
    "52": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 39-year-old man with ESRD due to immunoglobulin A (IgA) nephropathy is receiving CCPD. His medical history is also significant for allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia and underlying T10-level paraplegia. A chronic sacral decubitus ulcer is being managed by a wound care team. His appetite is poor, but his oral intake has improved over the past month with help from a dietician. Currently, his protein intake is estimated to be 0.9 g/kg per day and total nutritional intake to be 30 kCal/kg per day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>On physical examination, he is observed using his wheelchair and can independently wheel himself with fair upper body strength. Lungs are clear. Lower extremity muscular atrophy is present, but there is also moderate edema bilaterally. A 2.5 cm sacral decubitus ulcer is without erythema or discharge.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>Laboratory data reveal albumin 2.3 g/dL (reference range, 3.5–5.5) and potassium 3.1 mEq/L (reference range, 3.5–5.0). His weekly Kt/V is 2.2.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Intraperitoneal nutrition"
            },
            {
                "label": "B.",
                "text": "Total parenteral nutrition"
            },
            {
                "label": "C.",
                "text": "Enteral feeding via gastrostomy tube (G-tube)"
            },
            {
                "label": "D.",
                "text": "Oral protein supplementation"
            },
            {
                "label": "E.",
                "text": "No change in management"
            }
        ],
        "correct_answer": "Oral protein supplementation",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "Oral protein supplementation should be initiated for this patient with ESRD and hypoalbuminemia.Malnutrition is also referred to as undernutrition or protein energy wasting. In patients undergoing dialysis, malnutrition is usually due to a combination of inadequate protein intake and ongoing inflammation. It is most often identified by hypoalbuminemia. Other features include weakness and sarcopenia. The stepwise approach to management of malnutrition in patients with ESRD begins with the identification and treatment of reversible causes of inflammation and inadequate intake, such as inadequate dialysis or occult infection, coupled with dietary counseling. Nutritional supplementation is indicated if malnutrition persists after an attempt at optimizing diet and intake under the supervision of a dietician. In this case, despite dietary counseling, the patient is not achieving the recommended dietary protein intake of 1.2–1.3 g/kg per day for clinically stable patients receiving PD, and even less than the recommended 1.5 g/kg per day for patients with ESRD and significant wounds.If oral supplementation fails, enteral feeding via G-tube can be considered. This procedure would violate the peritoneum and interrupt administration of PD, requiring transition to HD until the G-tube tract seals. Thus, G-tube feedings would not be the best choice for this patient.Intraperitoneal nutrition (IPN) would be a reasonable next step if enteral supplementation fails or is not possible. This technique involves use of peritoneal dialysate containing amino acids. PD with IPN is usually performed daily (either intermittently administered with the daytime dwell or continuously with all exchanges). IPN is expensive and generally not intended to provide long-term protein support. Risks of peritonitis or ultrafiltration failure are not increased with IPN. Metabolic acidosis can result, and alkali supplementation is usually necessary. Some patients report nausea or discomfort with instillation of amino acid-containing dialysate. Evidence that IPN results in lower mortality is lacking.Total parenteral nutrition is invasive and associated with bloodstream infections and other complications and would not be indicated as the next best step in management for this patient before other options are exhausted.",
        "references": []
    },
    "53": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 59-year-old man with hypertension, hypothyroidism, and psoriasis presents with 2 months of fever, fatigue, and flank pain. He is a construction worker and has been exposed to asbestos. He is also an active smoker with a 40-pack-year history. He takes levothyroxine but no over-the-counter medications or herbal products. He reports no changes to his urine output.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient is overweight and appears well. His BP is 132/76 mm Hg and pulse 76/min. Cardiopulmonary examinations are normal. The abdomen is soft and nontender. There are no flank or abdominal bruits. Urinalysis reveals 1+ protein and trace blood by dipstick. The sediment is bland.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Other laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 mg/dL (baseline, 0.9)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Erythrocyte sedimentation rate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                46 mm/h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–15\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C-reactive protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.8\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 30px;\"><span>Kidney ultrasound shows a 9-cm right kidney and a 10-cm left kidney without hydronephrosis. A representative CT with IV contrast shows abnormal peri-aortic and peri-iliac soft tissue (arrows) that also encases the renal arteries and ureters:</span></p>\n<figure>\n<img alt=\"\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/91_Q53_(2).jpg\" style=\"align:left; width: 90%; height: auto;\"/>\n<figcaption>Image from Vaglio A, Maritati F. <i>J Am Soc Nephrol</i> 27(7): 1880–1889, 2016 </figcaption>\n</figure>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe doxycycline"
            },
            {
                "label": "B.",
                "text": "Prescribe tamoxifen"
            },
            {
                "label": "C.",
                "text": "Prescribe losartan"
            },
            {
                "label": "D.",
                "text": "Renal artery stenting"
            },
            {
                "label": "E.",
                "text": "Ureteral stenting"
            }
        ],
        "correct_answer": "Ureteral stenting",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "This patient with idiopathic retroperitoneal fibrosis (RPF) and AKI should be treated with ureteral stenting to relieve obstruction.Most cases of RPF are idiopathic (>75%). This condition is diagnosed more frequently in men and usually occurs in the fifth or sixth decade of life. Fibrosis in the retroperitoneum usually envelopes the aorta or iliac arteries and surrounding structures, including the ureters. Histopathology reveals inflammatory cells and collagen bundles. Presenting symptoms include fatigue, weight loss, low-grade fever, flank or abdominal pain, testicular complaints, and constipation. Nephrologic complications include AKI due to obstruction, often without hydronephrosis (30–50%), and kidney atrophy. Extrinsic compression of the renal arteries resulting in renal artery stenosis (RAS) can occur, and some authors propose that this may explain the tendency to kidney atrophy. Inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) are often elevated. Because ureteral obstruction is common when there is peri-iliac involvement as in this case, relief of obstruction with ureteral stents would be the first step. If kidney function failed to improve, or if clinical signs of RAS ensued, it would be reasonable to consider renal artery intervention.The most common risk factors for idiopathic RPF are toxin exposure (tobacco and asbestos) and inflammatory diseases (particularly autoimmune thyroiditis, but also immunoglobulin G4 [IgG4]-related disease, rheumatoid arthritis, vasculitis, lupus, and psoriasis). Other risk factors for RPF include medications (ergot alkaloids, bromocriptine, methyldopa, hydralazine, etanercept, and infliximab), malignancy (carcinoid, lymphoma, sarcomas, and numerous carcinomas), infections (tuberculosis, histoplasmosis), radiation exposure, and abdominal surgery. Diagnosis of RPF is made by contrast CT showing fibrous encasement of the aorta or iliac vessels, with or without ureteral involvement. This can also be seen on MRI. Ultrasound has low sensitivity. Biopsy is also diagnostic.After relief of ureteral obstruction, medical therapy with glucocorticoids and other immunosuppression (mycophenolate mofetil, azathioprine, methotrexate, or cyclophosphamide) may be added; rituximab or tocilizumab is suggested for highly resistant cases. Tamoxifen has been advocated as a steroid-sparing antifibrotic agent but was less effective than prednisone when compared in a clinical trial. Surgical intervention is pursued if medical therapy fails.Although the patient has low-grade fever, no other clinical findings or imaging supports infection. Therefore, doxycycline, a tetracycline antibiotic, would not be indicated. Similarly, neither the anti-inflammatory activity of doxycycline nor the antifibrotic properties of ARBs (such as losartan) are known to be effective in treating RPF.",
        "references": []
    },
    "54": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 70-year-old woman presents to the emergency department with a 3-day history of generalized muscle weakness and difficulty walking. Her medical history includes hypertension, chronic constipation, and CKD stage 3b (eGFR 42 mL/min/1.73 m<sup>2</sup>). Her prescribed medications are lisinopril and hydrochlorothiazide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, she is lethargic and flushed, with BP 75/40 mm Hg and pulse 46/min. Diffusely diminished muscle tone is observed along with generalized hyporeflexia. The remainder of the examination is unremarkable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data show the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                126 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                94 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2 mg/dL (baseline, 1.3)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">Urinalysis shows specific gravity of 1.009, pH 6, and no protein. Microscopy shows &gt;10 granular casts/HPF and no cells.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">A 12-lead EKG shows bradycardia, normal rhythm, PR interval 0.23 ms, and QRS duration 510 ms (both increased).</p>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which ONE of the following is the MOST likely cause of this patient’s symptoms?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypophosphatemia"
            },
            {
                "label": "B.",
                "text": "Hyponatremia"
            },
            {
                "label": "C.",
                "text": "Hypermagnesemia"
            },
            {
                "label": "D.",
                "text": "Hypokalemia"
            },
            {
                "label": "E.",
                "text": "Hypocalcemia"
            }
        ],
        "correct_answer": "Hypermagnesemia",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "The symptoms of muscle weakness, hypotonia, flushing, and hypotension along with elevated magnesium levels are typical of magnesium toxicity. Magnesium-containing antacids, laxatives, and enemas can increase serum magnesium levels in patients with impaired kidney function. Patients with chronic constipation, such as this one, are at risk to overuse magnesium-based over-the-counter remedies. Unless specifically asked, patients might not disclose their use of over-the-counter medications, herbal products, or home remedies.Magnesium is an effective calcium channel blocker, resulting in vasodilation, flushing, and hypotension when the concentration is elevated. Intracellular magnesium also blocks several cardiac potassium channels, which causes cardiac conduction defects. Bradycardia is seen when magnesium levels exceed 4–5 mEq/L. Additional EKG changes are apparent at concentrations of 5–10 mEq/L. These changes include prolongation of PR and QT intervals and increased QRS duration. Hypermagnesemia can also decrease the release of acetylcholine, blocking transmission at the neuromuscular junction and causing hypotonia and hyporeflexia.Hyponatremia can present with symptoms of nausea, weakness, gait instability, and falls. However, the hypotonia, hypotension, and EKG changes described in the case are not consistent with the clinical features of hyponatremia. Furthermore, in a case series of thiazide-induced hyponatremia, women who had symptoms of malaise, lethargy, dizzy spells, and vomiting had a mean plasma sodium of 114 mEq/L, much lower than the patient described.Hypophosphatemia can present with weakness, paresthesias, delirium, ventricular arrhythmias, and impaired myocardial contractility. However, these neurological and cardiac manifestations are typically seen only with severe hypophosphatemia (<1 mg/dL).Severe hypokalemia (<2.5 mEq/L) is associated with significant muscle weakness and rhabdomyolysis. Hypokalemia can cause a wide range of arrhythmias. Concomitant hypomagnesemia increases the risk of arrhythmias. This patient’s potassium is not low enough to account for her weakness and would not explain the other signs and symptoms.Acute hypocalcemia can present with hypotension and QT prolongation. However, hypocalcemia causes neuromuscular excitability and tetany. Therefore, hypotonia and hyporeflexia argue against hypocalcemia as the explanation for this patient’s presentation. Hypermagnesemia can cause hypocalcemia by suppressing PTH secretion.Hypermagnesemia leads to increased magnesium cations that are not included in the anion gap calculation. However, the concentration of the accompanying anion (chloride) will also increase. Thus, there is no change in “measured cations” but an increase in “measured anions,” resulting in low measured anion gap.",
        "references": []
    },
    "55": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 49-year-old woman with a medical history of asthma, Graves disease, mitral valve prolapse, systemic sclerosis, and celiac disease is admitted to the hospital for progressive fatigue.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Physical examination shows a BP of 211/102 mm Hg and heart rate 81/min. Exam is notable for skin induration and tightness affecting her hands, arms, and face. Retinal hemorrhages and cotton wool spots are identified along with an S4 gallop and bibasilar crackles.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.48 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">Urinalysis reveals 1+ protein and 6 WBCs/HPF without hematuria or cellular casts.</p>\n<p style=\"margin-bottom: 15px;\">Kidney histopathology is shown below.</p>\n<figure><img alt=\"\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/94_blobid0.jpg\" style=\"width: 6.5in; height: 5.15in;\"/>\n<figcaption><em>Image courtesy of Janis Cho, MD, Yashpal Kanwar, MD, and Cybele Ghossein, MD, Northwestern University</em></figcaption>\n</figure>\n<p style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Diltiazem"
            },
            {
                "label": "B.",
                "text": "Eculizumab"
            },
            {
                "label": "C.",
                "text": "Methylprednisolone"
            },
            {
                "label": "D.",
                "text": "Cyclosporine"
            },
            {
                "label": "E.",
                "text": "Captopril"
            }
        ],
        "correct_answer": "Captopril",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "This patient with accelerated hypertension associated with retinopathy and AKI (“malignant hypertension”), and a kidney biopsy demonstrating marked arteriolosclerosis, onion-skinning, and luminal thrombosis, has scleroderma renal crisis (SRC) and should be treated with captopril.SRC is characterized by 3 major features in a patient with systemic sclerosis: (1) abrupt onset of moderate-to-severe hypertension, (2) AKI, and (3) urinalysis that is normal or reveals only mild proteinuria with few cells or casts. The key therapy in SRC is prompt BP control. Compared with other antihypertensive agents, a number of observational and uncontrolled studies have shown that ACEI are associated with better preservation of kidney function and improved survival in patients with SRC. Even patients who require dialysis should be treated with ACEI because some will recover kidney function after prolonged dialysis dependence. Mild degrees of hyperkalemia, such as in this case, should not dissuade from ACEI therapy. Captopril has been the most used ACEI, as its short half-life is useful in the acute setting. The incidence of SRC seems to have decreased in recent decades, possibly because of the widespread use of vasodilators to treat Raynaud phenomenon and hypertension. Interestingly, there seems to be no role for prophylactic use of ACEI, and some cases of SRC appear to be precipitated by ACEI use.Glucocorticoids are commonly used to manage some features of systemic sclerosis or associated autoimmune conditions, but doses of prednisone >7.5 mg/day appear to confer an increased risk for SRC. Similarly, SRC has been reported in patients receiving cyclosporine, possibly because it causes vasoconstriction of the afferent arteriole, with increased frequency of microangiopathy. Thus, neither glucocorticoids nor calcineurin inhibitors are recommended to manage SRC.Diltiazem is a relatively weak antihypertensive and would not be preferred to manage malignant hypertension associated with SRC. Dihydropyridine calcium channel blockers such as nifedipine are effective second-line agents after ACEI. Eculizumab, an anti-C5 complement monoclonal antibody, has been used rarely in ACEI-refractory SRC, with mixed results.",
        "references": []
    },
    "56": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 64-year-old man with ESRD secondary to ADPKD started APD 2 months ago. He weighs 80 kg. His APD prescription is four 2-L exchanges of 2.5% dextrose. After 1 month of APD, the following information is obtained:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 50%;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60 mg/dL\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Dialysate urea (DU)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mg/dL\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine urea  nitrogen (UUN)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                480 mg/dL\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine volume (UV)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 L/d\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ultrafiltration volume (UF)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 L/d\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the closest approximation of the weekly Kt/V urea provided by this patient’s residual kidney function?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "1.2"
            },
            {
                "label": "B.",
                "text": "0.5"
            },
            {
                "label": "C.",
                "text": "1.4"
            },
            {
                "label": "D.",
                "text": "1.9"
            },
            {
                "label": "E.",
                "text": "Unable to calculate"
            }
        ],
        "correct_answer": "1.4",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The weekly Kt/V urea provided by residual kidney function in this patient is 1.4.The daily residual kidney Kt/V is calculated as (UUN × UV)/(BUN × TBW), where TBW is total body water, estimated as 60% of body weight.For this patient, residual kidney Kt/V = (480 mg/dL × 1.2 L)/(60 mg/dL × 48 L) = 0.2.Multiplied by 7 days, the weekly residual kidney Kt/V is 1.4.Daily peritoneal urea clearance may be calculated similarly, but total dialysate effluent (TDE) substitutes for urine volume. In this case, TDE is the sum of dialysate infused (four 2 L exchanges = 8 L) plus the UF volume (2.4 L), for a value of 10.4 L:(DU × TDE)/(BUN × TBW) = (90 mg/dL × 10.4 L)/(60 mg/dL × 48 L) = 0.325.Weekly peritoneal Kt/V would be 0.325 × 7 = 2.275, for a total weekly Kt/V of 1.4 + 2.275 = 3.675.",
        "references": []
    },
    "57": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 35-year-old man with cirrhosis due to alcohol use disorder and hepatitis C virus (HCV) infection, refractory ascites, and esophageal varices presents to clinic with progressive kidney injury. His creatinine 1 year ago was 1.1 mg/dL and 6 months ago was 1.5 mg/dL. He has required large-volume paracenteses, usually accompanied by IV albumin, on an increasingly frequent basis. Medications include furosemide and spironolactone, both of which have been increased without impact on ascites accumulation. He does not use NSAIDs. He has chronic fatigue and weakness but no new symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"></p>His examination is notable for BP 100/50 mm Hg, pulse 90/min, temperature 36.5°C, clear mentation, spider angiomas, moderate gynecomastia, a protuberant abdomen, 2+ edema of the extremities, and no asterixis.<p></p><p></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data reveal:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                International normalized ratio (INR)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3-1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.1 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ascitic fluid leukocyte count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                49/µL (7% neutrophils)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">Ultrasound shows a right kidney of 10.1 cm and a left kidney of 10.6 cm without hydronephrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">The patient is admitted to the hospital, diuretics are discontinued, and albumin is infused IV without improvement in kidney function. Norepinephrine and octreotide are added, but kidney function and urine output continue to decline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following strategies is MOST LIKELY to result in improved kidney function?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Pentoxifylline"
            },
            {
                "label": "B.",
                "text": "Midodrine"
            },
            {
                "label": "C.",
                "text": "Rifaximin"
            },
            {
                "label": "D.",
                "text": "Prednisolone"
            },
            {
                "label": "E.",
                "text": "Transjugular intrahepatic portosystemic shunt (TIPS)"
            }
        ],
        "correct_answer": "Transjugular intrahepatic portosystemic shunt (TIPS)",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation": "Placement of a TIPS is the intervention most likely to result in improved kidney function in this patient with hepatorenal syndrome (HRS).HRS is a functional form of AKI that occurs in patients with liver failure complicated by ascites. HRS usually occurs in the setting of cirrhosis, but it can also occur in cases of fulminant hepatic failure. HRS is subclassified as AKI, non-AKI, or CKD depending on the chronicity of kidney disease. The diagnosis of HRS typically requires the absence of evidence for nephrotoxins, glomerulonephritis, obstruction, or acute tubular necrosis. Initial management consists of withdrawal of diuretics coupled with volume expansion with albumin. If this is unsuccessful, vasopressor therapy consisting of midodrine, norepinephrine, or terlipressin is provided with a target of increasing the mean arterial pressure (MAP) by >5 mm Hg (some patients respond better to relatively greater increases in MAP, so this target should be individualized). Vasopressor therapy is combined with ongoing albumin infusions and often with octreotide. Response rates of up to 50% are reported with terlipressin and norepinephrine, though seem to be lower with midodrine. Thus, resorting to midodrine after a lack of response to norepinephrine would not be appropriate.A TIPS addresses ascites formation by reducing portal hypertension. It is analogous to surgical portosystemic shunts but less invasive and generally well tolerated. Immediate procedure-related complications such as bleeding or AKI are uncommon. After a TIPS, preexisting encephalopathy may worsen or new encephalopathy may develop. A decline in liver function can also be observed. A retrospective, matched-cohort analysis of 276 patients showed improvement in eGFR 90 days after placement of TIPS compared with serial large-volume paracentesis. Significant preexisting hepatic encephalopathy is a contraindication to placement of a TIPS. This patient who has relatively preserved liver function and does not have encephalopathy is a reasonable candidate for TIPS.Rifaximin is used to prevent spontaneous bacterial peritonitis in patients with cirrhosis and ascites, but it does not have a known direct role in the treatment of HRS. Pentoxifylline and prednisolone have been used to treat acute alcoholic hepatitis but not HRS.",
        "references": []
    },
    "58": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 67-year-old woman presents to the hospital with shortness of breath. She has a history of CKD stage 3, aortic stenosis, and systolic heart failure. Her baseline creatinine is 1.8 mg/dL. Over the past 3 weeks, she has had worsening lower extremity edema and dyspnea on exertion despite doubling her diuretic dose. Outpatient medications include aspirin, bumetanide, cholecalciferol, famotidine, isosorbide, hydralazine, and potassium chloride.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, her BP is 168/63 mm Hg, pulse 63/min, respiratory rate 22/min, and oxygen saturation 88% while breathing 2 L/min of oxygen by nasal cannula. A loud systolic ejection murmur and an S4 gallop are present. She has bilateral crackles throughout both lungs and 3+ lower extremity edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory studies include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ANA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:2560, homogeneous pattern\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1:40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                115 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Antibodies to double-stranded DNA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2 IU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–7\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis C antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antigen\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B surface antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ANCA, cytoplasmic\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1:20\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1:20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ANCA, perinuclear\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:320\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1:20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-GBM antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1 unit\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1 unit\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-histone antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:32\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;1:16\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">Urinalysis shows 2+ proteinuria and 4+ blood; microscopy shows &gt;30 RBCs/HPF, almost all of which are dysmorphic, as well as 2 RBC casts/HPF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A representative light microscopy image of her kidney biopsy is shown below.</p>\n<figure><img alt=\"Picture 1\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/162_58v6m1.jpg\" style=\"width: 532px; height: 252px;\"/>\n<figcaption><span><span style=\"\"><span style=\"\">Masson trichrome stain; Jennette JC, Nachman PH,</span></span><em> Clin J Am Soc Nephrol </em>12(10): 1680–1691, 2017</span></figcaption>\n</figure>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which ONE of the following is the MOST likely immunofluorescence staining pattern observed in this patient’s kidney biopsy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Linear capillary wall deposition of IgG"
            },
            {
                "label": "B.",
                "text": "Mesangial deposition of IgA"
            },
            {
                "label": "C.",
                "text": "Absent or scant immunoglobulin deposition"
            },
            {
                "label": "D.",
                "text": "Full-house deposition in capillary wall and mesangium (IgG, IgM, IgA, C3, and C1q)"
            },
            {
                "label": "E.",
                "text": "Subepithelial capillary wall deposition of IgG and C3"
            }
        ],
        "correct_answer": "Absent or scant immunoglobulin deposition",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "In this patient with AKI and nephritic syndrome and positive test results for ANA, ANCA, and anti-histone antibodies, the most likely diagnosis is drug-induced vasculitis, which is typically characterized by absent or scant immunoglobulin deposition (“pauci-immune”). In this case, the most likely culprit is hydralazine. The trichome stain light micrographic image demonstrates a cellular crescent (largest arrow) and fibrinoid necrosis of the capillary tuft and arteriole wall (small arrows).Hydralazine is a direct-acting vascular smooth muscle potassium channel opener leading to vasodilation. It is used in the treatment of hypertension and, in combination with isosorbide, congestive heart failure. It is known to cause two drug-induced rheumatic syndromes: lupus and ANCA-associated vasculitis (AAV). Drug-induced lupus generally presents with constitutional symptoms and serositis; kidney involvement is relatively uncommon. It resolves with cessation of the drug. Hydralazine-induced AAV can present with hemoptysis and pauci-immune glomerulonephritis (GN). Cessation of the drug is necessary, but patients often need systemic immunosuppression as well. ANA and anti-histone antibodies are often positive in both hydralazine-induced lupus and AAV.Full-house immunofluorescence is typical of proliferative lupus nephritis. Linear capillary wall IgG deposition is expected in anti-GBM disease. Mesangial IgA deposition occurs in IgA nephropathy. Subepithelial IgG and C3 deposition occurs in postinfectious GN, classically after a streptococcal infection. Although any of these entities can be associated with crescent formation, the concomitant arteritis, the serologic results, and the clinical scenario favor hydralazine-induced AAV.",
        "references": []
    },
    "59": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 67-year-old woman is evaluated for nephrotic syndrome. She has had progressive lower extremity edema and a weight gain of 9 kg over 3 months. A transthoracic echocardiogram was normal. She was previously well and takes no medications or supplements.</p>\n<p dir=\"ltr\">Physical examination reveals a BP of 146/80 mm Hg and pulse 78/min. Lungs are clear to auscultation, and there is no jugular venous distension. She has 3+ lower extremity edema bilaterally.</p>\n<p dir=\"ltr\"><span> <span style=\"\">Laboratory data include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                374,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                56 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.78 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18.2 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\">Urinalysis reveals clear, yellow urine with 3+ albumin and moderate blood.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney biopsy is performed. By light microscopy, all glomeruli demonstrate capillary loop and mesangial expansion by eosinophilic material. No endocapillary proliferation or crescent formation is noted. Tubules are non-atrophic. Faint glomerular birefringence\n    is present on Congo red staining. By IF microscopy, staining is 3+ for IgG in the capillary loops. κ and λ staining are present in equal intensity. EM shows capillary loop and mesangial accumulation of randomly arranged\n    fibrils measuring 15–30 nm in diameter with no immune complexes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>A representative electron micrograph is shown below:</span></p>\n<figure><img alt=\"Picture 1\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/136_blobid0.png\" style=\"width: 6.5in; height: 5.43333in;\"/>\n<figcaption>\n<p dir=\"ltr\" style=\"margin-bottom: 0px;\">46,000× magnification; Nasr SH et al., <em>Clin J Am Soc Nephrol</em> 6(4): 775–784, 2011<br/><br/></p><p dir=\"ltr\" style=\"margin-bottom: 0px;\">Mass spectrometry performed on the biopsy specimen identifies the presence of DNAJB9 protein.</p>\n</figcaption>\n</figure>\n<p style=\"margin-top: 20px; margin-bottom: 15px;\"><span><strong>Which ONE of the following is the most likely diagnosis?</strong></span></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fibrillary glomerulonephritis"
            },
            {
                "label": "B.",
                "text": "Cryoglobulinemic vasculitis"
            },
            {
                "label": "C.",
                "text": "Immunotactoid glomerulonephritis"
            },
            {
                "label": "D.",
                "text": "Collagenofibrotic glomerulopathy"
            },
            {
                "label": "E.",
                "text": "AL amyloidosis"
            }
        ],
        "correct_answer": "Fibrillary glomerulonephritis",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "This patient, presenting with nephrotic (and possibly nephritic) syndrome with randomly arranged 15–30 nm fibrils and DNAJB9 protein on kidney biopsy has fibrillary glomerulonephritis (GN).The clinical presentation of fibrillary GN is variable, ranging from purely nephrotic to nephritic or in between. Because the light microscopic findings can vary, the diagnosis is traditionally made by demonstrating characteristic fibrils on electron microscopy of a biopsy specimen. Congo red staining is usually negative. DNAJB9, a heat-shock protein, is a highly sensitive and specific marker for fibrillary GN that can be confirmed by immunoelectron microscopy or mass spectrometry of kidney biopsy material. Immunohistochemical staining and measurement of serum DNAJB9 are also emerging as potentially useful markers. Patients confirmed to have fibrillary GN should be investigated for an underlying malignancy, plasma cell dyscrasia, or autoimmune disease.Light microscopy in amyloidosis shows acellular periodic acid-Schiff staining. Deposits can appear amorphous. The gold standard for diagnosis is Congo red positivity. Characteristic EM findings include randomly distributed small fibrils, 10–12 nm in diameter. Light chain (AL) amyloidosis will demonstrate a light chain predominance by immunofluorescence microscopy. In this case, the size of the fibrils, lack of light chain specificity, and the presence of DNAJB9 protein all point away from AL amyloidosis.Parallel arrays of microtubules with diameter >30 nm are seen in immunotactoid GN. Patients with this disorder have a more favorable prognosis compared to those with fibrillary GN.Collagenofibrotic glomerulopathy is a rare glomerulopathy with organized deposits. These deposits are composed of type III collagen. The pathognomonic finding is a transverse band pattern of fibrils approximately 60 nm in diameter on EM. Light microscopy shows a lobular appearance of glomeruli that can be confused with Kimmelstiel-Wilson nodules. Immunofluorescence is generally unremarkable. The pathogenesis of this disease is unknown.Curved microtubules around 30 nm in diameter, often described to resemble a fingerprint pattern, are typical of GN related to cryoglobulinemia.",
        "references": []
    },
    "60": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span style=\"margin: 0;padding: 0;white-space: pre-wrap;\">A 73-year-old man with CKD stage G5A3 due to primary membranous nephropathy presents to establish care. His kidney disease has been unresponsive to immunosuppressive treatment. Medical history is significant for hypertension, microcytic anemia, and a recent episode of community-acquired pneumonia that was treated as an outpatient. He is currently asymptomatic except for mild fatigue.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span style=\"margin: 0;padding: 0;white-space: pre-wrap;\">His medications include carvedilol, nifedipine, and atorvastatin. He does not take renin-angiotensin-aldosterone system inhibitors because of hyperkalemia. He received oral ferrous sulfate 325 mg (65 mg elemental iron) 3 times daily for 3 months but did not tolerate it because of nausea and constipation. He had an unremarkable endoscopy and colonoscopy 8 months ago.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span style=\"margin: 0;padding: 0;white-space: pre-wrap;\">His BP is 135/82 mm Hg and pulse 68/min. Physical examination is remarkable for mild pallor, clear lungs, normal cardiac sounds, mild lower extremity edema, and clear mentation. There is no asterixis.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span style=\"margin: 0;padding: 0;white-space: pre-wrap;\"><span>Current laboratory data are as follows:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Transferrin saturation (TSAT)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24–336\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Folate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.2 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Vitamin B<sub>12</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                780 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200–800\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management of his anemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Transfuse 1 unit of packed RBCs"
            },
            {
                "label": "B.",
                "text": "Iron sucrose 300 mg IV for three doses"
            },
            {
                "label": "C.",
                "text": "Epoetin alfa 100 units/kg subcutaneously every week"
            },
            {
                "label": "D.",
                "text": "Ferrous gluconate 325 mg (36 mg elemental iron) orally twice daily"
            },
            {
                "label": "E.",
                "text": "No change in management; start treatment at initiation of HD"
            }
        ],
        "correct_answer": "Iron sucrose 300 mg IV for three doses",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient with anemia associated with CKD stage 5 and iron deficiency should receive IV iron.KDIGO defines anemia in adults with CKD as a hemoglobin concentration <13 g/dL in men and <12 g/dL in women. In patients with CKD, iron deficiency is defined as a relative deficiency resulting in impaired response to an erythropoiesis-stimulating agent (ESA). Iron therapy should be started in CKD patients with anemia, ferritin <500 ng/mL, and TSAT <30%. The goal of iron therapy is to correct anemia, optimize responsiveness to ESA, and avoid the need for transfusion. A recent systematic review of trials of iron therapy in patients with CKD stages 3–5 found that IV iron was superior to oral in replenishment of iron stores and hemoglobin response, with the majority of patients demonstrating an increase in hemoglobin levels >1 g/dL regardless of the formulation of iron. Hypotension occurred more frequently in the IV group, whereas gastrointestinal adverse effects were more common with oral preparations.Studies regarding the use of IV iron in the presence of infection have shown conflicting results. Although it is biologically plausible that IV iron would predispose to infection or exacerbate existing infection, confirmatory data in humans are lacking. A meta-analysis in 2015 found that IV iron is not associated with increased frequency of infections. Despite lack of definitive evidence, some guidelines suggest that IV iron not be given in the presence of active infection.A variety of IV iron preparations are available, and each may be used in a variety of regimens. Iron sucrose is often infused in 100-mg or 200-mg increments for a total dose of 1 g over 2 weeks. Larger doses of 300–500 mg requiring only 2–3 infusions may be more convenient for patients not yet receiving dialysis.Oral iron is available in a variety of formulations touted to improve tolerability, but most have a high incidence of gastrointestinal adverse effects. A dose of 200 mg of elemental iron daily is recommended, but some patients tolerate lower doses better. In this case, oral iron would likely be less effective than IV iron and more likely to cause gastrointestinal adverse effects based on his previous experience with a trial of oral iron.It would be inappropriate to begin ESA therapy, such as with epoetin alfa, prior to correction of the iron deficiency. If iron repletion alone did not result in a satisfactory increase in hemoglobin, an ESA would then be indicated.In the absence of active, severe bleeding or severe symptoms of anemia, transfusion of RBCs should be avoided to minimize the risks of infections, transfusion reactions, and allosensitization.It would be inappropriate to delay treatment of the anemia until this patient requires initiation of dialysis. Effective correction of anemia to target hemoglobin can alleviate symptoms such as fatigue and favorably impact cardiovascular indices such as left ventricular hypertrophy. Whether anemia treatment delays the need for dialysis is uncertain, with some but not all trials showing benefit.",
        "references": []
    },
    "61": {
        "question": "<div class=\"qtext\"><p>A 51-year-old woman with hypertension presents to nephrology clinic for follow-up. She was diagnosed with hypertension 10 years ago and has been prescribed various classes of antihypertensives ever since. She has experienced adverse effects from each class of medication and has not been able to find a tolerable regimen. She developed dizziness and fatigue with chlorthalidone, nausea and abdominal pain with lisinopril and valsartan, and nonspecific malaise with spironolactone. She reported palpitations with nifedipine, headaches with amlodipine, and excessive fatigue with carvedilol. She reported having a “black-out episode” with doxazosin. Lower doses of these medications or alternate drugs in the same class were tried without success. </p>\n<p>Currently, she is not taking any antihypertensive medications and feels well. She checks her BP daily at home and reports average readings of 150/90 mm Hg. She has a history of depression, fibromyalgia, plantar fasciitis, and vertigo. She sees a psychiatrist regularly and reports that depression is well-controlled. She is adherent to her office visits and all other prescribed medications that include a multivitamin, sertraline, and over-the-counter acetaminophen. She does not use NSAIDs or illicit drugs. She describes her diet as healthy and does not add salt to her food. Renal artery duplex ultrasonography and investigation for endocrine-mediated hypertension have been negative.</p>\n<p>Her weight is 73 kg. Her BP is 164/104 mm Hg in both arms, heart rate 88/min, temperature 37.8°C, and oxygen saturation on room air 98%. Fundoscopy reveals copper wiring of the arterioles. Jugular venous distention is absent. S1 and S2 are normal. A loud S4 gallop is present. Lungs are clear. Abdomen is soft with active bowel sounds. The legs have trace edema, and neurological examination is normal.</p>\n<p style=\"margin-bottom: 15px;\"><span><span>Initial laboratory results include the following:</span></span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                189,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                109 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\">EKG reveals sinus rhythm meeting voltage criteria for left ventricular hypertrophy (LVH), as well as nonspecific T-wave changes. Echocardiogram reveals moderate concentric LVH and an ejection fraction of 70%.</p>\n<p style=\"margin-top: 20px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Renal denervation"
            },
            {
                "label": "B.",
                "text": "Increase sertraline dose"
            },
            {
                "label": "C.",
                "text": "Transdermal clonidine"
            },
            {
                "label": "D.",
                "text": "24-Hour ambulatory blood pressure monitor (ABPM)"
            },
            {
                "label": "E.",
                "text": "Acupuncture therapy"
            }
        ],
        "correct_answer": "Transdermal clonidine",
        "abim_content_category": "Hypertension",
        "explanation": "The next best step in management of this patient is to prescribe transdermal clonidine.This patient has multiple drug-intolerant hypertension (MDI-HTN), which is defined as intolerance to ≥3 classes of antihypertensive drugs. MDI-HTN is an important cause of pseudoresistance and medication nonadherence in patients with hypertension. It is a relatively common phenomenon, especially in women and older patients. It has been associated with psychiatric morbidity (depression and anxiety). There are limited guidelines on helping patients address MDI-HTN, but the literature suggests some success with a stepwise approach:Prescribe fractional doses of conventional antihypertensives, use liquid formulations of conventional antihypertensives, or both.Use transdermal preparations such as clonidine.Consider unconventional antihypertensives such as 5-phosphodiesterase inhibitors.Consider device therapy such as renal denervation.In this patient, step 1 has been attempted without success. If intolerance appears to be related to pills or tablets, changing to a liquid formulation may be efficacious. In this case, progression to transdermal therapy is warranted.In a study by Schuster et al, the clinical efficacy of transdermal clonidine in BP control in patients with MDI-HTN was good, with a reduction in clinic systolic BP of 23 ± 33 mm Hg (p<0.001) and a reduction in clinic diastolic BP of 10 ± 18 mm Hg (p= 0.002) over a duration of 11 weeks with a good tolerability profile.Renal denervation should be considered only when medical therapy options have been exhausted. Acupuncture therapy has shown inconsistent benefit for BP control, so it is not the best approach. A 24-hour ABPM will confirm the diagnosis of uncontrolled hypertension but will not necessarily change management for this patient who already has evidence (S4, LVH, and retinopathy) of suboptimally controlled hypertension. ABPM would be useful if the diagnosis of hypertension was in doubt or there was suspicion that home control was adequate despite high office BP. Although MDI-HTN is linked to depression, this patient has well-controlled symptoms, and there is no indication to increase the dose of her antidepressant.",
        "references": []
    },
    "62": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 73-year-old woman is referred for evaluation of a kidney mass. Her medical history includes preeclampsia, poorly controlled hypertension, peripheral vascular occlusive disease (PVOD), coronary artery disease, and a 60-pack-year history of smoking. The patient was hospitalized 4 months ago for hypertensive urgency. Six months ago, she received 4 coronary stents. During a recent evaluation for intermittent nausea, vomiting, and diarrhea, she underwent CT of the abdomen and pelvis with and without contrast, which revealed a 2.5-cm, enhancing, cortical mass in the mid-pole of the right kidney. There were no adenopathy or liver abnormalities. Extensive aortomesenteric atherosclerosis was felt to be the explanation for her symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vital signs include BP 168/88 mm Hg and heart rate 63/min. Abdominal examination reveals slight tenderness to deep palpation but is otherwise unremarkable, and the remainder of the exam is notable for features consistent with her diagnosis of PVOD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\">Laboratory data reveal normal kidney function and urinalysis. Chest x-ray is negative.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the BEST NEXT STEP in evaluation and management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Surgical nephrectomy"
            },
            {
                "label": "B.",
                "text": "Percutaneous needle biopsy"
            },
            {
                "label": "C.",
                "text": "Radiofrequency ablation with biopsy"
            },
            {
                "label": "D.",
                "text": "MRI with gadolinium"
            },
            {
                "label": "E.",
                "text": "Repeat CT in 18–24 months"
            }
        ],
        "correct_answer": "Radiofrequency ablation with biopsy",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "This patient with a small renal mass (SRM) who is a poor surgical candidate should undergo radiofrequency ablation (RFA) with biopsy.Nephrologists are frequently called on to participate in the evaluation of patients with an SRM. SRMs are suspicious solid or cystic lesions seen on either high-quality CT or MRI performed with and without contrast that measure <4 cm and are limited to the kidney (stage T1a). Imaging characteristics that suggest a greater risk of malignancy include enhancement with contrast and cystic lesions with irregular or thickened septae. The diagnostic accuracy of CT and MRI with contrast are similar, but MRI with gadolinium may provide better imaging than CT with contrast for SRM <2 cm in greatest diameter.Approximately 55% of contrast-enhancing SRMs are renal cell carcinoma (RCC), of which 55% are clear cell carcinoma (CCC), followed by papillary (20%) and chromophobe (5%) RCC. The clinical course for CCCs is variable and determined by stage and grade. In general, papillary and chromophobe RCCs <4 cm have an indolent course and a better prognosis than CCCs. Benign lesions include oncocytomas, angiomyolipomas, and metanephric adenomas.There is no single approach to the management of SRMs, and management decisions require consideration of individual patient- and tumor-specific characteristics. Factors affecting the patient’s suitability for surgery include age, comorbidities, life expectancy relative to the expected rate of tumor growth, presence and severity of CKD, expected progression to ESRD in the setting of a partial or total nephrectomy, and need for removal of the SRM to achieve kidney transplant candidacy.In this patient, nonsurgical interventions like RFA or cryoablation are reasonable approaches. RFA is most effective for SRMs <3 cm. It is associated with an increased risk for local recurrence, so post-intervention imaging is necessary, with repeat RFA for persistent or recurrent disease. A biopsy of the mass can be obtained at the time of the procedure and may be helpful, because the histology can guide prognosis and inform the need for additional therapy or surveillance.This patient is a high-risk surgical candidate given the presence of diffuse atherosclerotic vascular disease, uncontrolled hypertension, and recent treatment for cardiac ischemia. Therefore, surgical nephrectomy (partial or full) would not be the best choice.Serial radiographic imaging would be a reasonable option if this patient declines RFA at this time, but the mass should be followed more closely, at least initially. A reasonable approach for this patient would include serial radiographic imaging to monitor for an increase in the size of the mass over time, initially at 3 and 6 months to establish that the mass has a slow growth rate, then every 6–12 months for 2 years, and thereafter annually.The nondiagnostic rate of biopsies of kidney masses is approximately 15%, and the negative predictive value is 63%. Therefore, a biopsy that is negative for the presence of malignancy does not exclude that possibility. If the patient is a reasonable surgical candidate and is willing to undergo partial or total nephrectomy, percutaneous biopsy of the mass is not expected to influence treatment and is therefore not indicated. If the patient is a reasonable surgical candidate and confirmation of malignancy is desired by the patient or the surgeon, then a biopsy can be performed with the above caveats, assuming the mass is accessible for biopsy. Traditionally, concerns for neoplasm seeding of the biopsy tract limited the role of biopsy, but this appears to be a very rare complication.This patient has already had an appropriate imaging study consisting of CT with and without contrast, so it is unlikely that an MRI would add diagnostic value.",
        "references": []
    },
    "63": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old woman with ESRD presents to the dialysis clinic for her scheduled treatment. She has been HD-dependent for 2 years, using a left brachiocephalic arteriovenous (AV) fistula since inception. Her medical history includes coronary artery disease, heart failure with reduced ejection fraction, and peripheral arterial disease. She dialyzes thrice weekly for 210 minutes with an achieved blood flow rate of 450 mL/min and a dialysate potassium concentration of 2 mEq/L. She completes all treatments as prescribed. Medications include carvedilol, lisinopril, and aspirin. She is employed full-time and travels to her job after her dialysis sessions. She has received dietary counseling and restricts her potassium intake as advised.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, BP is 125/75 mm Hg and heart rate 76/min. The AV fistula has a soft thrill and bruit, without excessive pulsatility, aneurysms, edema, or skin changes. There is no peripheral edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data pre-dialysis include the following:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>3 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>2 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.37\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.43\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;1.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urea reduction ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                69%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                73%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;65%\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP in managing hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe a potassium-binding resin"
            },
            {
                "label": "B.",
                "text": "Refer for AV fistula angiography"
            },
            {
                "label": "C.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "D.",
                "text": "Increase dialysis time to 270 minutes"
            },
            {
                "label": "E.",
                "text": "Decrease potassium concentration in dialysate to 1 mEq/L"
            }
        ],
        "correct_answer": "Prescribe a potassium-binding resin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient with ESRD and chronic hyperkalemia should receive a potassium-binding resin, such as patiromer or sodium zirconium cyclosilicate.Population studies have shown increased mortality in patients receiving HD with serum potassium levels >5.8 mEq/L. The risk is especially pronounced in the long interdialytic window that occurs in thrice-weekly HD. The lowest risk for sudden cardiac arrest was observed at a serum potassium level of 5.1 mEq/L. Based on this evidence, this patient would benefit from improved control of serum potassium.A potassium-binding resin will lower her serum potassium. Although the action of the newer resins appear to be significantly faster than that of the older sodium polystyrene sulfonate, none these drugs is indicated for the treatment of acute hyperkalemia. They have been shown to be effective in control of chronic hyperkalemia. Risks of patiromer include hypomagnesemia, and magnesium level should be monitored. Patients receiving sodium zirconium cyclosilicate can develop edema. Both of these newer agents appear to have better efficacy and safety profiles than sodium polystyrene sulfonate, although head-to-head studies are lacking.Data on the use of renin-angiotensin-aldosterone system (RAAS) blockade in patients with ESRD have been conflicting, with some studies showing improved cardiovascular mortality and other studies showing no benefit. However, none of these studies had large numbers of patients with prior coronary artery disease. A 2003 study of 1000 patients with ESRD who had experienced myocardial infarction showed that aspirin, β-blocker, and ACEI therapy were less likely to be prescribed to patients with ESRD, but that ACEI prescription was associated with a 48% lower 30-day mortality among this population. A recent analysis of data from the Dialysis Outcomes and Practice Patterns Study that included >37,000 patients receiving dialysis showed a small survival benefit with RAAS inhibition, with ARBs showing greater benefit than ACEIs. Meta-analyses have shown a reduction in left ventricular hypertrophy in patients with ESRD receiving ARBs. RAAS blockers should not worsen the risk for hyperkalemia in patients with ESRD who have little renal potassium excretion left to inhibit, although some studies have shown increased risk in patients with anuria. In sum, lisinopril may improve her cardiovascular mortality and should not be stopped.Increasing her dialysis time is not indicated. Laboratory results show that she has adequate clearance over the past 3 months. She is currently employed, and extending her treatment time could interfere with her ability to get to work punctually.Lowering her potassium bath to 1 mEq/L will put her at risk for adverse cardiac events. Risk is greatest when there is wider variation between serum potassium and dialysate potassium, and large population-based studies have shown an association between higher risk of sudden cardiac death and dialysate potassium concentrations <2 mEq/L.Access evaluation is not indicated. She has no evidence of access dysfunction on physical exam or by laboratory parameters.",
        "references": []
    },
    "64": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 42-year-old man with ESRD secondary to focal segmental glomerulosclerosis receiving PD for 3 years presents with painful swelling of his left index finger. The pain has been present for several months and has progressively worsened. The patient does not recall any trauma. The ventral surface of the finger is particularly tender. He has a history of tertiary hyperparathyroidism and underwent a subtotal parathyroidectomy 1 year ago. Despite a substantial improvement in PTH and phosphorus levels immediately after surgery, these values have gradually and continuously increased over the past year. His current medications include cinacalcet 90 mg daily and sevelamer carbonate 3200 mg with each meal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On examination, the external skin overlying the finger appears normal. The finger pad is tender, firm, and nodular.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">X-ray of the left hand is shown below.</p>\n<figure><img alt=\"Picture 2\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/138_blobid0.png\" style=\"width: 4.10417in; height: 5.57292in;\"/>\n<figcaption><em>Image courtesy of Scott Liebman, MD, University of Rochester</em></figcaption>\n</figure>\n<p dir=\"ltr\" style=\"margin-top: 30px; margin-bottom: 15px;\"><span>His most recent laboratory results are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                135 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                94 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                84 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Intact PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1128 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585 (dialysis patients)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.65\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n</tbody>\n</table><p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Abscess"
            },
            {
                "label": "B.",
                "text": "β2-microglobulin amyloidosis"
            },
            {
                "label": "C.",
                "text": "Brown tumor"
            },
            {
                "label": "D.",
                "text": "Myositis ossificans"
            },
            {
                "label": "E.",
                "text": "Tumoral calcinosis"
            }
        ],
        "correct_answer": "Tumoral calcinosis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "Tumoral calcinosis is the most likely diagnosis in this patient with ESRD and recurrent tertiary hyperparathyroidism, severe hyperphosphatemia, and evidence of soft tissue calcification on x-ray.Tumoral calcinosis is an uncommon complication in patients with ESRD, in which extensive calcification of soft tissues leads to the formation of nodules that can be painful. This diagnosis is usually associated with severe perturbations in mineral metabolism parameters, including calcium, phosphorus, and PTH. Although more common in large joints, tumoral calcinosis has been described in the fingertip.Brown tumors, or osteitis fibrosa cystica, are manifestations of severe hyperparathyroidism. Brown tumors, which are collections of active osteoclasts, may present in several locations, including long bones, clavicles, and digits. Although this patient has severe hyperparathyroidism, the radiography in this case is not consistent with the presence of a brown tumor. Brown tumors appear as well-defined, radiolucent areas within the bone, whereas the lesion seen here is extra-osseous with increased calcification.β2-microglobulin amyloidosis is characterized by deposition of amyloid β2-microglobulin fibrils in bones and joints, causing arthralgias. It typically presents in hips, knees, wrists, and the spine. Calcification in the soft tissue of the fingertip would be highly atypical. β2-microglobulin amyloidosis has decreased in prevalence, possibly because of the increased use of high-flux HD membranes.Myositis ossificans is an ossifying soft tissue mass typically occurring in skeletal muscle. Patients typically recall a specific preceding trauma or repetitive motion injury. This condition is most common in flexor muscles of the arm and extensor muscles of the thigh; again, involvement of the fingertip would be extremely unusual. There is no known relationship between myositis ossificans and ESRD.A felon, or fingertip abscess, is unlikely in this case. Patients typically present with pain, swelling, and erythema in the affected digit, often following a puncture wound. No history or examination features suggest infection in this case. Additionally, this degree of calcification would not be expected in an abscess.",
        "references": []
    },
    "65": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 65-year-old man with ESRD due to type 2 diabetes and hypertension presents with a 1-year history of decreased libido and sexual function. He receives HD thrice weekly. His medical history also includes coronary artery disease and prostate cancer currently being managed with watchful waiting. He reports that most times, he is unable to achieve erections, and when he does, they are not hard enough to engage in sexual intercourse. This problem has become an increasing source of friction between him and his partner and significantly affects his quality of life.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.2–10.4\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Intact PTH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                650 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585 (dialysis patients)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Testosterone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                120 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                291–1100\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Prolactin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;20\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\">Kt/V is 1.4.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the NEXT BEST STEP to manage sexual dysfunction?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Sildenafil"
            },
            {
                "label": "B.",
                "text": "Citalopram"
            },
            {
                "label": "C.",
                "text": "Calcitriol"
            },
            {
                "label": "D.",
                "text": "Bromocriptine"
            },
            {
                "label": "E.",
                "text": "Testosterone"
            }
        ],
        "correct_answer": "Sildenafil",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The next step in treating this patient with ESRD and erectile dysfunction is to prescribe a phosphodiesterase-5 inhibitor such as sildenafil.Erectile dysfunction (ED) is common in patients with ESRD, affecting 80% and rated as severe in 50%, often adversely affecting quality of life. In this case, the patient has ED that is severe enough to adversely affect his relationship with his partner. Therapy with a phosphodiesterase-5 inhibitor such as sildenafil can improve ED and is usually well-tolerated. Medications in this class should be avoided by patients receiving nitrates. Interactions with other drugs such as α-adrenergic blockers can also be a concern.Although there is an association between secondary hyperparathyroidism and ED, there are no data to show that treating secondary hyperparathyroidism results in any improvement.There is no indication for antidepressant medications, such as citalopram, for this patient in the absence of depression. However, depression is common among patients with ESRD and other comorbidities, so screening for depression (even in the absence of ED) is worthwhile. Although depression may be associated with sexual dysfunction, ED does not always improve with antidepressant treatment.Studies are mixed on whether testosterone repletion improves ED in testosterone-deficient men receiving HD. Furthermore, diagnosis of testosterone deficiency in patients with ESRD requires measuring total testosterone at least twice in the early morning and in the absence of acute illness. Free testosterone measurement may be more accurate, as sex hormone-binding globulin is altered by age, liver disease, thyroid disease, obesity, and diabetes. Irrespective of its efficacy, however, testosterone supplementation is contraindicated in this patient with prostate cancer.Prolactin levels are often elevated in men receiving dialysis, as in this case. The cause of mild hyperprolactinemia is unknown but may be related to elevated PTH levels. Hyperprolactinemia, particularly when extreme, is associated with sexual dysfunction in men with ESRD. Although bromocriptine has been shown to lower prolactin levels to near normal, the effect on sexual function has been inconsistent. Hypotension may also limit the use of bromocriptine. A trial of bromocriptine could be considered if the response to sildenafil is inadequate, but it would not be the first choice.",
        "references": []
    },
    "66": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 48-year-old woman presents to the emergency department with right flank pain. A motor vehicle crash 3 years ago resulted in lower extremity paralysis and a left kidney laceration necessitating nephrectomy. Her subsequent course has included recurrent urinary tract infections. Her most recent episode was approximately 1 year ago. A CT scan performed to evaluate her right flank pain demonstrated a staghorn calculus in the right kidney with evidence of partial obstruction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 20px;\"><span>On examination, BP is 118/64 mm Hg and pulse 71/min. She has right costovertebral angle tenderness to percussion. </span><span>Laboratory data include a stable creatinine of 1.8 mg/dL (reference range, 0.5–1.1) with normal electrolytes. Urine pH is 7 (reference range, 4.5–8.0). Urine culture reveals 100,000 colony-forming units/mL of </span><em>Klebsiella </em><span>species.</span></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST appropriate next step in treating the nephrolithiasis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Antibiotics and hydrochlorothiazide"
            },
            {
                "label": "B.",
                "text": "Acetohydroxamic acid"
            },
            {
                "label": "C.",
                "text": "Tiopronin"
            },
            {
                "label": "D.",
                "text": "Extended course of antibiotics based on culture sensitivity"
            },
            {
                "label": "E.",
                "text": "Surgical stone removal"
            }
        ],
        "correct_answer": "Surgical stone removal",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation": "This patient with a partially obstructing staghorn calculus and CKD should undergo surgical stone removal.This patient has a staghorn calculus that developed from a struvite or carbonated apatite stone. These stones can grow rapidly over a period of weeks to months into large staghorn calculi involving the calyces and entire renal pelvis. If left untreated, this condition can lead to deterioration of kidney function and ESRD. This patient already has CKD in the setting of a solitary kidney. Surgical removal of the staghorn calculus would be the preferred treatment.Staghorn calculi are composed of magnesium ammonium phosphate (struvite) and calcium carbonated apatite. Struvite stone formation occurs only when ammonia production is increased and the urine pH is elevated. The only situation in which this process occurs in humans is with an upper urinary tract infection with a urease-producing organism, such asProteusorKlebsiella. Women and patients susceptible to urinary tract infections, such as those with neurogenic bladder, are more likely to develop struvite stones.Medical therapy alone is not the best choice, except for patients who are too ill to tolerate, or who refuse, surgical stone removal. Bacteria live within the stone where antimicrobial agents cannot penetrate. If surgery is not possible, then administration of a culture-specific antimicrobial agent can sometimes prevent further stone growth. However, antibiotics would not address the partial urinary tract obstruction that has developed in this patient.Treatment with urease inhibitors such as acetohydroxamic acid can be attempted in patients who are not surgical candidates. Urease inhibitors can cause complete, noncompetitive inhibition of urease production, with stone growth arrested in up to 80% of patients. Adverse effects are common, and up to 60% of patients can experience palpitations, edema, nausea, vomiting, diarrhea, headache, loss of taste, hallucinations, rash, abdominal discomfort, and anemia. For these reasons, acetohydroxamic acid is infrequently used.Tiopronin is a sulfhydryl donor used to prevent cystine stones. Hydrochlorothiazide may be useful to treat hypercalciuria.",
        "references": []
    },
    "67": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 57-year-old woman was admitted to the hospital for partial colectomy due to refractory diverticulitis. She underwent surgery without complication. She is now receiving IV piperacillin/tazobactam 3.375 g three times daily. She has a history of type 2 diabetes and hypertension, for which she takes metoprolol and insulin. Review of systems is significant for decreased oral intake as well as diarrhea since surgery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">On physical examination, her BP is 127/63 mm Hg, pulse 78/min, and body mass index 24 kg/m<sup>2</sup>. The abdomen is mildly tender consistent with her recent surgery; sparse bowel sounds are present. She has no swelling in the extremities. The rest of the examination is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Despite IV supplementation, her serum potassium concentration has progressively declined over the past few days. In the prior 24 hours, she received a total of 80 mEq of IV potassium chloride.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><span>Laboratory data are as follows:</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                104 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                157 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin-top: 30px; margin-bottom: 20px;\">Urine output was 2.5 L in the prior 24 hours. Urinalysis shows specific gravity of 1.010, pH 7.0, no blood, and no protein. Urine potassium is 22 mEq/L and urine creatinine 40 mg/dL.</p>\n<p style=\"margin-bottom: 15px;\"><strong>Which ONE of the following is the MOST likely cause of hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decreased oral intake"
            },
            {
                "label": "B.",
                "text": "Diarrhea"
            },
            {
                "label": "C.",
                "text": "Metoprolol"
            },
            {
                "label": "D.",
                "text": "Insulin"
            },
            {
                "label": "E.",
                "text": "Piperacillin/tazobactam"
            }
        ],
        "correct_answer": "Piperacillin/tazobactam",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "This patient has urinary potassium loss due to piperacillin/tazobactam. It is thought that piperacillin causes hypokalemia and metabolic alkalosis by the same mechanism as that of penicillin. Two hypotheses have been put forward for explaining the mechanism of hypokalemia. First, piperacillin behaves as a non-reabsorbable anion, enhancing transepithelial electronegativity in the distal nephron and resulting in increased distal sodium delivery and potassium excretion. Second, the large amount of sodium administered with piperacillin increases distal delivery of sodium and excretion of potassium through the renal outer medullary potassium (ROMK) channel. Lastly, the solute diuresis causes a high flow rate in the cortical collecting duct and potassium excretion through maxi-K channels.Evaluation of urinary potassium excretion is best accomplished by measuring potassium excretion in a 24-hour urine collection. Excretion of more than 25–30 mEq of potassium per day indicates inappropriate renal potassium loss. Here, the urine output of 2.5 L × 22 mEq/L is 55 mEq/d, which is inappropriately high. Measurement of the potassium and creatinine concentrations in a spot urinalysis is an alternative if collection of 24-hour urine is impractical. A spot urine potassium-to-creatinine ratio >15 mEq/g creatinine (or 1.5 mEq/mmol) usually indicates inappropriate renal potassium loss. Here, the urine K/Cr ratio is 22 mEq/L ÷ 0.4 g/L = 55 mEq/g, which is inappropriately high.Metoprolol has not been associated with urinary potassium losses. Insulin can cause potassium to shift into cells but would not explain the renal potassium losses. Neither poor oral intake nor diarrhea would explain the inappropriate potassium losses in the urine, but they could be additional contributing factors for hypokalemia.",
        "references": []
    },
    "68": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>A 62-year-old woman returns for scheduled follow-up regarding CKD stage G3b attributed to hypertensive nephropathy. Her current medications include lisinopril, hydrochlorothiazide, and metoprolol. She feels well and reports no swelling, fevers, chills, or urinary symptoms. Medical history is significant for a urinary tract infection approximately 5 years ago.</span></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>Her BP is 127/58 mm Hg and pulse 62/min. She is alert and appears well. Her heart is normal, lungs are clear, extremities have no edema, and abdomen is nontender.</span></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>Her creatinine remains stable at 2 mg/dL (reference range, 0.5–1.1).</span></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\"><span>Urinalysis shows a specific gravity of 1.025, pH 6.5, negative blood, and negative protein. There are 5–10 WBCs/HPF and moderate bacteria. Nitrite and leukocyte esterase are negative.</span></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the NEXT BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Repeat the urinalysis"
            },
            {
                "label": "B.",
                "text": "No change in management"
            },
            {
                "label": "C.",
                "text": "Prescribe trimethoprim/sulfamethoxazole twice daily"
            },
            {
                "label": "D.",
                "text": "Obtain a urine culture and prescribe antibiotics based on sensitivity results"
            },
            {
                "label": "E.",
                "text": "Prescribe prophylactic trimethoprim/sulfamethoxazole thrice weekly"
            }
        ],
        "correct_answer": "No change in management",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "This patient with asymptomatic bacteriuria does not require any change in management and may be reassured that there is no indication for antibiotics.Pyuria is frequently observed in patients with asymptomatic bacteriuria (ASB) and is not an indication for antibiotic therapy. The prevalence of pyuria in patients with diabetes mellitus and ASB is almost 70%.ASB is a common finding in many populations, including healthy women and those with underlying urologic abnormalities. The recently updated guidelines from the Infectious Diseases Society of America (IDSA) recommends ASB screening and treatment only\n        in pregnant women or before invasive urologic procedures. Treatment is not recommended for healthy women; older women or men; or patients with diabetes, indwelling catheters, or spinal cord injury.Treatment with trimethoprim/sulfamethoxazole would thus not be warranted. Additionally, this medication can cause hyperkalemia and transiently increased creatinine. A follow-up urine culture or repeat urinalysis would not be indicated based on IDSA\n        guidelines. Furthermore, there is no role for prophylaxis for an individual who does not have frequent urinary tract infections.",
        "references": []
    },
    "69": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 57-year-old woman presents to the emergency department with dyspnea and confusion. She reports fever, malaise, and chills. She has a history of bladder cancer. Two years ago, she underwent a cystectomy, and a neobladder was created from a portion of her ileum. She has been well until now and is not prescribed any medications long-term.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She is afebrile. Her BP is 114/52 mm Hg, heart rate 103/min, and respiratory rate 24/min. Her oxygen saturation is 98% on ambient air. Her breathing is deep and regular. The lungs are clear. She is somewhat slow to answer questions but is oriented and does not have focal neurologic signs. The remainder of her physical examination is unrevealing. Ultrasound of the kidneys is negative for hydronephrosis.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                252,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                134 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                117 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                83 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Hemoglobin A<sub>1c</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0–5.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Arterial blood gas\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.09\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n</tbody>\n</table>\n<p>EKG reveals sinus tachycardia.</p>\n<p style=\"margin-top: 30px; margin-bottom: 15px;\"><strong>Which of the following is the MOST likely etiology of this patient’s metabolic disturbances?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Neobladder"
            },
            {
                "label": "B.",
                "text": "Type 4 renal tubular acidosis"
            },
            {
                "label": "C.",
                "text": "Diarrhea"
            },
            {
                "label": "D.",
                "text": "Aspirin overdose"
            },
            {
                "label": "E.",
                "text": "Vomiting"
            }
        ],
        "correct_answer": "Neobladder",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "Bicarbonate excretion and chloride reabsorption by the neobladder is the most likely explanation for the metabolic derangements observed in this patient.This patient presents with a normal anion gap metabolic acidosis (NAGMA). The general approach to NAGMA involves distinguishing between gastrointestinal (GI) and renal losses of bicarbonate, which are the most common etiologies. Occasionally, NAGMA is observed because of the addition of chloride, such as during resuscitation with isotonic sodium chloride. The differential also includes a post-hypocapnic condition in which the serum bicarbonate has decreased in response to respiratory alkalosis that has subsequently resolved. A history of severe diarrhea is often present when NAGMA is due to stool losses. If the etiology of NAGMA is not apparent from the clinical presentation, measurement of urine electrolytes and osmolality followed by calculation of the urine anion and osmolal gaps was traditionally used to differentiate between renal and nonrenal causes. By estimating urinary ammonium excretion, these techniques inferred whether the renal response to acidosis is appropriate. However, neither of these calculations correlates very well with direct urine ammonium measurement. In this case, urinary electrolyte results are not provided, but are not necessary to establish the diagnosis of neobladder dysfunction.Neobladders and urinary conduits are often formed by using a portion of the ileum, which is conveniently mobilized on its vascular supply and less prone to metabolic complications than neobladders formed from colon. Nevertheless, ileal neobladders and conduits can predispose patients to developing NAGMA, particularly if there is urinary stasis. The mechanism underlying this predisposition is the presence of chloride-bicarbonate exchangers in the ileal epithelium. Chloride in urine that remains in contact with the neobladder is exchanged for bicarbonate, which is subsequently excreted in the urine, resulting in NAGMA. Diabetes, CKD, and a large-capacity neobladder have been identified as risk factors. The severity of the acidosis in this case implies stasis. Investigation for urinary retention and urinary tract infection and urologic consultation should be considered.Type 4 renal tubular acidosis (RTA) can be seen in a variety of conditions, most commonly diabetic nephropathy. Type 4 RTA typically causes only mild NAGMA. A similar RTA due to impairment of the epithelial sodium channel in the distal nephron occurs in the setting of urinary tract obstruction. This can result in more severe NAGMA and hyperkalemia. In this case, there is no evidence of hydronephrosis, which usually accompanies obstruction. Rather, stasis of urine and reabsorption of chloride by the neobladder is a more likely explanation than obstruction.Aspirin poisoning results in a metabolic acidosis with an elevated anion gap, along with a respiratory alkalosis. Vomiting usually results in metabolic alkalosis and hypokalemia.",
        "references": []
    },
    "70": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 22-year-old man who is an inpatient resident of an eating disorders unit is evaluated for CKD. He was first diagnosed with anorexia nervosa at the age of 15 years and has required prior hospitalization for management on multiple occasions. He has had features of both food restriction and binging with purging. He has no other medical history. His family history is negative for kidney disease. Previous measurements of serum creatinine have ranged from 1.4 to 1.7 mg/dL.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">His medications include olanzapine 7.5 mg daily, a multivitamin, and magnesium hydroxide and potassium chloride repletion based on a sliding scale.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">On examination, he is a thin man in no distress. His heart rate is 56/min, BP 90/50 mm Hg, temperature 35°C, and body mass index 16 kg/m<sup>2</sup>. Lanugo is present on his arms.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Laboratory results include the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                141 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                136–144\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                3.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                104 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                19 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                1.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                90 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n</tbody>\n</table>\n \n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Random urine protein-to-creatinine ratio is 0.8 mg/mg (reference range, &lt;0.2). Urinalysis reveals specific gravity 1.005 and 1+ protein. Urine microscopy shows 1–2 isomorphic RBC/hpf and 1–2 WBC/hpf. There are no casts.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">Ultrasound of the kidneys demonstrates increased echogenicity, thin cortex, and multiple cysts bilaterally. Both kidneys are 8.7 cm in length.</p>\n<div style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely explanation for his CKD?</strong></div></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Olanzapine"
            },
            {
                "label": "B.",
                "text": "Autosomal dominant polycystic kidney disease"
            },
            {
                "label": "C.",
                "text": "Focal segmental glomerulosclerosis"
            },
            {
                "label": "D.",
                "text": "Chronic hypokalemia"
            },
            {
                "label": "E.",
                "text": "Reflux nephropathy"
            }
        ],
        "correct_answer": "Chronic hypokalemia",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation": "Chronic hypokalemia is the most likely explanation for CKD in this young man with a history of a binging and purging eating disorder.Anorexia nervosa is a general term for an eating disorder manifested by low body weight, fear of gaining weight, and a strong desire to be thin. It can be associated with food restriction, binging and purging, excessive exercise, and the use of drugs or medications to promote weight loss. Nephrologic complications include both AKI and CKD. Acute and chronic electrolyte disturbances are common, and chronic hypokalemia can be a prominent feature, observed in up to 20% of cases.Chronic hypokalemia may cause hypokalemic nephropathy, characterized by interstitial fibrosis, tubular vacuolization, and multiple renal cysts. The urine sediment is bland. Mild low-molecular-weight proteinuria, with only modest albuminuria, is observed. Chronic hypokalemia may also cause a urinary concentrating defect with a fixed low urine specific gravity that can present as a form of nephrogenic diabetes insipidus.Olanzapine has been implicated as a cofactor in cases of AKI related to serotonin syndrome or neuroleptic malignant syndrome but has not been identified to cause CKD.Primary focal segment glomerulosclerosis (FSGS) is a genetic or immunologic cause of nephrotic syndrome. Secondary FSGS is a nonspecific glomerular hemodynamic response to a variety of insults, notably hyperfiltration injury. Both forms can lead to CKD and cortical thinning with increased echogenicity, but heavier proteinuria would be expected.Reflux nephropathy results most commonly from congenital vesicoureteral reflux and recurrent urinary tract infection. Ultrasound imaging typically demonstrates focal cortical scarring and sometimes hydronephrosis. Chronic manifestations include CKD and secondary FSGS. In this case, the ultrasound and other clinical features do not support this diagnosis.Although a negative family history of autosomal dominant polycystic kidney disease is not uncommon, occurring in up to 15% of cases, the cortical atrophy and relatively small kidney size would not be typical for this disorder.",
        "references": []
    },
    "71": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 59-year-old man is admitted to the hospital with fever, abdominal pain, and bright red blood per rectum. He has experienced flu-like symptoms for 1 week prior to presentation.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">On physical examination, his BP is 156/90 mm Hg and heart rate 101/min. Pertinent physical exam findings include a non-blanching, purpuric rash on his upper and lower extremities. He has no murmurs. Lungs are clear to auscultation bilaterally. His abdomen is diffusely tender to palpation but without guarding. Bowel sounds are normal, and no organomegaly is identified.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Laboratory studies yield the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                129 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                108 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                34 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                85 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Antimyeloperoxidase antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Antiproteinase 3 antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Anti-GBM antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2 mg/mg\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">Urinalysis reveals 3+ protein, 5–10 RBC/hpf, and no casts.<br/></p><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A kidney biopsy is performed. Thirty-three glomeruli are present for evaluation, of which 5 are globally sclerotic. Several glomeruli demonstrate crescent formation with\n    segmental necrosis and endocapillary proliferation of the glomerular capillary tufts. Two of the obsolescent glomeruli have fibrous crescents. No spike formation is noted in the capillary tufts. Tubules show evidence of vacuolation.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">IF shows 1+ staining for fibrinogen and albumin. EM does not show any immune complex deposits.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which one of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Infection-associated glomerulonephritis"
            },
            {
                "label": "B.",
                "text": "Idiopathic membranoproliferative glomerulonephritis"
            },
            {
                "label": "C.",
                "text": "Crescentic membranous glomerulonephritis"
            },
            {
                "label": "D.",
                "text": "ANCA-associated vasculitis"
            },
            {
                "label": "E.",
                "text": "IgA vasculitis"
            }
        ],
        "correct_answer": "ANCA-associated vasculitis",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation": "This patient’s clinical findings and kidney biopsy findings are consistent with ANCA-associated vasculitis (AAV), despite negative serum assays for antibodies to myeloperoxidase and proteinase 3, the two most widely identified ANCA antigens.Although <10% of patients with clinical and pathologic features of AAV with necrotizing glomerulonephritis (GN) are negative for ANCA using current clinical assays, a negative ANCA does not exclude this diagnosis. The explanation for negative ANCA testing in these patients is uncertain. AAV includes granulomatosis with polyangiitis (previously Wegener granulomatosis), microscopic polyangiitis, renal-limited vasculitis, or eosinophilic granulomatosis with polyangiitis (previously Churg-Strauss syndrome).Normal serum complement and the absence of immune complexes or basement membrane abnormalities on EM and IF make idiopathic MPGN and infection-associated GN very unlikely. Most cases of idiopathic MPGN (>95%) are caused by hepatitis C and demonstrate subendothelial and mesangial immune complex deposition. Less commonly, MPGN is due to C3 glomerulopathy (C3GN or dense deposit disease), which has characteristic basement membrane findings that are absent on this biopsy. Infection-associated GN is also associated with immune complex deposits. Subepithelial humps are identified in classic post-streptococcal GN and mesangial IgA deposits in staphylococcal-associated GN.Crescent formation in membranous glomerulopathy (MGN) is rare but has been described. Generally, patients with MGN present with nephrotic syndrome, in contrast to the nephritic features in this case. Moreover, biopsy findings typically include basement membrane spikes on silver stain as well as subepithelial deposits by IF and EM.This patient who presented with a vasculitic rash, constitutional symptoms, rectal bleeding, and crescentic, pauci-immune GN, would be diagnosed with AAV despite the negative ANCA test.",
        "references": []
    },
    "72": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 68-year-old woman with ESRD receiving maintenance PD for the past 9 months presents with cloudy effluent and severe abdominal pain. Her medical history is significant for ADPKD, hypertension, hyperlipidemia, diverticulosis, and obesity. Her daily PD prescription is 4 manual exchanges with 2.5 L of 1.5% dextrose dialysate. She is unaware of any recent breaks in sterile technique or other sources of contamination, and she has not had any symptoms related to the catheter tunnel or exit site. For the past 2 days, the drained dialysate has appeared cloudy. Review of systems is negative for cough, shortness of breath, rash, constipation, or diarrhea. She produces a small amount of urine daily and has not had dysuria or urgency.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">On physical examination, the patient appears ill. Her BP is 99/66 mm Hg, heart rate 98/min, and temperature 38.8°C. Heart and lung examinations are normal, but the abdomen is firm, with hypoactive bowel sounds, diffuse guarding, and rebound tenderness. The PD catheter site appears clean, without erythema or exudate. There is no peripheral edema.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">Laboratory data include the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15,400/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Dialysate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Cell count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1800/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;100\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Differential\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                92% neutrophils, 8% monocytes\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Gram stain\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Gram-positive cocci in chains, gram-negative rods, and gram-positive rods\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n</tbody>\n</table>\n \n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">IV vancomycin and cefepime are administered.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which of the following MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Surgical evaluation"
            },
            {
                "label": "B.",
                "text": "Intraperitoneal metronidazole"
            },
            {
                "label": "C.",
                "text": "Fluconazole prophylaxis"
            },
            {
                "label": "D.",
                "text": "Removeperitoneal dialysiscatheter"
            },
            {
                "label": "E.",
                "text": "Rapidperitoneal dialysisexchanges"
            }
        ],
        "correct_answer": "Surgical evaluation",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "This patient receiving PD has evidence of polymicrobial peritonitis, which should raise suspicion for secondary peritonitis from a perforated abdominal viscus; thus, she requires urgent surgical evaluation.Peritonitis in patients receiving PD is typically acquired by contamination of the catheter or its exit site and usually consists of monomicrobial skin flora such asStaphylococcusorStreptococcusspecies. Patients may be febrile but rarely demonstrate signs of septic shock, as in this case. Both polymicrobial infection and septic shock should increase suspicion for intra-abdominal pathology, such as diverticulitis with perforation.Broad-spectrum antibiotics are indicated, and metronidazole should be included to treat infection by anaerobic bacteria. However, an antibiotic prescription would not take the place of surgical evaluation for definitive management. In addition, metronidazole should be administered IV rather than intraperitoneally.Fluconazole prophylaxis has been recommended to prevent fungal peritonitis after antibiotic treatment of bacterial peritonitis in patients receiving PD. However, this would not be the most important next step in management. Catheter removal may be indicated in cases of refractory or relapsing peritonitis but would not affect acute management of polymicrobial peritonitis from an intra-abdominal source. Rapid PD exchanges (1–2) may help reduce abdominal pain and endotoxin load before instillation of antibiotics in routine cases of peritonitis but would not be the next step in the management of this case.",
        "references": []
    },
    "73": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><span>A 19-year-old man presents to the emergency department with progressive weakness of the lower extremities for the past 12 hours. The patient is a competitive bodybuilder. For the past few days, he has been consuming high-calorie meals, after having dieted for several weeks to reduce body fat prior to an upcoming competition.</span></p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\"><span>His temperature is 36.6°C, BP 130/70 mmHg, and heart rate 88/min. Physical examination reveals severe generalized weakness, and the patient is unable to walk. Reflexes are diffusely hypoactive.</span></p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">142 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.8 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">107 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">15 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.3 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Magnesium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.2 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.6–2.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">129 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70–99 (fasting)</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">9.2 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Arterial blood gas</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.34</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.38–7.44</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  PCO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">44 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">38–42</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">74 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">56 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n</tbody>\n</table>\n \n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which of the following is the MOST likely cause of this patient’s hypokalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypokalemic periodic paralysis"
            },
            {
                "label": "B.",
                "text": "Laxative abuse"
            },
            {
                "label": "C.",
                "text": "Gitelman syndrome"
            },
            {
                "label": "D.",
                "text": "Vomiting"
            },
            {
                "label": "E.",
                "text": "Diuretic abuse"
            }
        ],
        "correct_answer": "Hypokalemic periodic paralysis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation": "The most likely diagnosis is hypokalemic periodic paralysis (PP), triggered by high-calorie meals.The differential diagnosis of hypokalemia includes excessive loss, inadequate intake, and cellular shift. Potassium losses, in turn, may be either renal or gastrointestinal in etiology. The low urine potassium (<25 mEq/L or urine potassium-to-creatinine\n        ratio <15 mEq/g) in this case suggests a nonrenal cause of hypokalemia. Thus, ongoing diuretic abuse and Gitelman syndrome are unlikely.Complications of inappropriate use of diuretics and laxatives, as well as eating disorders such as bulimia, are reported in bodybuilders. Remote (several days) use of diuretics could present as hypokalemia with appropriate urinary potassium retention,\n        but the absence of hypotension, metabolic alkalosis, or renal sodium retention argue against this possibility. Vomiting is also unlikely, as the hypokalemia results from increased sodium delivery to the distal nephron related to chloride depletion,\n        volume contraction, and aldosterone stimulation, all of which lead to excess potassium loss in the urine. Laxative abuse would present with a low urine potassium and typically would also be accompanied by hypovolemia and non–anion gap metabolic\n        acidosis, both of which are absent in this patient.Low potassium intake is an uncommon cause of hypokalemia in adults but may occur in chronically malnourished patients, especially during refeeding. This otherwise healthy bodybuilder would not be expected to have drastically low potassium intake.Hypokalemic PP is a rare (prevalence, 1 in 100,000) autosomal dominant defect of calcium or, less commonly, sodium channels in skeletal muscle. Men are more often affected. Hypokalemic PP tends to present before age 20 years and is precipitated by\n        stress, exercise, and carbohydrate loading. Treatment includes avoiding these triggers and taking potassium-sparing diuretics, carbonic anhydrase inhibitors, or both. A clinically similar syndrome, thyrotoxic PP, is associated with hyperthyroidism\n        in patients of Asian ancestry. Hypokalemia in thyrotoxic PP is thought to result from thyroxine-mediated overstimulation of the Na-K-ATPase. Thyrotoxic PP is also associated with hypophosphatemia.",
        "references": []
    },
    "74": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 36-year-old man with ESRD managed with APD presents for evaluation of abdominal pain. He has been undergoing APD for 3 years without prior peritonitis, exit site infection, or abdominal pain. His prescription consists of 4 overnight exchanges of 2 L each, and a manual 2-L drain/fill cycle during the day. For the past few weeks, he has experienced pain during the drain periods of his overnight exchanges but not during his manual exchange. Bowel function has been regular, and his dialysate effluent has been clear.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">His vital signs include a BP of 146/62 mm Hg, heart rate 85/min, respiratory rate 18/min, oxygen saturation 98% on room air, and temperature 36°C. Examination of the heart, lungs, abdomen, and extremities is unremarkable. The catheter exit site shows\n    no erythema, crusting, or drainage.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">His effluent is clear, and a cell count returns at 4/μL with a pending differential.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>In addition to a trial of laxatives, which of the following is the MOST appropriate next step in the management of this problem?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Intraperitoneal morphine"
            },
            {
                "label": "B.",
                "text": "Neutral pH dialysate"
            },
            {
                "label": "C.",
                "text": "Decreased dwell volume"
            },
            {
                "label": "D.",
                "text": "Tidal peritoneal dialysis"
            },
            {
                "label": "E.",
                "text": "Increased drain time"
            }
        ],
        "correct_answer": "Tidal peritoneal dialysis",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation": "The most likely intervention to improve the abdominal pain in this patient is a switch to a tidal mode of PD. Tidal PD involves incomplete drainage of the peritoneum prior to the addition of the next dwell.APD uses hydraulic suction to facilitate drainage. It has been proposed that the suction transmits negative pressure to the sensitive parietal peritoneum when the peritoneum is nearly empty, resulting in pain. Residual fluid in the cavity acts as a liquid barrier and may cushion, or otherwise protect, the parietal peritoneum from direct exposure to suction, thereby preventing drain pain. The prescriber can specify the percentage of the instillation volume to be drained. Typically, a drain volume of 85% is initially prescribed and subsequently titrated if relief is not achieved. If tidal PD is unsuccessful at alleviating pain, a trial of CAPD can be attempted, because gravity drainage may be less prone to provoke drain pain.Neutral pH dialysate, which is available as a commercial solution or can be generated via the addition of sodium bicarbonate to lactate-based dialysate, can alleviate instillation pain, which is attributed to the effect of acidic dialysate entering an empty peritoneal cavity. It would not address drain pain.Pain related to overfill, or distention of the peritoneum, typically presents with pain at the end of instillation or during a dwell, when ultrafiltration has increased the peritoneal fluid volume. To address pain related to abdominal distention, either reduction of instillation volume or a decreased concentration of dialysate dextrose to reduce ultrafiltration would be appropriate.Intraperitoneal morphine has been studied for the evaluation of postsurgical pain but is not routinely used in the management of dialysis-associated pain syndromes.Increasing drain times have not proved to be effective in the management of drain pain.",
        "references": []
    },
    "75": {
        "question": "<div class=\"qtext\"><p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">A 45-year-old woman with CKD stage 5 due to IgA nephropathy is undergoing evaluation for kidney transplant. Her current eGFR is 12 mL/min/1.73 m<sup>2</sup> and she has no uremic symptoms. Her medical history is significant for hypertension, which is controlled with amlodipine and carvedilol. Her calculated panel reactive antibody (PRA) is 93% and blood type is A+. Based on her geographic location and blood type, her expected waiting time for a deceased donor kidney is 4–5 years.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">Her 41-year-old husband is interested in serving as a living donor, and he has been deemed medically suitable for donation with an eGFR of 125 mL/min/1.73 m<sup>2</sup>. His blood type is O+. The donor and recipient human leukocyte antigen (HLA) tissue typing are listed below.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                HLA Locus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                A\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                B\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                DR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                DQ\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Recipient alleles\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1\n<br/>68\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65\n<br/>38\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1<br/>7</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2\n<br/>5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Donor alleles\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3\n<br/>11\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7\n<br/>27\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7<br/>15\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2<br/>6\n            </td>\n</tr>\n</tbody>\n</table>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\">The recipient has 2 donor-specific antibodies: anti-DR15, mean fluorescence index 8000, and anti-A3, mean fluorescence index 6000 (mean fluorescence index &gt;1000 is considered positive). Both the flow cytometry cross-match and the cytotoxic cross-match are positive.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 20px;\">The patient has no other potential living donors.</p>\n<p dir=\"”ltr”\" style=\"margin-bottom: 15px;\"><strong>Which one of the following would be the BEST recommendation regarding her transplant options?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decline this donor and undergo desensitization to optimize opportunity for a cross-match–negative deceased donor transplant"
            },
            {
                "label": "B.",
                "text": "Proceed with transplant from this donor once flow cross-match is negative after desensitization"
            },
            {
                "label": "C.",
                "text": "Proceed with transplant from this donor now without desensitization"
            },
            {
                "label": "D.",
                "text": "Enter the recipient and donor pair into a kidney exchange program"
            },
            {
                "label": "E.",
                "text": "Do not proceed with this donor and wait for a compatible deceased donor kidney"
            }
        ],
        "correct_answer": "Enter the recipient and donor pair into a kidney exchange program",
        "abim_content_category": "Kidney Transplantation",
        "explanation": "The best choice is to enter this donor-recipient pair into a kidney exchange program, where this donor will donate to a different recipient, and in return, the recipient receives a compatible living donor transplant from a different living donor.General nephrologists defer to transplant specialists for recommendations regarding live kidney donation, but an understanding of the impact that donor-specific antibodies and positive pretransplant cross-match have on graft survival is important.\n        Potential donor and recipient pairs undergo tissue typing and cross matching. Tissue typing identifies which HLA alleles are expressed. The more alleles shared, the closer the match. Recipients are tested for the presence of preformed, or existing,\n        antibodies that target donor alleles. In addition, cross-matching is performed in which donor lymphocytes are exposed to recipient serum. The cytotoxic cross-match identifies complement fixing antibodies against donor antigens. The flow cytometry\n        cross-match is more sensitive to low levels of anti-donor antibody or non-complement fixing antibodies. Both tests can have false positives, and the interpretation can be nuanced. In this case, the patient has significant titers of anti-DR15 and\n        anti-A3 antibodies, two HLA antigens expressed by the potential donor. Both the cytotoxic and flow cytometry cross-matches are positive. These are circumstances that increase the risk of graft failure for this pair and should discourage proceeding\n        with the transplant.However, because compatible living donor kidney transplants offer the highest patient and graft survival, alternative strategies to achieve a living donor transplant should be pursued. One such strategy is to enroll the patient in a kidney paired\n        donation and exchange program. In these programs, the incompatible recipient/donor pair exchange kidneys with a similar pair such that two living donor transplants are accomplished.Although HLA-incompatible transplantation is an option, with or without desensitization, outcomes of HLA-incompatible transplantation are inferior to HLA-compatible living donor transplantation. Thus, transplant of an HLA-compatible kidney through\n        a paired exchange program offers superior outcomes to desensitization. As such, proceeding with this donor now would not be recommended ahead of pursuing kidney exchange.Waiting for a compatible deceased donor transplant is not the best answer because of inferior outcomes and long and uncertain waiting times. Recent studies suggest that patients who wait for a compatible deceased donor transplant may have decreased\n        overall survival than patients who receive HLA-incompatible living donors. Based on these data, waiting for a compatible deceased donor with or without desensitization is not the best choice.",
        "references": []
    }
}